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Abstract 
Apoptosis is an important process in normal mammary gland 
physiology and evasion of apoptosis has also been identified as a 
hallmark of cancer. In breast cancer cells apoptotic resistance is an 
acquired feature that can promote tumour growth and progression. 
Induction of apoptosis by the extrinsic death ligand TRAIL has been 
shown to be a promising clinical therapy targeting a number of 
different cancer cells whilst sparing normal cells. Unfortunately most 
breast cancers are inherently resistant to TRAIL treatment. Herein it is 
shown that by reducing the expression of the downstream TRAIL 
inhibitor c-FLIP, a range of different breast cancer subtypes can be 
sensitised to TRAIL treatment resulting in significant cancer cell death. 
Significantly, suppression of c-FLIP in combination with TRAIL 
(FLIPi/TRAIL) ablated the tumour-initiating breast cancer stem cell 
(bCSC) subset, as defined by mammosphere formation assay, within 
cell lines. This selective killing of bCSCs translated to reduced tumour 
initiation and metastasis in animal transplant models. However, 
continued culture of FLIPi/TRAIL treated cell lines in adherent 
conditions resulted in bCSC re-acquisition suggesting a phenotypic 
plasticity of non-bCSC cells. Re-acquired bCSCs also demonstrated 
sensitivity to repeated FLIPi/TRAIL treatment and maintaining reduced 
c-FLIP expression prevented bCSC re-acquisition. These results 
substantiate the importance of resistance to apoptosis in tumour 
initiation and metastasis and identify the targeting of c-FLIP proteins 
as a promising anti-cancer therapeutic approach.  
Acquired resistance to existing mainstay therapies such as 
antiestrogens (AEs) (tamoxifen and Faslodex) and aromatase 
inhibitors (AIs) is an ongoing obstacle in treatment of a large number 
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of breast cancer patients. AE-resistant models of breast cancer and a 
multiple endocrine-resistant patient sample demonstrated 
hypersensitivity to TRAIL. This sensitivity was observed in both in vitro 
and in vivo models of AE resistance and cell death was prevalent in 
both bulk tumour cells and bCSCs. Sensitisation was not attributed to 
combination AE/TRAIL treatment suggesting cellular changes during 
the acquisition of AE resistance are responsible for TRAIL sensitivity in 
these models. Further investigation suggested that the mechanism of 
AE-resistant cell sensitivity to TRAIL was not dependant on functional 
estrogen receptor signalling and is most likely dependant on the AE 
agent that the cancer cells have acquired resistance to. Interestingly 
tamoxifen-resistant MCF-7 cells were shown to have reduced c-FLIP 
protein expression compared to parental cells, further supporting c-
FLIP’s potential in cancer therapy.  
Recent success in the use non-MHC-restricted !" T cells as a 
targeted immunotherapy in clinical trials has identified this therapeutic 
methodology as desirable. Here it is shown that TRAIL is readily 
expressed by this subset of T cells that also demonstrate cytotoxicity 
to breast cancer cell lines. Neither the secretion of TRAIL or surface 
expression of TRAIL appeared to contribute significantly towards !" T 
cell cytotoxicity and the majority of breast cancer cell death induced 
by !" T cells would seem to be perforin-mediated. The suppression of 
c-FLIP in target cells increased !" T cell cytotoxicity but again not via 
TRAIL. Preliminary results also indicated that the bCSCs of some cell 
lines were exquisitely sensitive to !" T cell treatment. In summary 
these results indicate that targeting c-FLIP and TRAIL can be 
therapeutically beneficial in a range of different breast cancer subtypes 
by certain therapeutic strategies. 
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1.1 Breast Cancer 
 
1.1.1 Introduction 
Development of cancer is a multistage process through which 
cells progress from a state of normalcy through a series of pre-
malignant states into invasive cancers (Hanahan and Weinberg 2000). 
This process involves the accumulation and acquisition of oncogenic 
signals through genetic and epigenetic mutations in gene expression 
and/or function. Despite a vast array of cancer cell genotypes it has 
been suggested that the progression through to malignant growth is 
dictated by six essential physiological cell alterations: self-sufficiency 
in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis (Hanahan and 
Weinberg 2000). These six “hallmarks of cancer” are deemed essential 
in order to successfully overcome the intrinsic anticancer mechanisms 
that exist in every cell and tissue.  
Breast cancer is the most prevalent form of cancer in women 
worldwide, in 2009 nearly 50,000 new diagnoses were made (Cancer 
research UK). This accounted for 31% of all new female cancers in the 
UK and although there have been significant advances in detection, 
therapy and surgical techniques over recent years, 50% of these 
sufferers will eventually die as a result of their disease (Caldas and 
Aparicio 2002). A large proportion of these deaths can be attributed to 
progression to metastasis and therapy resistance, however breast 
cancer is an inherently difficult disease to treat due to its biological 
complexity and both intra- and inter- tumour heterogeneity.  
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Tumours that originate from connective tissue are denoted as 
sarcomas and those that originate from epithelial tissue are known as 
carcinomas. Thus the majority of tumours arising in the breast are 
characterised as adenocarcinomas due to their origin within the 
glandular epithelia. These can be further subcategorised based on the 
different originating glandular epithelia within the breast that the 
tumour arises from. Initially neoplastic evolution commences in the 
form of flat epithelial atypia or hyperplasia of a normal cell that then 
progress to atypical hyperplasias that then become carcinoma in situ 
which may then progress to the final stage of invasive carcinoma such 
as lobular adenocarcinomas and ductal adenocarcinomas, the latter of 
which accounting for up to 75% of breast carcinomas (Bombonati and 
Sgroi 2010). This is representative of a normal cell that mutates and 
begins to grow uncontrollably with abnormal nuclear morphology until 
the lumen is almost completely constricted with the basement 
membrane remaining intact. Only when these cells evade the 
encapsulating basement membrane into the surrounding tissue can the 
tumour be described as invasive carcinoma (Wellings et al. 1975). 
 
1.1.2 Heterogeneity of breast cancer 
 Gene expression profiling of breast cancer has recently identified 
the presence of multiple molecular subtypes of the disease. 
Microarrays performed characterised gene expression patterns in 65 
samples of human breast tumours from 42 different individuals (Perou 
et al. 2000), revealing that the phenotypic diversity of breast tumours 
was associated with corresponding diversity in gene expression. These 
gene expression profiles were subsequently used to subdivide breast 
cancers into five different molecular groups: the oestrogen receptor 
(ER)-positive luminal A and luminal B tumours and the ER-negative 
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basal-like, ErbB2-positive and normal breast tumours (Perou et al. 
2000; Sorlie et al. 2001). The luminal A and luminal B cancers over-
express ER, oestrogen-responsive genes and genes that are 
characteristically expressed in luminal epithelial cells (Perou et al. 
2000). The luminal A tumours often express the transcription factors, 
GATA-3 and FOXA1, and the progesterone receptor (PR) (Badve et al. 
2007; Sorlie et al. 2003), whereas the molecular phenotype of luminal 
B tumours is not so well understood, they are however known to be 
PR-negative and express higher levels of the proliferation marker Ki67 
and possibly the tyrosine kinase receptor ErbB2 (Cheang et al. 2009). 
As their name suggests the ErbB2-positive tumours over-express 
ErbB2 and other neighbouring genes such as growth factor receptor-
bound protein-7 (GRB7); they commonly lack ER expression and 
generally have high levels of NF-!B activation (Bertucci et al. 2004; 
Biswas and Iglehart 2006; Sorlie et al. 2001). Basal-like tumours over-
express a range of genes that characterise basal epithelial cells (Perou 
et al. 2000). These tumours are often also denoted ‘triple-negative’ 
due to their general lack of ER, PR and ErbB2 (Perou et al. 2000). 
Whilst the majority of basal-like tumours are triple-negative, this is not 
always the case as some basal-like tumours can express ErbB2 
(Rouzier et al. 2005) and conversely some triple-negative tumours do 
not express basal markers (Tan et al. 2008; Tischkowitz et al. 2007). 
The normal breast-like tumours resemble normal breast tissue 
samples and over-express many genes that characterise non-epithelial 
mammary cells and lack luminal epithelial cell markers, but do have 
strong expression of basal epithelial genes (Perou et al. 2000; Sorlie et 
al. 2001). Notably, these different subtypes can be used to predict 
clinical outcome, luminal A cancers tend to have the best prognosis 
and ErbB2-positive and basal-like tumours are more aggressive with a 
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worse prognosis (Sorlie et al. 2003; Sotiriou et al. 2003). The most 
recently identified subtype of breast cancers is termed the claudin-low 
subtype. This group gains its name from the low expression of claudin 
genes that are involved in epithelial cell tight-tight junctions. These 
tumours are triple-negative and show similar gene expression profiles 
to the basal-like triple-negative tumours. Important features of the 
claudin-low tumours are that they lack cell-cell junction proteins such 
as E-cadherin and have stem cell-like features and features of EMT and 
are believed to be the subtype most similar to breast cancer stem cells 
(Perou 2010). 
 
1.1.3 Estrogen receptor signalling and breast cancer 
  The estrogen receptor (ER) signalling pathway is a 
complex biological pathway that controls cell proliferation, apoptosis, 
invasion and angiogenesis (Curtis Hewitt et al. 2000; Warner et al. 
1999) and expression of ER defines a major subtype of cancer. There 
are two types of ER, ER$ and ER#, with ER$ being the main subtype 
that is expressed in human mammary epithelium. Upon binding, ER 
monomers dimerise, activate and translocate to the nucleus to bind to 
its responsive element in the target gene promoter stimulating gene 
transcription (McDonnell and Norris 2002; McKenna et al. 1999). ER 
has been shown to bind to the transcription factors activator protein-1 
(AP-1) and specificity protein-1 (SP-1), at their specific sites on DNA, 
serving as coregulators of ER signalling (Kushner et al. 2000). 
Coregulators of ER signalling serve the important purpose of restricting 
the transcriptional activity of the receptor (Smith and O'Malley 2004). 
ER signalling can also be regulated by epidermal growth factor 
receptor (EGFR), HER2 and insulin-growth factor receptor (Schiff et al. 
2004). These membrane receptor tyrosine kinases signal to 
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phosphorylate ER and its co-activators/repressors leading to its 
activation (Shou et al. 2004; Wu et al. 2005). Conversely ER signals 
can also suppress the expression of EGFR and HER2 (Newman et al. 
2000; Yarden et al. 2001). ER signalling is frequently exploited by 
cancer cells to help drive tumour cell growth and as such 75% of all 
breast tumours diagnosed are ER+ve (Musgrove and Sutherland 
2009). The discovery that the naturally produced hormone estrogen is 
capable of driving tumour growth led to the development of drugs 
specifically targeting ER signalling. Initially tamoxifen and fulvestrant 
(Faslodex) were developed to directly target estrogen receptors on 
tumour cell surface, this was then followed by the development of 
aromatase inhibitors that prevent the synthesis of circulating estrogen 
(Johnston and Cheung 2010; Jordan 2006; Taylor and Howell 1999). 
tamoxifen functions by competing for binding with estrogen at the 
ligand-binding domain on ER inducing a conformational change 
destabilising the AF-2 domain resulting in an overall stabilisation of 
receptor (Shiau et al. 1998). The other AE, Faslodex, prevents the 
translocation of ER from cytoplasm to the nucleus inducing cytoplasmic 
aggregation and and proteasomal degredation of receptors (Howell 
and Abram 2005). On the other hand, aromatase inhibitors, as their 
name suggests, inhibit the enzyme aromatase that is responsible for 
synthesis of estrogens from adrogenic substrates, specifically the 
synthesis of estrone from androstenedione and estradiol from 
testosterone (Chung and Carlson 2003).  Typically the anti-estrogen 
(AE) tamoxifen is the first-line therapy for premenopausal breast 
cancer patients, however disease resistance to tamoxifen frequently 
occurs (Johnston 1997). However, aromatase inhibitors (AIs) are 
limited for use in postmenopausal women where the ovaries are no 
longer the primary source of estrogen production (Longcope et al. 
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1986). In premenopausal women aromatase inhibition leads to an 
increase in gonadotrophin secretion as a result of reduced estrogen 
feedback to the hypothalamus and pituitary resulting in an over-
production of estrogen by the ovaries that can produce cystic 
hyperplasia (Sinha et al. 1998). Due to its distinct ER inhibitory 
mechanism Faslodex is a common second-line therapy for patients 
that have become resistant to tamoxifen or AI (Johnston and Cheung 
2010). However, as with the other endocrine agents, tumour cells also 
frequently become resistant to Faslodex. The high incidence of 
resistance to endocrine therapies has encouraged the investigation 
into discovering novel therapeutics that can eliminate resistant 
tumours. 
 
1.1.4 Breast cancer and metastatic progression 
Treatment of primary breast cancers has improved drastically 
over the last decade; this can be mostly attributed to great advances 
in early detection and surgical techniques and disease-specific therapy 
approaches. Despite these advances in local and systemic therapies 
many primary tumours are not completely eradicated and develop to 
become invasive metastatic carcinoma. Metastasis is a complex 
process during which tumour cells must detach and evade the site of 
the primary tumour, invade the surrounding stromal tissue, migrate 
into and survive in the vasculature before extravasating and colonising 
at a distant secondary site (Figure 1.1) (Smith and Theodorescu 
2009).  
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For metastasis to take place there must be a suitable amount of 
vasculature available for the cells to invade, the process by which this 
vasculature is generated is termed angiogenesis. As the primary 
tumour begins to grow there is an increasing demand for oxygen and 
as a result the normal physiological conditions surrounding the tumour 
are disrupted. Consequently an imbalance between matrix 
metalloproteinases (MMPs), a family of enzymes that degrade the 
basement membrane, and their tissue inhibitors of metalloproteinases 
Figure 1.1: Stages of the metastatic cascade 
Carcinoma in situ is maintained locally by surrounding basement membrane. 
Alterations such as EMT that increases invasive properties of cells encourage 
invasion through the basement membrane into the vasculature. Once in the 
bloodstream or lymphatic system, cells passively travel to secondary sites where 
single cells extravasate and establish micrometastases or undergo MET to form 
a new carcinoma (macrometastases). 
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(TIMPs) occurs. Concurrently the hypoxic environment during 
hyperplasia causes the accumulation of the hypoxia-inducible 
transcription factors HIF-1 and HIF-2. Under hypoxic conditions the 
HIF-1$ subunit is no longer degraded and an increase in vascular 
endothelial growth factor is observed (Bos et al. 2001; Salceda and 
Caro 1997; Schneider and Miller 2005). The importance of 
angiogenesis extends beyond metastasis as it not only provides an 
avenue for cells to metastasise but additionally serves a purpose as a 
supply of oxygen and nutrients to the growing tumour. With suitable 
blood or lymph vasculature in close proximity, the primary tumour 
cells enter the lymphatic system or bloodstream and migrate toward 
secondary sites for colonisation stimulated by chemokine gradients. 
Common secondary sites such as lymph, liver, lung and bone marrow 
have an increased expression of the chemokine ligand CXCL12. This 
attracts the tumour cells with high expression levels of the chemokine 
receptor CXCR4 (Muller et al. 2001). Upon reaching their secondary 
site, tumour cells tether to the vasculature walls and chemoattractant 
gradients draw the cell into the new tissue. Once colonised the 
tumours may then divide and grow to become macrometastases. The 
importance of metastatic disease cannot be understated, despite an 
88% 5-year survival rate of stage I breast cancers the 5-year survival 
rate of stage IV disease is still limited to just 15% (American cancer 
society). With the current statistics it is not surprising that much 
research focus is currently directed at the prevention and treatment of 
metastatic disease.   
 
1.1.4.1 Epithelial-mesenchymal transition 
 The cellular process of epithelial to mesenchymal transition 
(EMT) is important throughout embryonic development for 
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organogenesis (Baum et al. 2008). Some of the key features of EMT 
include the loss of E-cadherin expression together with the loss of cell-
cell adhesion proteins. As such, a cell that has undergone EMT would 
express mesenchymal markers such as N-cadherin, fibronectin and 
vimentin. A visible morphological change from cuboidal epithelial cells 
with apical-basal polarity to an appearance with an invasive leading 
and trailing edge asymmetry becomes evident (Christiansen and 
Rajasekaran 2006). Stimuli such as hypoxia, cell-stroma interactions 
and some intracellular signalling pathways, namely transforming 
growth factor " (TGF- "), NF-%B, hepatocyte growth factor (HGF), Wnt, 
Notch and Sonic Hedgehog (Hh) are capable of inducing EMT. These 
diverse stimuli converge in the expression of a group of EMT-inducers 
that orchestrate the EMT process. The EMT-inducers are a group of 
transcription factors including Twist, Snail, Slug, Zeb1, Zeb2 and 
FoxC2 (Polyak and Weinberg 2009).  
The EMT program of cancer cells is similar to that observed in 
embryonic development but its activation is a result of aberrant 
stimuli. EMT has been associated with tumour progression and 
metastasis, creating cancer cells with more motile and invasive 
phenotype (Hugo et al. 2007; Yang and Weinberg 2008). This 
phenotype as a result of EMT is particularly important at the early 
stages of the metastatic cascade when cancer cells need to invade 
through the basement membrane into surrounding tissue and 
vasculature. Moreover, there is also evidence to indicate that EMT aids 
trans-differentiation of breast cancer cells to a stem cell-like 
phenotype (Mani et al. 2008; Morel et al. 2008). In addition to EMT, 
the reverse process of mesenchymal to epithelial transition (MET) has 
also been demonstrated for the colonization of cancer cells at 
secondary sites (Dykxhoorn et al. 2009). This supports observations 
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that metastases maintain a similar epithelial phenotype to its primary 
tumour. It also indicates that the mesenchymal cell state is transient 
in cancer cells and its maintenance can be influenced by the tumour 
micro-environment (May et al. 2011). Although aspects of the EMT 
program may be modulated in many cancers, these cancers may not 
appear as phenotypic EMT cells. Clinically, EMT cells are observed as 
spindle cell metaplasias, these cells have an EMT-like molecular make-
up and correlate with poorer prognosis (Geyer et al. 2010). However, 
certain tumour subtypes do not commonly have metaplastic spindle 
cells despite their apparent EMT molecular make-up (Fulford et al. 
2006). Thus defining EMT in breast cancer cells is still a difficult 
practice and may not be defined by a small collection of molecular 
attributes.  
 
 
Figure 1.2: Features of epithelial-mesenchymal transition (EMT) 
During EMT cells lose their cell-cell adhesion proteins and acquire a more invasive, 
more migratory, phenotype/behaviour. The reverse process of MET is also possible 
where cells revert back to their epithelial traits. 
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1.1.5 Experimental models of breast cancer 
 
1.1.5.1 Breast cancer cell lines 
 Deregulation of normal cell processes such as genome instability, 
proliferation, apoptosis, motility and angiogenesis is necessary in the 
development of immortalised metastatic cells (Hanahan and Weinberg 
2000). The use of immortalised breast cancer cell lines to provide 
insights to cellular physiology has been invaluable in advancing 
therapeutic research (Alimandi et al. 1995). As a heterogeneic disease, 
there have been over a thousand genes found to be deregulated in 
breast cancer and use of cell lines provides a means for investigating 
this heterogeneity in vitro (Fridlyand et al. 2006). Importantly, cell 
lines have been shown to display the same heterogeneity as primary 
tumours in terms of copy number and expression abnormalities (Neve 
et al. 2006). Furthermore, cell lines also cluster into basal-like and 
luminal expression subsets in a similar manner to primary tumours 
and show heterogeneous responses to targeted therapeutics mirroring 
observations in the clinic (Neve et al. 2006). Clearly there are distinct 
advantages for the use of cell lines, however, their relevance in 
disease is somewhat limited due to the lack of a surrounding 
microenvironment (stroma, vasculature etc.) that plays a major role in 
the development and progression of human disease (Place et al. 2011; 
Weaver et al. 1996).  
 
1.1.5.2 Mouse models of breast cancer 
 The development of cancer mouse models has provided 
important insight into the development of breast cancer. Moreover, 
these models serve as preclinical platforms to verify efficacy of 
potential drug therapies. In some of the early models, mammary 
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lesions were induced by external factors such as the mouse mammary 
tumour virus (MMTV) and chemical carcinogens. Progress in transgenic 
technology then led to the development of a new generation of models 
where tumour suppressors can be knocked out, or onocogenes over-
expressed, genetically. Apart from providing insight into the role of 
specific genes in breast carcinogenesis or progression, these models 
have also been useful in elucidating molecular pathways. The use of 
mammary gland-specific promoters such as MMTV-long terminal 
repeat (MMTVLTR), "-lactoglobulin (BLG) and whey acidic protein 
(WAP) gene promoters have allowed spatial control of transgene 
expression specifically in the mammary compartment. Despite these 
advances, there are still limitations to constitutively active promoters 
especially when a transgene of interest has unwanted effects 
throughout development. This problem has been addressed with the 
use of inducible transgenic systems. In addition, conditional gene 
expression models, such as the tetracycline-controlled system, have 
also proved useful in revealing mechanisms such as oncogene 
addiction. This is feasible with conditional systems because gene 
expression can be switched on or off in the presence or absence of its 
inducer (Allred and Medina 2008). 
 
1.1.5.3 Transplantation models of breast cancer 
 An alternative approach to mouse modelling breast cancer has 
been the use of cell line transplantation. This can be performed either 
syngeneically where murine cells are transplanted into an appropriate 
host of the same background, termed allografts, or the transplant of 
human cancer cells into immunocompromised mice, termed 
xenografts. All of these approaches have their limitations and 
advantages (Vargo-Gogola and Rosen 2007). It has been hypothesized 
that tumour xenografts produce tumours that are more closely related 
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to breast cancers observed in humans in the clinic, since human 
cancer cell lines can be transplanted. However, the use of 
immunocompromised mice to establish xenografts neglects the 
contribution of certain components of the immune system to tumour 
progression. In general, using established transformed cancer cell lines 
for transplantation omits certain aspects related to tumour initiation. 
Equally, transplantation can be a way of rapidly elucidating questions 
pertaining to the latter, arguably more important, stages of breast 
cancer progression. Hence the selection of a particular model depends 
largely on the questions being addressed in the study because to date, 
none of the available models fully encompass all the features of breast 
cancer initiation and progression or indeed consistently predict clinical 
outcome (Vargo-Gogola and Rosen 2007). 
 
1.1.6 Breast cancer stem cells 
 The classic models of carcinogenesis propose that cancer arises 
via a series of stochastic events whereby, given the right combination 
of mutations, any cell within an organ is able to be transformed and 
give rise to tumours containing cells that are all equally malignant 
(Nowell 1976). There is increasing evidence that now supports a 
fundamentally different model for describing cancer initiation, 
maintenance and progression. The ‘cancer stem cell hypothesis’ states 
that cancers originate from only stem or progenitor cells (Reya et al. 
2001). Stem cells are defined by their ability to undergo both self-
renewal and multi-lineage cell differentiation. The process of self-
renewal can be either symmetrical or asymmetrical, either producing 
two daughter stem cells or one daughter stem cell and one cell capable 
of differentiating along one of a variety of lineages respectively. The 
cancer stem cell hypothesis states that deregulation of these normally 
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tightly controlled processes of self-renewal results in heterogeneous 
tumours that are driven by a small subset of cells referred to as cancer 
stem cells (CSCs) or tumour-initiating cells (TICs) (Wicha et al. 2006). 
Evidence supporting the existence of CSCs was first observed in acute 
myelogenous leukemia (AML) (Bonnet and Dick 1997). In this study, 
leukemic stem cells were identified by their ability to initiate human 
AML when transplanted into immunocompromised mice. This approach 
was then extended to demonstrate the existence of breast cancer stem 
cells. It was shown that, when grown in immunocompromised mice, 
only a small percentage of human breast cancer cells were capable of 
initiating tumours (Al-Hajj et al. 2003). Furthermore, this research 
also revealed that human breast cancers contain a small cellular 
population characterised by the expression of certain cell surface 
markers, which display stem cell-like properties. As few as 100 cells 
expressing these surface markers were able to initiate tumours when 
transplanted into immunocompromised mice. In accordance with the 
cancer stem cell hypothesis, the tumours formed in these mice had the 
same phenotypic heterogeneity as the initial tumour, suggesting they 
were driven by multipotent cells. Additionally, cells from these tumours 
were able to generate further new tumours after transplantation into 
new recipient mice, demonstrating the self-renewal ability of the cells. 
In contrast, transplantation of up to 20,000 cells lacking expression of 
these surface markers failed to initiate any tumours at all (Al-Hajj et 
al. 2003). However, recent studies have also shown that once the CSC 
subset has been depleted the remaining differentiated cells have the 
capability to re-acquire CSC properties, this is discussed in more depth 
later in this chapter. The identification of CSCs as the subset of cells 
responsible for tumour initiation and metastasis has driven research 
toward specifically targeting this subset. Traditional therapies targeting 
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bulk tumour cells may give significant regression; however, without 
targeting the CSC subset tumour relapse would seem inevitable 
(Figure 1.3). Thus CSC therapeutic intervention is now at the forefront 
of much cancer research.  
 
 
 
 
 
 
 
 
 
Figure 1.3: Therapeutic strategies of treating cancer 
Conventional treatment can result in marked regression of a tumour but cancer 
stem cells remain as they are resistant to these therapeutic approaches and 
ultimately tumours relapse. CSC targeted therapies remove the cells responsible for 
tumour relapse and may have better long-term therapeutic benefit. 
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1.1.6.1 Functional identification of breast cancer stem cells 
 Advances in cell culture techniques have been important in the 
identification and study of both normal mammary and breast cancer 
stem cells. The in vitro study of mammary stem cells was developed 
along the lines of work from the neuronal field in which a cell culture 
assay, known as the neurosphere assay, was used to identify neural 
stem cells (Dontu et al. 2003a; Ponti et al. 2005). These cell culture 
conditions have since been adopted to aid the identification and study 
of both normal mammary and breast cancer stem cells (Dontu et al. 
2003a). Plating normal human mammary epithelial cells in non-
adherent, serum-free conditions with a specific set of growth factors 
results in the formation of spherical colonies termed mammospheres 
(Dontu et al. 2003a). Indeed these culture conditions mimic those 
which cells must survive in vivo to metastasise and these 
mammosphere colonies were shown to be enriched for cells that 
exhibit functional characteristics of stem/progenitor cells such as 
multipotency and self-renewal (Bhat-Nakshatri et al. 2010; Dontu et 
al. 2004; Fillmore and Kuperwasser 2008; Tao et al. 2011). The 
mammosphere-forming assay is now routinely used to identify key 
mediators of stem cell behaviour and maintenance in both human and 
rodent cell populations (Al-Hajj et al. 2003; Ponti et al. 2005).  
The use of flow cytometry for isolating breast cancer stem cells 
on the basis of cell surface markers has also been crucial in studying 
these populations. Both limiting dilution transplant experiments and 
analysis of cell surface markers in mammosphere cultures helped 
identify the CD44+ve/CD24-ve cell population as having human breast 
cancer stem cell attributes (Ginestier et al. 2007). An additional 
surface marker, aldehyde dehydrogenase 1 (ALDH1), an enzyme 
responsible for the oxidation of aldehydes to carboxylic acids, has also 
  Chapter 1: General Introduction 
L Piggott  Cardiff University 18 
recently been shown to be over-expressed in the human breast cancer 
stem cell population (Aktas et al. 2009; Charafe-Jauffret et al. 2009; 
Korkaya et al. 2008; Morimoto et al. 2009; Tanei et al. 2009). ALDH1 
activity is detected by an enzymatic ‘Aldefluor’ assay resulting in 
fluorescence detectable by flow cytometry or immunohistochemistry 
and is now routinely used in the identification of this cell population 
(Hay 2005).  
 
1.1.6.2 Interconversion between cancer stem and non-stem 
phenotypes. 
 Cellular phenotypic plasticity is a well-established phenomenon in 
developmental and embryonic stem cell research (Hay 1995; Thiery 
and Sleeman 2006).  This describes the ability of cells to transition 
between differentiated and de-differentiated states and is best 
illustrated by the reversible process of epithelial to mesenchymal 
transition (EMT) in the embryo (Asiedu et al. 2011; Aslakson and Miller 
1992; Chao et al. 2010; Charafe-Jauffret et al. 2009). EMT has long 
been implicated in breast tumour biology, as being a key step in the 
dissemination of tumour cells to distal sites during metastasis and has 
been more recently extended to include the reverse process of MET to 
explain the expansion of more differentiated cell progeny at the distal 
site (Mani et al. 2008; Morel et al. 2008). However, recently a 
conceptual link between EMT and CSCs (bCSCs) has been described 
(Scheel and Weinberg 2011) that implies the existence of functional 
plasticity between cancer stem and cancer non-stem populations. Thus 
like embryonic and adult stem cells, CSCs are not a static population, 
and that under permissive conditions, possibly dictated by the tumour 
microenvironment, cancer cells transition between stem-like and non-
stem-like states (Drasin et al. 2011; Scheel and Weinberg 2011) 
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(Figure 1.4). 
 This has broad implications.  It helps to explain how a minority 
population of CSCs can drive clonal tumour expansion through 
spontaneous mutations, thus successfully marrying current theories of 
CSC biology with models of tumour development (Scheel and 
Weinberg 2011). It is at the heart of tumour heterogeneity as 
described above; and at least conceptually, it provides an additional 
explanation for tumour relapse. The clinical implication of this is that 
even if all cancer stem cells were eliminated from a tumour by a 
selective cytotoxic agent (in itself an obstacle due to EMT dependent 
drug resistance, as described below), residual bulk tumour cells 
remaining in the tumour microenvironment have the capacity to de-
differentiate to a CSC-like phenotype and consequently re-seed 
tumour growth (Polyak and Weinberg 2009). Future therapeutic 
strategies therefore will need to both eliminate CSCs and prevent their 
reacquisition from the residual tumour microenvironment (Figure 1.3). 
 The evidence for a link between an EMT-like process and the 
acquisition of stemness is compelling, particularly in breast cancer 
(reviewed in Polyak and (Mani et al. 2008; Morel et al. 2008)). Two 
independent studies from the Weinberg and Puisieux laboratories 
showed that cells that had undergone EMT possessed stem-like 
properties including increased tumour initiation and self-renewal 
capacity (Chaffer et al. 2011; Iliopoulos et al. 2011; Sarrio et al. 
2012). Thus enforcement of an EMT through the ectopic expression of 
EMT mediators, Snail or Twist or with TGF#1 treatment in immortalised 
human mammary epithelial cells (HMECs) promoted the formation of 
CSC-like cells from non-stem cells, a process which was augmented by 
oncogenic transformation. However, in these early studies, uninduced 
non-CSC-like cells failed to spontaneously generate a mesenchymal 
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CSC-like phenotype, suggesting a persistent unidirectionality in the 
stem-progenitor hierarchy that could only be overcome with direct 
intervention on EMT pathways – possibly mirroring EMT-like events 
during malignancy.   
 This unidirectional model of stem cell biology has since been 
challenged by a number of studies that demonstrate in normal, 
immortalised and neoplastic breast epithelial cells the spontaneous 
conversion of non-stem-like cells to a stem-like state (Chaffer et al. 
2011; Iliopoulos et al. 2011). Thus non-stem-like breast epithelial cells 
isolated either from HMECs or basal cell lines (eg. MCF-10A) and 
cultured in isolation for prolonged periods re-acquired a subpopulation 
of cells with stem-like characteristics. The efficiency of this stem-like 
transition, however, was poor compared to the opposing conversion of 
mesenchymal-like stem cells to more differentiated luminal subtypes, 
providing a putative explanation for the small but stable proportion of 
stem cells found in tumours and in established cell cultures. The stem 
conversion rates ranged from 1% to 5% over 8-9 days of cell culture 
(Chaffer et al. 2011; Iliopoulos et al. 2011) and was dependent on the 
cellular context, with primary luminal HMECs and immortalised cells 
grown as 3D structures exhibiting marked reductions, or even 
reversals in the interconversion rates. Furthermore oncogenic 
transformation augmented the transition of non-stem cells to a stem-
like phenotype and consequently increased the proportion of cancer 
cells with stem-like attributes in the transformed cell populations 
(Meyer et al. 2009). Breast cancer cell lines exhibit similar CSC 
plasticity, CD44+ve subpopulations derived from both luminal and 
mesenchymal breast cancer cell lines exhibited phenotypic plasticity 
both in vitro and in vivo (Sarrio et al. 2012). Interestingly therefore, 
unlike HMECs, the original phenotype of established breast cancer cell 
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populations had little bearing on the ability of non-CSCs to acquire 
stem-like characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 These studies represent a paradigm shift in the way that we 
perceive the origin and behaviour of cancer stem cells.  Yet a number 
of questions remain. For example, does the spontaneous 
interconversion of non-CSCs and cancer stem cells require an EMT, 
and if so do regulators of EMT initiate/drive this plasticity? Clues to the 
first of these questions were provided in a recent elegant study looking 
at epithelial and mesenchymal subpopulations within normal basal-like 
breast cell lines (Sarrio et al. 2012). A spontaneous, yet partial EMT 
was observed in the epithelial population resulting in two 
subpopulations of cells that exhibited distinct stem/progenitor 
Figure 1.4: Phenotypic plasticity of cancer cells 
Accumulating evidence now suggests that cell state is plastic whereby CSCs can 
differentiate into all other cellular subsets found in a tumour and differentiated cells 
and, under certain conditions, can also return to a CSC-like state. This plasticity 
appears to be under the influence of various signalling pathways including Notch, 
Wnt, Hh, hypoxia and interleukins. 
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characteristics of invasive behaviour and self-renewal on the one hand 
and regenerative potential, ALDH1 activity and formation of 
differentiated 3D structures on the other (Meyer et al. 2009). Similarly 
the interconversion of CD44+ve subpopulations derived from breast 
cancer cell lines was shown to be dependent upon activin/nodal 
signalling (Yang and Weinberg 2008).  These data suggest that EMT is 
integral to the plasticity of basal-like breast cells but is not necessarily 
the sole mediator of the stem/progenitor phenotype.  
 Whether these apparently spontaneous events occur in direct 
response to the upregulation of EMT regulators or in response to other 
locally derived factors has yet to be determined. However several lines 
of evidence suggest that the tumour microenvironment plays a key 
role in the modulation of plasticity. Cellular stress concomitant with 
the tumour microenvironment such as hypoxia, or arising as a direct 
result of anti-hormonal or chemotherapy may also impart selective 
pressures that result in CSC expansion (Santisteban et al. 2009). 
Moreover, immune mediated (CD8 T cell) induction of EMT in a mouse 
model of antigen-modified primary breast cancer lead to the 
enrichment of bCSCs in resultant tumour outgrowths (Liu et al. 2011). 
Bone marrow-derived (BMD) mesenchymal stem cells have also been 
demonstrated to traffic to the primary tumour site and expand the 
bCSC population through a cytokine loop involving CXCL7 and IL-6 
(Iliopoulos et al. 2011). The relevance of this cytokine axis on bCSC 
plasticity was confirmed in genetically distinct breast cancer cell lines 
and primary tumours using a blocking antibody to IL-6 in conditioned 
culture medium (Bomken et al. 2010; McDermott and Wicha 2010). 
The influence of intra-tumour heterogeneity on bCSC plasticity may 
therefore also encompass BMD cells and the immune cell repertoire.  
 There are a number of other CSC-related signalling pathways 
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implicated in the maintenance/expansion of bCSCs, including Wnt, 
Notch, Hedgehog, p53, PI3K and HIF (reviewed in (Hardy et al. 2010)) 
but it remains to be established whether factors that influence self-
renewal also direct phenotypic plasticity.  Some of these pathways are 
known to induce an EMT, including EGF/Akt (Yook et al. 2006), Wnt 
(Leong et al. 2007), Notch (Kasper et al. 2009) and Hedgehog (Lopez-
Tarruella and Martin 2009) and are therefore likely candidates for 
having such a role. More studies will be required using rigorous assays 
of plasticity to elucidate this. 
The most recent evidence described above suggest that while 
phenotypic plasticity mirrors many aspects of EMT, blocking EMT may 
in itself be insufficient to prevent the acquisition of at least some 
stem/progenitor characteristics. Ultimately a better understanding of 
the signals that control the equilibrium between non-stem and stem-
like compartments is required in order to prevent the reacquisition of 
bCSCs during therapy. 
 
1.1.7 Treatment of breast cancer  
The treatment of a newly diagnosed breast cancer patient 
generally depends on the extent of the disease and typically involves 
surgery in combination with post-operative radiotherapy. Adjuvant 
therapy in combination with chemotherapy regimens such as CMF 
(Cyclophosphamide, Methotrexate, Fluorouracil) or FEC (Fluorouracil, 
Epirubicin, Cyclophosphamide) in an attempt to reduce recurrence 
following surgery is also common (O'Shaughnessy 2005). In spite of 
treatment advances of newly diagnosed breast cancers, about 30% of 
patients still eventually develop metastatic disease that is generally 
incurable (reviewed in O'Shaughnessy 2005). The recent molecular 
identification and characterisation of distinct breast cancer subtypes 
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has allowed the development of more targeted therapies that are 
specifically directed towards certain biological features of individual 
tumours.  
 
1.1.7.1 Target-based agents in breast cancer  
Target-based therapies can be divided into three broad 
categories: subtype specific agents, signaling pathway inhibitors, and 
tumour microenvironment targeted drugs. The first target-based 
therapy developed for breast cancer was endocrine treatment for 
ER+ve subtypes of the disease, firstly with anti-estrogens such as 
tamoxifen and fulvestrant (Nicholson et al. 2003; Osborne et al. 1994) 
and then later with aromatase inhibitors (Nicholson and Johnston 
2005). Since then, many agents that are active against the EGFR 
family receptors have also been developed. These include monoclonal 
antibodies such as trastuzumab, which bind the extracellular domain of 
the HER2 receptor (Carter et al. 1992) and small-molecule tyrosine 
kinase inhibitors that prevent their phosphorylation, such as lapatinib 
(Rusnak et al. 2001). When used in combination with chemotherapy, 
these agents have been shown to have considerable efficacy in 
treating certain subtypes of breast cancer that over-express certain 
EGFR family receptors (Gasparini et al. 2007; Geyer et al. 2006; 
Slamon et al. 2001). Additionally, agents targeting downstream 
signaling pathways of the EGFR family receptors (e.g. mTOR and Src) 
have been developed with limited success (Lombardo et al. 2004; Yeh 
et al. 2007; Yu et al. 2001). However, preclinical findings do suggest 
that they may be useful in certain breast cancer subtypes. 
While responses to some of these treatments have been 
encouraging, resistance is still prevalent, and disease improvement 
can be short-lived. In particular, triple-negative cancers do not 
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respond to most targeted therapies due to their lack of molecular 
targets. Therefore, there is still a need to identify new or synergistic 
targets to treat all subtypes of the disease.  
One such target may be the NF-%B family of transcription factors 
which have been shown to be activated downstream of a number of 
cell surface receptors. NF-%B plays a key role in many physiological 
processes, including innate and adaptive immune responses, 
inflammation and cell proliferation, death and motility. The potential of 
NF-!B as a therapeutic target in breast cancer has already been 
addressed in a number of reports in the literature (Aggarwal et al. 
2005; Cao et al. 2007; Connelly et al. 2010; Helbig et al. 2003; Liu et 
al. 2010; Park et al. 2007). This has led to a great deal of interest in 
the development of signaling inhibitors of NF-%B. 
Elucidation of signalling pathways that regulate self-renewal has 
become of prime importance for gaining further understanding of how 
deregulation of this process can lead to carcinogenesis. Recent 
evidence suggests that key oncogenic pathways such as those 
mediated by ErbB2, NOTCH, Akt, Wnt and NF-%B signalling regulate 
breast stem cell behaviour (Dontu et al. 2004; Korkaya et al. 2009; 
Korkaya et al. 2008; Liu et al. 2010; Takahashi-Yanaga and Kahn 
2010; Wang et al. 2010) and as such may provide excellent targets for 
future breast cancer therapy.  
   
1.1.8 Drug resistance in breast cancer 
 Despite significant advances, the success of many first-line cancer 
therapeutics can be limited as significant amount of patients will 
ultimately become resistant to them. Most patients with ER+ve breast 
cancer are treated with endocrine adjuvant therapy and ithis is also 
the most effective treatment for ER+ve metastatic breast cancer. The 
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success of endocrine therapy is limited, however, by de novo and 
acquired resistance of tumour cells in up to 30% of patients (EBCTCG, 
2005). Tumours, especially advanced metastatic tumours, initially 
responsive to endocrine therapy will ultimately progress over time to 
the point where the endocrine agent is then driving tumour cell growth 
rather than inhibiting its proliferative ability (Nicholson et al. 2003; 
Osborne et al. 2003). In tamoxifen-resistant patients, subsequent 
Faslodex therapy can be beneficial but again the cells will become 
resistant to this anti-estrogen (AE) over time (Knowlden et al. 2003; 
McClelland et al. 2001; Nicholson and Johnston 2005). The 
mechanisms of AE resistance are complex and, in general, poorly 
understood. When retained, the ER signalling pathway interacts with 
growth signalling pathways that regulate cell survival and proliferation 
signalling resulting in the promotion of acquired resistance and relapse 
(Nicholson et al. 2003; Osborne et al. 2003). In particular the EGFR 
and ErbB2 pathways are believed to be particularly important in AE 
resistance (Knowlden et al. 2003; McClelland et al. 2001; Nicholson 
and Johnston 2005). Resistance is not limited to endocrine agents, 
resistance is also frequently observed in other forms of therapeutic 
intervention such as trastuzumab and as such many studies are now 
focussed on the underlying mechanisms of this resistance to aid in the 
development of further treatment options (Piccart 2008). 
 As the standard mode of treatment, the majority of breast cancer 
patients will receive some form of chemotherapy or radiotherapy 
during their treatment regime. However, there is increasing evidence 
to suggest that chemotherapy/radiotherapy treatment, even in 
patients showing significant response, does not target the 
heterogeneity of cells found within breast tumours, more specifically 
the CSC subset. As such, breast CSCs (bCSCs) are enriched in biopsies 
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taken from patients who received neoadjuvant chemotherapy (Li et al. 
2008; Tanei et al. 2009; Yu et al. 2007b). Similarly, tumours 
engrafted into animals receiving radiation therapy were also found to 
have an enriched CSC compartment (Phillips et al. 2006; Zielske et al. 
2011). The conclusion has been therefore that selective pressures 
predicated on the inherent resistance of bCSCs to chemotherapy and 
radiotherapy result in the skewed equilibrium of stem and non-stem 
cell populations in vivo.  Several mechanisms have been ascribed to 
this resistance phenotype in bCSCs.  ABC transporters, for example 
ABCG2, are upregulated in both stem and non-stem breast cancer cells 
(Patrawala et al. 2005). Signalling pathways such as Notch (Farnie and 
Clarke 2007) and Wnt (Yook et al. 2006) that, as already discussed, 
play a role in bCSC maintenance and potentially influence bCSC 
phenotypic conversion via EMT, are also associated with 
chemoresistance (Sajithlal et al. 2010) and radioresistance (Phillips et 
al. 2006; Woodward et al. 2007). Indeed there is direct evidence that 
EMT correlates with therapy resistance. Samples obtained from 
residual cancers (Creighton et al. 2009) or pleural effusions (Yu et al. 
2007a) after therapy were found to have an increased expression of 
mesenchymal EMT markers. A similar effect has been observed in vitro 
where breast cancer cells that underwent EMT were resistant to two 
common chemotherapeutics vincristine and paclitaxel (Li et al. 2009). 
Whether this resistance is a case of selection of CSCs as a result of 
having undergone EMT or if the therapy itself induces an EMT thus 
pushing cells towards a more CSC-like phenotype remains to be 
elucidated.  
 Endocrine therapy under permissive conditions may potentiate the 
conversion of non-stem cancer cells to bCSCs (O'Brien et al. 2011). 
For example, ER-negative basal-like cell lines exhibit an increased CSC 
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subset (Fillmore and Kuperwasser 2008) while endocrine resistance in 
breast cancer cell lines predisposes to a more basal phenotype (Hiscox 
et al. 2006). This is supported by studies of primary breast cancers 
where ER+ve patients receiving aromatase inhibitors acquired 
mesenchymal-like tumour phenotypes with bCSC properties (Creighton 
et al. 2009). Conversely, in a study of 88 ER+ve primary breast cancer 
patients, 86% of the patients had disseminated tumour cells that were 
exclusively ER-ve (Fehm et al. 2008). There is also evidence that 
estrogen receptor signalling directly influences EMT and bCSCs, as the 
EMT modulators snail and slug are directly suppressed by ER signalling 
(Ye et al. 2008).  
 As outlined, there is potential therapeutic benefit in the targeting 
of bCSCs.  Ideally the therapy must target both the tumour bulk and 
the CSCs due to the importance of cellular interactions within the 
microenvironment can result in phenotypic plasticity. Hirsch et al have 
recently demonstrated this concept by combining metformin, a 
diabetes drug that specifically kills CSCs by an unknown mechanism, 
with the chemotherapeutic drug doxorubicin resulted in long-term 
remission of MCF10A-ER-Src xenografts with no relapse up to 60 days 
later. However treatment with doxorubicin alone relapsed only 5 days 
after complete remission (Hirsch et al. 2009). Unfortunately such CSC 
targeted therapeutics may struggle to progress through phase II 
clinical trials given the current guidelines outlined by RECIST 
[response evaluation criteria in solid tumours] for progression to phase 
III (Eisenhauer et al. 2009). Objective response rates are traditionally 
used as the endpoint of phase II trials where tumour regression is 
seen as a predictive measure for prolonged survival. However in many 
cases there is weak correlation between tumour response and overall 
survival (Huff et al. 2006) and this may be due to the inability of such 
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therapies to target CSCs. The pitfalls of this model are clear in the 
circumstance of progressing CSC-specific agents. Whilst such agents 
may not give measurable shrinkage of the tumour itself, the overall 
effect on patient survival may be improved but not observed in the 
short duration of a specified phase II trial. Thus it has been suggested 
that the use of alternative endpoints evaluating CSC content may be 
more suitable for certain agents (Adjei et al. 2009; Huff et al. 2006). 
 
1.1.8.1 Drug resistant models of breast cancer 
 Estrogen receptor positive (ER+ve) breast cancers account for 
up to 75% of all breast cancers diagnosed in the clinic. As such 
endocrine therapies targeting estrogen receptor or circulating estrogen 
have been shown to have much success in treating this cohort of 
patients. As previously stated, their success has been somewhat 
limited due to intrinsic and acquired resistance and tumours that 
initially respond will invariably progress (Musgrove and Sutherland 
2009). To understand the mechanisms behind this resistance several 
groups have now developed anti-estrogen resistant preclinical models 
of the endocrine responsive, ER+ve, MCF-7 cell line (Berstein et al. 
2003; McClelland et al. 2001). Resistant MCF-7 models to two 
commonly used anti-estrogen drugs, tamoxifen (TAMR) and Faslodex 
(FASR), have been developed order to help elucidate resistance 
mechanisms and identify new agents that may prove beneficial in the 
clinical setting. These cell lines were produced by long-term exposure 
of the MCF-7 cell line to the 4-hydroxy forms of both tamoxifen and 
Faslodex (Knowlden et al. 2003; McClelland et al. 2001). These in vitro 
models display a similar phenotype to that observed in patients, 
whereby the cells have an invasive phenotype and elevated EMT-like 
behaviour (Borley et al. 2008; Hiscox et al. 2006; Zhou et al. 2012).  
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 Characterisation of the in vitro TAMR model revealed that they 
retained their ER and had elevated expression of both EGFR and HER2 
when compared to their parental MCF-7 cells (Knowlden et al. 2003). 
As such treatment of the TAMR cells with the tyrosine kinase inhibitor 
gefitinib or trastuzumab resulted in decreased TAMR cell growth 
(Knowlden et al. 2003; Valabrega et al. 2007), supporting 
observations that EGFR/HER2 inhibition can be beneficial in endocrine-
resistant patients in the clinic (Johnston 2008). During the 
development of the FASR cells, long-term exposure of the MCF-7 cells 
to Faslodex resulted in the complete loss of ER whilst still displaying an 
increased level of EGFR signalling (Nicholson et al. 2005). This 
increase in EGFR signalling is not limited to these MCF-7-derived 
models and is supported by studies undertaken by other groups in 
anti-estrogen-resistant models derived from alternative origins (Benz 
et al. 1992; Campbell et al. 2001; Coutts and Murphy 1998; Donovan 
et al. 2001; Kurokawa and Arteaga 2003; Kurokawa et al. 2000; Long 
et al. 1992). Studies have shown that this aberrant EGFR signalling 
drives anti-estrogen-resistant cell growth through the mitogen-
activated protein kinase (MAPK) and phosphotidylinositol 3-kinase 
(PI3K)/Akt signalling pathways. Clinical tissue also exhibits this 
increased EGFR, HER2 and MAPK in sequential samples obtained from 
tamoxifen treated patients, validating the in vitro findings of other 
groups (Gee et al. 2001; Gee et al. 2005). It has been shown that ER 
can be reactivated by increased MAPK phosphorylation in these cells 
contributing to their continued growth in the absence of ER ligands 
(Bunone et al. 1996; Kato et al. 1995). Indeed TAMR cells, in line with 
their clinical counterparts, continue to express ER following the 
acquisition of resistance and appears to be functional, as 
demonstrated by the observation that tamoxifen-resistant cells will still 
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respond to Faslodex (Brunner et al. 1993; Chan et al. 2002; 
Lykkesfeldt et al. 1994; Robertson 1996). The AE Faslodex functions 
by degrading ER and thus FASR cell growth cannot be promoted by 
growth factor driven ER signalling. However, it has been noted that 
FASR cells demonstrate focally increased EGFR expression (Gee et al. 
2004; Nicholson et al. 2005). Further analysis of Faslodex-resistant 
models elucidated a marked increase in the expression, nuclear 
translocation and transcriptional activity of NF-%B, this activity was 
also abrogated by treating these FASR cells with the IKK inhibitor 
parthenolide (Gee et al. 2006). Collectively these studies unveil the 
complex cell signalling that maintains cell growth in endocrine-
resistant cells and identify potential therapeutic targets to overcome 
endocrine-resistant cell growth. 
 
1.2 Mechanisms of apoptosis 
 
 There are two major pathways of apoptosis in mammals, 
namely, the extrinsic pathway that can be triggered through death 
receptors and the intrinsic pathway that is mitochondrial dependent. 
The extrinsic pathway involves stimulation of death receptors such as 
CD95, DR4, DR5 or TNF$ receptor by their respective ligands, which 
then induces receptor oligomerization and recruitment of adaptor 
proteins with death domains. A series of proteolytic cascades involving 
caspases are integral to the apoptotic process. Caspases are cysteine 
proteases which cleave their respective substrates at aspartate 
residues (Vaux and Strasser 1996). They are synthesized as zymogens 
and their activation is dependant on various apoptosis regulators. 
Caspase-8, the initiator caspase of the extrinsic pathway, associates 
with the activated receptor and adaptor proteins forming a death 
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inducing signaling complex (DISC). This is followed by auto-activation 
of caspase-8 which sets off the caspase cascade resulting in the 
activation of the effector caspases (caspase-3, -6 and -7) (Ashkenazi 
and Dixit 1998). Alternatively, the intrinsic pathway is mediated by 
release of cytochrome c from the mitochondrion into the cytoplasm, 
which associates with apoptosis protease activating factor 1 (Apaf-1) 
and caspase-9 to form the ‘apoptosome’. As with the DISC complex in 
the extrinsic pathway, the apoptosome then induces activation of 
caspase-9 and this leads to cleavage and activation of effector 
caspases, the point where both pathways converge (Shi 2002). 
Subsequently, other nucleases (e.g. caspase-activated DNase [CAD]) 
and proteases responsible for the terminal stages of apoptosis are then 
activated by the caspase cascade. Activation of caspase-8 via death 
receptor signalling can also lead to truncation of Bid and mitochondrial 
membrane permeation providing direct crosstalk between death 
receptor signalling and the intrinsic pathway in certain cell types 
(discussed later in 1.3.1.1.2) (Miller 1997). Caspases clearly play an 
important role in the apoptotic process and thus tight control of 
caspase activation is important as over-activation of caspases can lead 
to degenerative diseases whereas over-inhibition can promote 
tumourigenesis (Degterev et al. 2003). 
It is the balance of pro-apoptotic and anti-apoptotic regulators in 
a cell that determines the sensitivity of cells to a particular death 
stimulus. At the death receptor level, pro-survival proteins such as 
cellular FLICE-like inhibitory protein (c-FLIP) antagonize the activation 
of caspase-8, however c-FLIP regulation of caspase-8 activation is 
extremely complex. Similarly, pro- and anti-apoptotic proteins of the 
B-cell lymphoma 2 (Bcl-2) family control mitochondrial permeation. In 
addition, inhibitor of apoptosis proteins (IAPs) can inhibit the effector 
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caspases and caspase-9 through direct binding (Degterev et al. 2003).  
 
1.2.1 Evading apoptosis: A hallmark of cancer cells 
Since the initial observation that decreasing apoptosis in cancer 
cells can contribute to aberrant tissue turnover in tumours, it is now 
widely accepted that the ability to evade apoptosis is a hallmark of 
cancer cells (Hanahan and Weinberg 2000; Kerr et al. 1972). The first 
evidence for a role of anti-apoptotic proteins in tumourigenesis was 
provided through expression of Bcl-2 in haematopoietic cells, where it 
can cooperate with c-Myc to promote neoplastic progression (Vaux et 
al. 1988). From these observations it was proposed that apoptosis 
regulators, which are normally pro-survival, can behave as oncogenes. 
 
1.2.2 Apoptosis as a multistep barrier to metastasis 
During the process of metastasis, there are multiple stages 
where cancer cells are exposed to death-inducing stimuli. The first of 
which is when tumour cells detach from surrounding cells in the 
tumour and/or the extracellular matrix (ECM). In normal mammary 
epithelial cells, following the loss of adhesion, anoikis or cell death is 
induced (Martin and Leder 2001; Streuli and Gilmore 1999). 
Furthermore, tumour cells have been shown to die when they come 
into contact with endothelial cells of vasculature during intravastion 
(Wyckoff et al. 2000). Once in the blood vessels circulating tumour 
cells are then subjected to mechanical stress due to shear forces and 
surveillance by immune cells (Kim et al. 2000; Weiss 1993). When 
metastatic tumour cells arrive at secondary sites they need to adapt to 
a foreign microenvironment and only a small percentage will actually 
result in micro-metastases (Wong et al. 2001). Collectively, these 
stresses suggest that metastasis is a difficult process and the ability to 
prevent apoptosis is imperative for successful formation of metastases. 
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Indeed overexpression of anti-apoptotic Bcl-2 family proteins in 
tumourigenic mammary epithelial cells have been shown to increase 
the metastatic potential, identiying apoptosis as a limiting factor in the 
metastatic cascade (Del Bufalo et al. 1997; Martin et al. 2004; Pinkas 
et al. 2004). These studies were performed using transplants in 
immunocompromised mice, which disregards the early stages of 
metastasis where cells must overcome anoikis and immune 
surveillance. Hence, the development and use of models that are 
capable of recapitulating all stages of metastasis will help provide 
additional insight into the role of apoptosis as a safeguard from 
metastasis and ways of reactivating apoptotic pathways in cancer cells 
(Mehlen and Puisieux 2006). 
 
1.3 Instructive cell death as a putative cancer therapy 
 
1.3.1 The TNF superfamily 
 Members of the tumour necrosis factor (TNF) superfamily of 
cytokines are key extracellular mediators of apoptosis (Ashkenazi 
2002). TNF$, Fas and TRAIL are signalling pathways within the TNF 
superfamily that induce apoptosis in cells. Targeting the TNF$ and Fas 
pathways were originally believed to be desirable for cancer treatment, 
however, clinical use of TNF$ and FasL are severely limited by their 
toxicities (Aggarwal et al. 2006; Ogasawara et al. 1993). On the other 
hand TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis 
in cancer cells but shows almost no toxicity to normal cells and this 
attribute has led to much interest in targeting TRAIL for cancer 
therapy (Ashkenazi et al. 1999). 
1.3.1.1 TNF-related Apoptosis-inducing Ligand (TRAIL) 
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Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) 
or Apoptosis 2 ligand (APO-2L) was first identified due to its sequence 
homology to the extracellular domain of CD95 ligand (FasL) and 
tumour necrosis factor (Pitti et al. 1996; Wiley et al. 1995). TRAIL is a 
member of the TNF superfamily and is expressed in a wide range of 
tissues. The primary function of human TRAIL ligand is inducing 
extrinsic apoptosis in target cells; it performs this function by binding 
to its cognitive receptors found on the cell surface. As a naturally 
occurring ligand within the body, endogenous TRAIL is expressed on 
natural killer cells, macrophages, T-cells and dendritic cells and is 
believed to have an immune defense function destroying virus-infected 
and malignant cells (Duiker et al. 2006). Recently TRAIL has attracted 
much interest as one of the most promising anti-cancer molecules, 
despite being a membrane-bound ligand its extracellular region can be 
cleaved to produce a soluble recombinant form (Mariani et al. 1997). 
Furthermore, monoclonal antibodies (mAbs) directed against TRAIL 
agonistic receptors are currently being developed and investigated for 
their anti-tumour activity (Ashkenazi et al. 1999; Camidge et al. 2007; 
Kelley and Ashkenazi 2004). 
 
1.3.1.1.1 TRAIL structure and signalling 
Like other TNF cytokines TRAIL is a soluble homotrimeric 
molecule produced when the c terminus of the expressed type II 
transmembrane TRAIL protein is proteolytically processed. These 
homotrimers of TRAIL signal by cross-linking receptor molecules on 
the cell surface (Pitti et al. 1996). There are up to four surface 
receptors capable of binding TRAIL, two of which result in an induction 
of apoptosis whilst the remaining two, which maintain substantial 
sequence homology in the extracellular domain but lack the functional 
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death domain, serve as decoy receptors resulting in no subsequent 
signal transduction after binding (Ashkenazi 2002). Furthermore, 
TRAIL is also capable of binding to osteoprotegerin (OPG), a secreted 
TNF receptor homologue (Emery et al. 1998). 
 
1.3.1.1.2 TRAIL induction of apoptosis 
 Apoptosis is initiated when TRAIL or agonistic monoclonal 
antibodies (mAbs) bind to DR4 (TRAIL-R1) and DR5 (TRAIL-R2) on the 
cell surface. Binding of homotrimeric TRAIL molecules induces the 
oligomerisation of DR4 or DR5 receptors resulting in homotypic 
interactions between their respective death domains in the carboxy 
terminus of the receptors that subsequently gives the recruitment of 
the adaptor protein Fas-associated death domain (FADD). Death 
effector domains (DED) of FADD then recruit membrane proximal 
caspase-8 and caspase-10. This multi-protein complex, designated the 
death inducing signalling complex (DISC), provides the molecular 
platform for initiator caspase auto-activation and sets off the 
proteolytic cascade of caspase-3, -6 and -7 cleavage and activation 
that follows, ultimately triggering the apoptotic process (Ashkenazi 
and Dixit 1999; Falschlehner et al. 2007).  
Further to the apoptosis induction via the extrinsic pathway, 
TRAIL binding and DISC formation also engages the intrinsic apoptosis 
pathway by activation of Bcl-2 family members. The pro-apoptotic 
protein Bid is cleaved to activate its truncated form tBid, this in turn 
migrates to the mitochondria where it induces Bax and Bak activation 
and translocation to result in pore formation of the outer membrane of 
the mitochondria. Consequently, cytochrome C is released from within 
the mitochondria into the cytosol facilitating the interaction between 
apoptotic protease factor-1 (Apaf-1) and caspase-9 completing the 
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formation of the apoptosome complex and activation of caspase-9. The 
activation of the initiator caspase-9 in the apoptosome culminates in 
the activation of effector caspases and amplifies the apoptotic signal 
induced via the extrinsic pathway (Figure 1.6) (Chen et al. 2000; Gong 
et al. 1999). Although this process of amplification by intrinsic 
apoptosis occurs in all cells it is only required for activation of extrinsic 
apoptosis in type II cells, type I cells are capable of extrinsic apoptosis 
induction without this additional signal (Ozoren and El-Deiry 2002).  
 
 
 
 
 
 
1.3.1.1.3 Non-apoptotic signalling of TRAIL 
Figure 1.5: TRAIL signalling pathway 
TRAIL binds to its cognitive surface receptors DR4 and DR5 that trimerize to initiate 
the formation of the DISC including of FADD, pro-caspase-8 and/or c-FLIP. 
Caspase-8 is activated and initiates a caspase cascade leading to apoptosis. 
Additionally, in type II cells, Bid is truncated activating the intrinsic apoptotic 
pathway. Cytochrome C is released and the apoptosome formed ultimately leading 
to apoptosis. 
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 Classically TNF receptors binding to their respective ligand can 
result in the activation of the downstream NF-%B and MAPK signalling 
pathways having an effect on the subsequent transcription of 
particular genes. In general their signalling plays a role in regulating 
such processes as cell differentiation, survival and proliferation. It has 
been suggested that similar non-apoptotic roles may also exist for 
TRAIL signalling and that TRAIL is capable of activating NF-%B in the 
same manner as TNF (Harper et al. 2011). Here, receptor-interacting 
protein (RIP) is recruited to the TNF receptor complex via the death 
domain where it interacts with NF-%B essential modulator 
(NEMO)/IKK!, thus recruiting I%B kinase $ (IKK$) and IKK#. This 
ultimately leads to the degredation of inhibitors of %B (I%B) by 
phosphorylation allowing NF-%B activation and signalling (Harper et al. 
2001; MacFarlane 2003; Zandi et al. 1997). Additionally it has also 
been shown that in some instances DR4 and DR5 will recruit the 
adaptor molecule TNFR-associated death domain (TRADD) that in 
association with TRAF-2 is capable of activating the mitogen activating 
protein kinase (MAPK) pathway giving c-jun N-terminal kinase (JNK) 
activation (Hu et al. 1999). MAPK also activates extracellular signal-
regulated kinase (ERK) that in turn can have either an anti-apoptotic 
or pro-apoptotic effect depending on the context (Borges et al. 2007; 
Frese et al. 2003; Tran et al. 2001). 
 
1.3.1.1.4 Regulation of TRAIL and TRAIL signalling 
 As the platform for TRAIL signalling, death receptor expression 
can have an effect on determining cell sensitivity or resistance to 
TRAIL (Horak et al. 2005; Jin et al. 2004; Lee et al. 2001). DR4 and 
DR5 can be post-translationally regulated by glycosylation and 
palmitoylation modulating TRAIL signalling. It has been speculated 
  Chapter 1: General Introduction 
L Piggott  Cardiff University 39 
that O-glycosylation enzymes may serve as a useful biomarker in 
determining tumour sensitivity to TRAIL without altering cell response 
to other extrinsic or intrinsic stimuli (Wagner et al. 2007). 
Palmitoylation occurs in DR4, but not DR5, and appears to be 
important in its ability to form trimers in lipid rafts in the absence of 
ligand (Rossin et al. 2009). It is yet to be determined as to whether 
palmitoyl transferases have any direct effect on TRAIL-induced 
apoptosis. This is not the only example of death receptor localisation in 
lipid rafts as an important regulatory mechanism of TRAIL apoptosis 
(Uddin and Al-Kuraya 2011; Xiao et al. 2011; Xu et al. 2011). In one 
particular study it was shown that c-FLIP also mediates DISC 
formation in non-raft fractions of the cell membrane and selective 
knockdown of c-FLIP leads to the redistribution of DISC components to 
lipid rafts giving TRAIL-induced caspase-8-mediated apoptosis (Song 
et al. 2007). Functional death receptors may also be internalised by 
endocytosis and the absence of DR4 on tumour cell surface correlates 
with TRAIL resistance in colon and leukemia cancer cells (Cheng et al. 
2006; Jin et al. 2004). Notably, endocytosis of DR4 and DR5 has also 
been demonstrated to effect breast cancer cell responsiveness to 
TRAIL (Zhang and Zhang 2008).  
 In addition to the functional TRAIL receptors DR4 and DR5, 
there are two decoy receptors DcR1 and DcR2 that lack the functional 
death domain preventing them from recruiting DISC components but 
compete with agonistic death receptors for TRAIL ligand binding 
(Degli-Esposti et al. 1997). Methylation of decoy receptor genes has 
been shown in certain tumour tissues, such as primary breast and lung 
cancers (Shivapurkar et al. 2004; van Noesel et al. 2002). However 
their role in TRAIL resistance remains controversial as DcR expression 
has been observed in primary gastrointestinal, lung and prostate 
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cancers (Aydin et al. 2007; Riccioni et al. 2005; Sheikh et al. 1999). 
Furthermore, there is a fifth TRAIL receptor, osteoprotegerin (OPG), a 
secreted TNF receptor family member that inhibits osteoclastogenesis. 
TRAIL binding to OPG results in no induction of apoptosis as OPG is a 
secreted factor, thus, OPG acts in a smilar fashion to DcRs by 
competing with agonistic death receptors for TRAIL binding. This 
inhibitory effect of OPG was confirmed when overexpression of OPG 
blocked TRAIL-induced apoptosis in Jurkat cells (Emery et al. 1998). 
Indeed OPG has been investigated as a prognostic marker in cancer 
and as such elevated levels of OPG have been correlated with poor 
prognosis (Brown et al. 2001; Ito et al. 2003; Mizutani et al. 2004). 
OPG has been shown to be expressed by tumour cells in a range of 
cancers including breast, prostate and myelomas both in vitro and in 
vivo and it has been suggested that this may contribute to TRAIL 
resistance (Holen et al. 2005; Nyambo et al. 2004; Shipman and 
Croucher 2003). Despite its TRAIL inhibitory effects, OPG has been 
shown to reduce bone metastases in an in vivo breast cancer model 
(Morony et al. 2001). Given the contradictory evidence surrounding 
OPG in malignancy further research must be undertaken before the 
therapeutic benefit of OPG can be determined.  
Transcriptionally, the Myc oncogenic pathway has been shown to 
play a key role in the regulation of TRAIL sensitivity. It has been 
reported that Myc transcriptionally represses c-FLIP allowing caspase-8 
to be activated at the DISC (Ricci et al. 2004). In addition to this c-
FLIP repression, a marked increase in DR5 expression and increased 
coupled caspase-8 activation was also demonstrated (Wang et al. 
2004). Moreover, TRAIL-dependant NF-%B-mediated transcription of 
Mcl-1 and cellular inhibitor of apoptosis protein 2 (cIAP2) genes was 
shown to be regulated by Myc, determining cell sensitivity to TRAIL 
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(Ricci et al. 2007). Targeting regulators of TRAIL signalling has clear 
implications for treatment, wherby altering their regulatory ability can 
have the potential to sensitise previously resistant cells to TRAIL 
treatment. 
 
1.3.1.1.5 TRAIL and cancer 
 TRAIL is a particularly desirable target for cancer treatment as it 
induces apoptosis in cancer cells whilst sparing normal cells (Ashkenazi 
et al. 1999; Walczak et al. 1999). The exact mechanism of normal cell 
resistance to TRAIL is largely unknown, however, it has been shown 
that normal cells overexpress decoy receptors and that this may 
contribute to cell resistance to TRAIL (van Noesel et al. 2002). 
However, it is unlikely that this is the sole regulatory mechanism 
leading to normal cell resistance. Instead, it would seem more likely 
that a combination of intra- and extra-cellular factors act together to 
make normal cells resistant to TRAIL cytotoxicity (MacFarlane 2003). 
Additionally, many types of cancer cells also demonstrate resistance to 
TRAIL, for example only the mesenchymal triple-negative breast 
cancer cell lines respond to TRAIL in vitro (Rahman et al. 2009a). 
Nonetheless, the specificity demonstrated by TRAIL in preclinical 
studies to certain types of cancer has lead to the development of 
proapoptotic receptor agonists that target DR4 and DR5. Recombinant 
human (rh) APO2L/TRAIL is a soluble protein based on the naturally 
existing ligand capable of binding to the extrinsic death receptors DR4 
and DR5. In addition to soluble rhTRAIL, monoclonal antibodies 
directed to activate DR4 and DR5 have also been developed. Many 
phase I safety studies of TRAIL monotherapies in patients with 
advanced solid tumours have now been completed (Camidge 2008; 
Herbst et al. 2006; Hotte et al. 2008; Wakelee et al. 2009). In line 
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with in vitro studies, these agents were well tolerated and in most 
cases did not reach a maximum tolerated dose. Single agent treatment 
of patients with refractory disease has shown modest antitumour 
activity, 3 responses out of 40 treated patients were observed in a 
phase II clinical trial of mapatumumab in follicular non-hodgkins 
lymphoma (NHL) and no responses reported in treatment-refractory 
NSCLC and colorectal cancer (CRC) patients (Greco et al. 2008; 
Trarbach et al. 2010). Results from these early clinical trials suggest 
that the majority of human tumour cells are actually resistant to TRAIL 
therapies (Thorburn et al. 2008), contradicting many observations in 
transformed cell lines. As such, methods of sensitising tumours to 
TRAIL killing are underway. Combination therapies with chemo- and 
radio-therapeutics and targeted agents have provided much more 
promising results in preclinical models (Frew et al. 2008; Jin et al. 
2008; Jin et al. 2007; Keane et al. 1999; Shrader et al. 2007). The 
addition of TRAIL to either single agent cytotoxics (gemcitabine, 
doxorubicin and permetrexed), cytotoxic combinations (FOLFIRI, 
carboplatin/paclitaxel and cisplatin/gemcitabine), targeted agents 
(rituximab, panitumumab, bortezomib and vorinostat) displayed no 
significant increase in normal cell apoptosis in phase I studies and 
ongoing phase II trials of some of these combinations will help 
evaluate their clinical efficacy (Kindler et al. 2012; Leong et al. 2009; 
Mom et al. 2009; Niyazi et al. 2009; Rosevear et al. 2010; Smith et al. 
2007; Soria et al. 2010; Wu et al. 2007). 
 TRAIL also plays a physiological role in tumour 
immunosurveillance suggesting it may act as a natural cancer killer 
(Smyth et al. 2003). It is not expressed on the surface of resting 
peripheral blood T cells but when the T cells are activated, a marked 
increase in expression of TRAIL is observed in the presence of 
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interferon (IFN) (Kayagaki et al. 1999). Furthermore, bone marrow-
derived dendritic cells also express surface TRAIL (Lu et al. 2002). In 
both these instances it was demonstrated that TRAIL contributes to 
tumour cytotoxicity displayed by these cells further supporting a 
natural cancer killer role of TRAIL in the immune system.  
 
1.4 Cellular FLICE-Like Inhibitory Protein (c-FLIP) 
 
Cellular FLICE-Like Inhibitory Protein (c-FLIP) was first identified 
independently by a number of groups in 1997, as a cellular homologue 
to viral FLIPs. A number of c-FLIP mRNA splice variants exist but at 
present only three proteins have been isolated, c-FLIP short (c-FLIPs), 
long (c-FLIPL) and Raji (c-FLIPR). Both cFLIPL and c-FLIPS have been 
implicated as regulating a number of signalling pathways involved in 
cell survival and apoptosis, whereas the functional role of the cFLIPR 
isoform has not been extensively studied and is yet to be uncovered. 
The c-FLIPL and c-FLIPS isoforms have been shown to be 
overexpressed in a number of cancer cells and their downregulation 
using siRNA or non-specific compounds can successfully render 
previously resistant tumours sensitive to treatment with apoptotic 
cytokines and chemotherapy. Further study into this function of c-FLIP 
will help to understand the implications of its specific inhibition. 
Moreover, the study of signalling pathways in which c-FLIP has been 
implicated has the potential to lead to the identification of alternative 
targets for anti-cancer therapy.  
 
1.4.1 c-FLIP structure and function 
The c-FLIP isoforms, especially c-FLIPL, conform structurally to 
the pro-apoptotic caspases -8 and -10 and are also found in close 
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proximity on the genome suggesting they may have evolved from 
gene duplication. c-FLIPL is a 55kDa protein made up of two death 
effector domains (DEDs) and a c-terminal caspase-like domain. The 
caspase-like domain is catalytically inactive as a result of various 
amino acid substitutions, especially the critical cysteine residue found 
in catalytic domain which has been been substituted by a tyrosine 
residue. Cleavage sites at Asp 376 or Asp 198 on c-FLIPL produce the 
proteolytic variant 43kDa (p43c-FLIPL) and 22kDa (p22c-FLIPL) 
proteins respectively. c-FLIPS is a 26kDa isoform which is similar in 
structure to c-FLIPL but lacks the caspase-like domain. c-FLIPR is a 
24kDa protein similar to c-FLIPS but contains a shorter C terminus. All 
three isoforms are capable of interacting with the adaptor protein 
FADD through their DED at the DISC. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Structure of c-FLIP isoforms 
Death effector domains (DED) are conserved across all isoforms of c-FLIP, 
however, the p20 and p10 domains are only present in the c-FLIPL isoform. 
Additionally c-FLIPS has multiple phosphorylation sites not found on other 
isoforms. 
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Although c-FLIP has been implicated in development, cell 
proliferation and drug resistance, the primary function of c-FLIP 
protein is as an apoptosis regulator. The exact mechanism by which c-
FLIP regulates apoptosis still remains controversial, although it does 
seem clear that regulatory roles differ between the distinct isoforms. 
For example, it has been demonstrated that c-FLIPS directly inhibits 
TRAIL-induced DISC formation by interaction with the adaptor 
molecule FADD preventing the activation of caspase-8 (Kataoka et al. 
2000; Safa et al. 2008; Shirley and Micheau 2010). The role of c-FLIPL 
is somewhat more complicated, high expression of this isoform has 
been shown to inhibit Fas-induced caspase-8 activation whilst low 
expression appears to activate caspase-8 and caspase-10 (Boatright et 
al. 2004; Dohrman et al. 2005; Micheau et al. 2002). Some studies 
have established mechanisms by which c-FLIPL regulates caspase-8 
activation. Inducing c-FLIP overexpression in cell lines has been shown 
to more efficiently process caspase-8 to its p41/p43 form with the 
production of p18 being consistently blocked by p43-c-FLIPL, p43-
caspase-8 is then retained at the DISC preventing caspase-8 activation 
(Scaffidi et al. 1999). Additionally, higher levels of c-FLIPL may also 
directly compete with caspase-8 for downstream substrates. In the 
situation where c-FLIPL is expressed at low levels it is suggested that it 
is more efficiently processed into its proteolytically active p43 form 
that can activate procaspase-8. In this instance the heterodimerisation 
of p43-c-FLIP with procaspase-8 can result in a conformational change 
at the active site making the heterodimer enzymatically active with 
almost equal substrate specificity as caspase-8 homodimers (Boatright 
et al. 2004; Yu et al. 2009).  
Meanwhile c-FLIPS has only been demonstrated to be anti-
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apoptotic; not only does it directly prevent caspase-8 activation at the 
DISC by competition but it also inhibits the cleavage of c-FLIPL to the 
p43 form capable of procaspase-8 auto-activation (Kirchhoff et al. 
2000; Krueger et al. 2001). Interestingly, the overexpression of both 
isoforms of c-FLIP has more of an inhibitory effect on FasL and TNF$ 
than either isoform alone in BJAB cells (Krueger et al. 2001). However, 
in the same cells, overexpression of c-FLIPS only demonstrated more 
of an inhibitory effect against the administration of TRAIL. Conversely, 
in Jurkat and melanoma cells c-FLIPL appears to be more effective at 
blocking apoptosis than c-FLIPS (Irmler et al. 1997). Collectively, the 
variable ways in which c-FLIP isoforms regulate apoptosis in different 
cell types suggest that its apoptosis regulatory mechanism is cell-
dependent. 
 
1.4.2 c-FLIP and intracellular signalling pathways 
 In addition to regulating apoptosis, c-FLIP has also been shown 
to interact with a series of intracellular signalling pathways that 
contribute to proliferation, cell survival, motility, carcinogenesis and 
epithelial-mesenchymal transition. Recent studies have shown that c-
FLIP both induces and is regulated by NF-%B, enhancing proliferation 
signals in Jurkat cells (Kataoka et al. 2000). These studies showed that 
increased recruitment of RIP, TRAF1 and TRAF2 to the CD95 DISC 
activates NF-%B and ERK signalling pathways independent of caspase 
signalling (Kataoka et al. 2000). Cleavage of c-FLIPL to p43-c-FLIP 
efficiently recruits TRAF2 and RIP1 to the DISC, leading to NF-%B 
activation (Fang et al. 2004; Kataoka et al. 2000; Kataoka and 
Tschopp 2004). This was shown to occur in a concentration-dependant 
manner, whereby at high levels of c-FLIP the DISC is already occupied 
and c-FLIP activation of NF-%B does not occur (Kreuz et al. 2004). 
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Additionally, the heterodimer formed between c-FLIP and procaspase-8 
produces a NH2-terminal fragment of c-FLIP that binds directly to the 
IKK complex also activating NF-%B (Golks et al. 2006). Further studies 
demonstrated that TNF$ signalling induced proteasomal degradation of 
c-FLIP by c-jun kinase (JNK) activation that in turn increases the 
turnover of NF-%B- induced c-FLIP. Phosphorylation of JNK activates E3 
ubiquitin ligase Itch (ITCH) which specifically ubiquitinates c-FLIP 
leading to its degradation, thus antagonising NF-%B (Chang et al. 
2006). In contrast, c-FLIPL inhibits the activation of NF-%B and the 
degradation of IKappa B alpha (I%B$) by TRAIL in human 
keratinocytes, resulting in a significant decrease in proinflammatory 
cytokine IL-8. In this instance, NF-%B inhibition by c-FLIP was TRAIL-
specific as treatment with TNF$ resulted in NF-%B activation regardless 
of c-FLIP levels (Wachter et al. 2004). Not only does c-FLIP regulate 
NF-%B but NF-%B is also a key regulator of c-FLIP expression (Kreuz et 
al. 2001; Micheau et al. 2001). Studies showed that activation of NF-
%B results in upregulation of c-FLIP increasing resistance to Fas ligand 
(FasL) and TNF, whilst also showing that preventing NF-%B activation, 
by blocking TNF signalling or mutating Ikappa B/removing IKappa B 
kinase gamma expression, prevented c-FLIP mRNA upregulation in 
Jurkat cells (Kreuz et al. 2001). These conflicting results demonstrate 
both pro- and anti-apoptotic functions in the relationship between c-
FLIP and NF-%B and further investigation into this complex relationship 
may help identify novel methods to regulate both molecules.  
 The serine-threonine kinase Akt is an important transducer of 
cell survival signals and regulator of proteins involved in apoptosis 
signaling. A recent study has shown that Akt interacts with c-FLIPL 
through its caspase-like domain and that c-FLIPL modulates Gsk3#, 
enhancing the anti-apoptotic function of Akt (Quintavalle et al. 2010). 
  Chapter 1: General Introduction 
L Piggott  Cardiff University 48 
In this study it was also elucidated that c-FLIPL modulation of Gsk3# 
induced cancer cell resistance to TRAIL (Quintavalle et al. 2010). 
Similarly, inhibition of DNA-PK, decreasing Akt and Bad 
phosphorylation, resulted in increased sensitivity to TRAIL (Kim et al. 
2009). Here an increased expression of both TRAIL death receptors 
DR4 and DR5 was observed together with a decrease in c-FLIP 
expression, providing further evidence of an Akt/c-FLIP relationship. 
Further links between Akt and c-FLIP have been made where Akt 
signals lead to c-FLIP ubiquitination and degradation sensitizing 
glioblastoma cells to TRAIL. Atrophin-interacting protein 4 (AIP4) and 
ubiquitin-specific protein 8 (USP8) are both downstream targets of Akt 
and both also regulate the ubiquitination of c-FLIP (Panner et al. 2010; 
Panner et al. 2009).  
 Another regulator of c-FLIP ubiquitination is itchy E3 ligase 
(ITCH). $-tocopherol ether linked acetic acid analogue ($-TEA) induces 
ER stress-dependant activation of c-jun kinase (JNK) activating ITCH-
dependant ubiquitination, and subsequent degradation, of c-FLIP 
giving effective sensitisation of breast cancer cells to TRAIL (Tiwary et 
al. 2010; Yu et al. 2010b). A study performed on liver cells added 
further evidence of c-FLIP regulation by JNK. In this study TNF$ 
signalling increased JNK activation and ITCH-dependant degradation of 
c-FLIP (Chang et al. 2006). Furthermore, it was noted that 
chemotherapeutic treatment of target cells results in the 
downregulation of c-FLIP (Sanchez-Perez et al. 2009; Stagni et al. 
2010). This reduction was shown to be a result of increased 
proteasomal degradation that could be inhibited by the proteasome 
inhibitor MG-132. It was also revealed that chemotherapy treated 
breast cancer cells had sustained JNK phosphorylation, inhibition of 
which using SP600125 reversed c-FLIPL degradation and reduced 
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apoptosis (Sanchez-Perez et al. 2009). Interestingly, the relationship 
between c-FLIP and JNK has also been shown to work vice versa. c-
FLIPL can directly interact with MAP kinase activator 7 (MKK7), a JNK 
activator, in a TNF$-dependant manner inhibiting MKK7 interactions 
with MAP/ERK kinase kinase 1 (MEKK1) suggesting that c-FLIPL may 
also selectively repress JNK activation (Nakajima et al. 2006).  
 A number of studies have provided evidence that c-FLIP also 
functions within the classical Wnt signalling pathway. Wnt signalling 
mediates proliferation, differentiation and stem cell characteristics 
(Sethi and Vidal-Puig 2010). In brief, the binding of Wnts to frizzled 
receptors on the cell surface recruits Axin and leads to the dissociation 
of the degradation complex. This degredation complex is normally 
made up of Axin, adenomatous polyposis coli (APC) and glycogen 
synthase kinase-3 (GSK3) and degrades #-catenin. The dissociation of 
the degradation complex by Wnt binding prevents the degradation of 
#-catenin leading to its accumulation in the cytosol. The accumulation 
of #-catenin in the cytosol is then followed by its translocation to the 
nucleus where it activates a number of transcription factors (Sethi and 
Vidal-Puig 2010). The Wnt pathway was found to be significantly 
activated, following Wnt3a stimulation, in cell lines overexpressing c-
FLIPL but not in those overexpressing c-FLIPS or with wild-type c-FLIP 
(Naito et al. 2004). This elevated Wnt signalling was shown to be a 
result of c-FLIP increasing #-catenin ubiquitination (Naito et al. 2004). 
Later studies then revealed that c-FLIP itself accumulates and 
aggregates in the cells and disrupts the ubiquitin-proteasome system 
(Ishioka et al. 2007). Additional studies also unveiled a potential role 
for c-FLIPL in nuclear translocation of #-catenin. Potential nuclear 
localisation and nuclear exportation signals were identified at the c-
terminal of c-FLIP protein (Katayama et al. 2010). Mutating these 
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signals prevented this translocation and resulted in the localisation of 
c-FLIP solely in the cytoplasm or nucleus dependant on the mutant 
form. Interestingly, abrogating this translocation had no significant 
effect on extrinsic signalling but did prevent the enhanced Wnt 
signalling by Wnt3a previously observed. The accumulation of #-
catenin was also completely abolished in the localisation mutants, 
collectively suggesting that c-FLIP may have a function as a co-
transporter of #-catenin (Katayama et al. 2010). In the same manner, 
suppression of c-FLIPL in A459 cells was associated with decreased 
Wnt signalling (Naito et al. 2004).  
 Collectively, all these studies clearly demonstrate that c-FLIP 
does not solely function as an extrinsic anti-apoptosis factor but is also 
a regulator of many different intracellular signalling pathways that may 
effect cell proliferation, differentiation and function. 
 
1.4.3 c-FLIP and cancer 
 Expression of c-FLIP variants decreases apoptosis induced by 
death ligands and anticancer agents, thus their overexpression in 
cancer cells may cause resistance to anticancer drugs (Safa et al. 
2008). As a result, drugs targeting c-FLIP are very desirable as not 
only do they have the potential capability of inducing cell death but 
can also lower the threshold of cancer cell apoptosis, allowing a 
reduction in subsequent drug doses, decreasing systemic toxicities of 
agents such as chemotherapeutics. In its own right, reduction of c-
FLIP has been demonstrated to induce cell death without the need of 
combination therapy. Injection of liposomal c-FLIP-specific siRNA into 
MCF-7 xenografts destroyed neoplastic cells whilst having no effect on 
the normal stromal and fibroblastic cells (Day et al. 2009). This in vivo 
observation was consistent with the in vitro results seen in a previous 
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study, siRNA knockdown of c-FLIP induced a DR5, FADD, caspase-8 
and caspase-9 dependant cell death in MCF-7 cells (Day et al. 2008). 
Similar results have also been observed in lung (Sharp et al. 2005), 
colorectal (Wilson et al. 2007) and prostate (Zhang et al. 2004) cancer 
cells. Transient transfection experiments using a c-FLIP targeted 
antisense phosphorothioate oligonucleotide (AS PTO) demonstrated 
significant caspase-8 activation and apoptosis following the 
downregulation of c-FLIP (Logan et al. 2010). This effect was observed 
in non-small cell lung carcinoma (NSCLC), colorectal and prostate 
cancer cells but not normal cells. Similarly, this method of c-FLIP 
interference sensitised NSCLC cells to both TRAIL and chemotherapy 
(Logan et al. 2010). The in vivo results seen from these RNAi-based 
therapeutic interventions of c-FLIP warrant further preclinical 
development, however, siRNA design, delivery and stability are still 
difficulties that must be overcome before RNAi-based therapies are 
truly feasible as a clinical intervention.  
 Besides inhibiting c-FLIP proteins directly, alternative methods, 
including degradation and transcriptional regulation of c-FLIP, may 
also have potential for c-FLIP intervention. As previously discussed, 
chemotherapeutic agents have been demonstrated to reduce c-FLIP 
expression in multitude of cancer cells (Chatterjee et al. 2001; El-
Zawahry et al. 2005; Kinoshita et al. 2000; Logan et al. 2010; Longley 
et al. 2006). In many of these studies, cancer cell pre-treatment with 
chemotherapy has proven to be a successful method of sensitisation to 
extrinsic cell death ligands. Histone deacetylase inhibitors are another 
set of compounds that have displayed similar properties of malignant 
cell growth inhibition and sensitisation to further therapy (Bangert et 
al. 2012; Seo et al. 2011; Yerbes and Lopez-Rivas 2010). Specifically, 
the HDACi, suberoylanilide hydroxamic acid (SAHA, vorinostat), has 
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been demonstrated on numerous occasions to inhibit c-FLIP proteins 
(Bijangi-Vishehsaraei et al. 2010; Carlisi et al. 2009; Ellis and Pili 
2010; Shankar et al. 2009; Yerbes and Lopez-Rivas 2010). The use of 
HDACis that suppress c-FLIP in combination with extrinsic death 
ligands have also proven to be successful sensitisers in different types 
of cancer, in fact, SAHA or droxinostat treatment successfully 
sensitised previously resistant breast cancer cells to TRAIL (Bijangi-
Vishehsaraei et al. 2010; Shankar et al. 2009). One particular study 
identified degradation of c-FLIP isoforms by ubiquitination following 
SAHA treatment, although this degradation was found to be 
independent of ITCH/AIP4 (Yerbes and Lopez-Rivas 2010). Other 
agents also lead to the degradation of c-FLIP and several of these 
agents successfully act as sensitisers to TRAIL and other extrinsic 
apoptosis death signals (Jeon et al. 2005; Olsson et al. 2001; Perez et 
al. 2010; Sayers et al. 2003; Schimmer et al. 2006; Seki et al. 2010; 
Shanker et al. 2008; Tiwary et al. 2010; Tobinai 2007).  
Clearly this evidence makes c-FLIP an ideal target for disruption 
using small molecule inhibitors. Unfortunately, to date there has not 
been a c-FLIP specific inhibitor developed since it has such significant 
structural similarity to caspase-8. Due to this structural similarity, 
small molecules that inhibit c-FLIP may also hinder caspase-8 function 
too, providing no apoptotic benefit. Specific drug design to c-FLIP is an 
ongoing area of research both for individual and combined therapy of 
many different types of cancer.  
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1.5 T Cell immunity and the surveillance of cancer 
 
 T cells are immune cells that move through tissues in search for 
their corresponding major histone compatibility complex (MHC)-
peptides that specifically activate their cell surface T cell receptors 
(TCRs). Typically these TCRs are made up of variable $ and # protein 
chain heterodimers (~95%) expressed as part of a complex with the 
invariant CD3 chain molecules (Janeway and Bottomly 1994). $# T 
cells respond to a variety of different signals that alert them to 
threatening pathogens and cancer. $# T cells are activated at tumour 
cells by tumour-associated antigens presented by antigen presenting 
cells (APCs) and dendritic cells (DCs). However, once $# T cells are 
activated they are capable of directly recognising these tumour 
antigens themselves. Further evidence of T cell recognition of tumours 
is demonstrated by the isolation of tumour-infiltrating lymphocytes, 
whereby tumours are commonly enriched for T cells, that can then be 
isolated, specific for the tumour in which they are found (Ahmadzadeh 
et al. 2009). Unfortunately, neoplastic cells are particularly difficult to 
recognise for many T cells as they frequently downregulate their MHC 
molecules helping tumour cells evade classical T cell-dependant 
immune responses (Bubenik 2004; Restifo et al. 1996). This led to 
much interest in a small subset of T cells that are not MHC-restricted, 
the !" T cells. 
 
1.5.1 !" T cells  
!" T cells are a small subset of cells that account for 
approximately 1-5% of circulating T cells in the blood. The V!9V"2 T 
cells account for up to 90% of the !" T cell population and herein is the 
specific gene pair that will be referred to in the generalised term ‘!" T 
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cells’ (Hayday 2000). Although the effector functions of both !" T cells 
and $# T cells are extremely similar to each other, producing the 
various cytokines such as TNF$ and IFN!, the immune system has 
maintained these two separate types of TCR as they seem to recognise 
different ligands, thus providing additional immunosurveillance (Girardi 
et al. 2001; Hayday 2000). Additionally, selective recognition of 
bacterial metabolites and viral antigens by !" T cells identifies a non-
redundant role for !" T cells. !" T cells are unique in that they are not 
MHC-restricted and show low dependence on co-stimulation and, in 
line with this, lack expression of CD4 and CD8 (Hayday 2000).  
 
1.5.1.1 !" T cell activation 
 Early studies showed that !" T cells are activated by a range of 
bacteria and parasites (Hayday 2000) by non-peptidic phosphorylated 
intermediates (phosphoantigens) of the non-mevalonate pathway of 
bacterial isoprenoid biosynthesis (Viey et al. 2005). In contrast, 
eukaryotic cells use the mevalonate pathway for isoprenoid 
biosynthesis producing isopentenyl pyrophosphate (IPP), which has 
also been suggested to activate !" T cells. However, non-transformed 
cells are incapable of producing high enough concentrations of IPP to 
be recognised by !" T cells, whereas some tumour cells are (Girardi et 
al. 2001; Gober et al. 2003). There is now substantial evidence that 
this class of compounds contains multiple members and the natural 
phosphoantigen with the highest bioactivity is (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMB-PP), an intermediate of the 2-
C-methyl-D-erythritol (MEP) pathway utilised by eubacteria and 
protozoa but not eukaryotes (Thedrez et al. 2007). HMB-PP also has 
the ability to induce the formation of high-density TCR nanoclusters on 
!" T cell surface further increasing the activation properties of HMB-PP 
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stimulation (Chen et al. 2008). Aminobisphosphonates (NBPs) can 
alter intracellular levels of IPP by inhibiting the IPP-processing enzyme 
farnesyl pyrophosphate synthase leading to IPP accumulation that in 
turn activates !" T cells, inducing them to differentiate toward a more 
IFN! producing effector memory phenotype (Bonneville and Scotet 
2006; Dieli et al. 2007; Eberl et al. 2002; Gober et al. 2003; 
Kunzmann et al. 2000). Due to their apoptosis-inducing properties in 
osteoclasts, NBPs such as zoledronate and ibandronate have been 
clinically developed and approved for therapeutic treatment of 
osteoporosis and bone metastasis (Body et al. 2003; Costa 2007).  
 
1.5.1.2 !" t cells and cancer 
 !" T cells have been consistently isolated from TILs in a number 
of different cancers including colorectal, breast, ovarian, and renal cell 
carcinoma (Corvaisier et al. 2005; Groh et al. 1999; Viey et al. 2005; 
Xu et al. 2007). Isolating !" T cell lines from these TILs display potent 
antitumour activity not only to their autologous tumour but also to 
closely related tumour cells. Importantly these !" T cells maintain a 
tumour specificity and exhibit almost no effect on non-transformed 
cells (Corvaisier et al. 2005; Viey et al. 2005). Subsequently, the 
therapeutic potential of !" T cells was explored in a variety of cancers 
using different activating compounds in an array of in vitro and in vivo 
models (Correia et al. 2009; Naoe et al. 2010). HMB-PP in combination 
with IL-2 activation of !" T cells was shown to induce MEK/ERK and PI-
3K/Akt-dependant anti-tumour properties in leukaemia cells (Correia 
et al. 2009). Further investigation into the in vivo activation and 
cytotoxicity of !" T cells stimulated by HMB-PP will help support its 
transition into clinical application. The use of NBPs to activate !" T cells 
has clear advantages over other methods due to the inherent anti-
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tumour effects of zoledronate as a monotherapy, whereby metastasis 
and tumour cell invasion can be reduced and cell death increased in 
tumour cells, most notably, breast cancer cells (Body et al. 2003; 
Boissier et al. 2000; Boissier et al. 1997; Lowe et al. 2005; van der 
Pluijm et al. 1996; Verdijk et al. 2007). Furthermore, combining 
zoledronate with the frequently used endocrine therapies in 
premenopausal women significantly increased disease-free survival of 
patients compared to placebo (Gnant et al. 2009). These anti-cancer 
properties of zoledronate together with the fact that zoledronate is 
already approved for clinical use meant it attracted much attention to 
determine any additional benefits that can be exploited as an activator 
of !" T cells. Preclinical models of various cancers showed that in vivo 
and ex vivo zoledronate activated !" T cells show potent tumour cell 
cytotoxicity (Beck et al. 2010; Kondo et al. 2008; Meraviglia et al. 
2010; Saitoh et al. 2008; Siegers et al. 2011). Furthermore, the use of 
zoledronate has now been extended to clinically activate and expand !" 
T cells ex vivo for adoptive transfer therapy in some forms of cancer 
(Bennouna et al. 2008; Dieli et al. 2007; Kobayashi et al. 2011; 
Kunzmann et al. 2000; Nicol et al. 2011). Further investigation of 
zoledronate’s potential as a !" T cell activator and anti-cancer agent in 
breast cancer is currently ongoing and elucidating the mechanisms of 
cell death induced by activated !" T cells may help to identify further 
cooperative treatments for clinical translation.  
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1.6 Aims of this study 
  
Research has identified that there are specific cohorts of patients 
that require novel therapeutic intervention techniques. Those 
diagnosed with later stage disease and those that have become 
resistant to existing therapies, with the prevention of metastasis the 
key to controlling disease progression in these patients. With this in 
mind, using cell lines as in vitro and in vivo models that represent the 
heterogeneic nature of breast cancers, the aims of this study were to: 
  
1) Determine if TRAIL has potential as a treatment for breast 
cancer  
 
2) Assess the extent of any treatment that proves successful on 
the inter- and intra-tumour heterogeneity that exists 
between breast cancers 
 
3) Uncover alternative delivery methods of TRAIL to breast 
tumours.  
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2.1 Animal experiments 
 
All procedures involving the use of animals were carried out 
according to the institutional guidelines in compliance with UK Home 
Office Regulations (Animals [scientific procedures] Act 1986) 
 
2.1.1 Animals 
The generation of c-FLIP transgenic mice has been previously 
described (Zhang and He 2005). These animals were obtained from 
the Zhang lab (Duke University, NC, US) and crossed with mice 
expressing Cre under the control of #-lactoglobulin milk gene (BLG-
cre) (Selbert, Bentley et al., 1998) on a BL6 background. These 
animals were then in-bred creating the cohorts of mice BLG-cre/c-
FLIPfl/fl, BLG-cre/c-FLIPfl/+, BLG-cre/c-FLIPWT. 
For immunocomprised animal transplantation experiments 
Balbc/SCID mice were obtained from Charles River Laboratories 
(Wilmington, US) or Athymic Nude (Hsd:Athymic Nude-Foxn1nu) mice 
were obtained from Harlan Laboratories (Indianapolis, US). Animals 
were acquired at six to eight weeks of age and maintained in 
individually ventilated cages (Allentown Inc. NJ, US) with a 12hr 
day/night cycle. Mice received a Teklad global 19% protein extruded 
rodent diet (Harlan Laboratories) and water ad libitum. All food, drink, 
saw dust and water bottles were sterilised by autoclaving prior to use. 
All procedures and animal husbandry was performed within a laminar 
flow hood (Allentown). 
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2.1.2 Genotyping 
All animals were genotyped using polymerase chain reaction 
(PCR) using DNA extracted from tail or ear biopsies after weaning at 4 
weeks of age. 
 
2.1.2.1 DNA extraction 
Prior to DNA isolation ear and tail biopsies obtained were stored 
in 1.5ml eppendorf tubes at -20oC. DNA was then extracted by the 
addition of 0.5ml lysis buffer (100mM Tris-HCl; pH8.5 [Sigma], 5mM 
EDTA [Fisher Scientific], 0.2% w/v sodium dodecyl sulphate [SDS; 
Sigma], 200mM sodium chloride [Fisher Scientific] and 5µl proteinase 
K [Roche]) to each biopsy and incubated overnight at 55oC. Samples 
were mixed thoroughly and centrifuged at 13,000rpm for 10 minutes. 
Supernatants were transferred to a clean eppendorf containg 0.5ml of 
isopropanol (Fisher Scientific) and left for 5 minutes to allow DNA to 
precipitate. Samples were centrifuged for 5 minutes to pellet the DNA 
that was subsequently washed in 70% ethanol (Fisher Scientific) and 
then dried at 55oC before being re-suspended in 100µl of RNAse and 
DNAse free H2O at 55oC for 1 hour. This DNA was then used for the 
PCR protocols outlined in Table 2.2 
 
2.1.2.2 Generic PCR protocol 
Primers were purchased from Sigma-Genosys and were either 
designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) or 
using previously published sequences (Table 2.3). In silico PCR was 
then used to verify all sequences checking for any mis-priming 
(http://genome.csdb.cn/cgi-bin/hgPcr). 
In general, 2µl of DNA extract or DNAse/RNAse free water 
(Sigma) were loaded into 0.2ml PCR 8-strip tubes (StarLabs) and 23µl 
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of PCR mastermix, as described in Table 2.1 added to each reaction. 
Gentle pipetting homogeneously mixed the reactions and the tubes 
sealed using 8-strip PCR caps (StarLabs). Tubes were briefly spun in a 
Technico Mini Centrifuge (Technico) prior to being run in an iCycler 
PCR machine (BioRad) according to the cycling programs detailed in 
Table 2.2. 
 
2.1.2.3 Gel electrophoresis 
After completion of the PCR reactions, DNA products were 
visualised by gel electrophoresis. An appropriate DNA marker (e.g. 
EasyLadder 1 [Bioline]) and all samples were loaded onto a 3% 
agarose gel (made by dissolving 0.5g agarose tablets in 1x Tris-
Borate-EDTA [TBE] Buffer [Sigma] containing 0.006% [v/v] SafeView 
Nucleic Acid Stain [NBS Biologicals]). Gels were run in 1x TBE buffer at 
150V for 20 minutes and PCR products visualised under UV-light using 
a GelDoc trans-illuminator (BioRad). 
 
 
 
 
PCR Reaction component FLIP/Flox BLG-Cre 
Crude DNA 
PCR-grade Water (Sigma) 
GoTaq Buffer (Promega) 
Magnesium Chloride (25mM; Promega) 
dNTPs (25mM; dATP, dCTP, dGTP, dTTP) 
Forward Primer (Sigma Genosys, 100µM) 
Reverse Primer (Sigma Genosys, 100µM) 
GoTaq DNA Polymerase (Promega) 
Final Volume 
2µl 
15µl 
5µl 
2µl 
0.4µl 
0.1µl 
0.1µl 
0.5µl 
25µl 
2µl 
32.2µl 
10µl 
5µl 
0.4µl 
0.1µl 
0.1µl 
0.2µl 
50µl 
Table 2.1: PCR reaction components 
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2.1.3 Experimental procedures involving animals 
 
2.1.3.1 Orthotopic cell transplants 
Prior to transplantation, cells were prepared as single cell 
suspensions. Cells were washed in serum-free L-15 media (Invitrogen, 
Paisley, UK), then serum-free Joklik’s media before another wash in 
serum-free L-15. Cells were then passed through a 40um cell strainer 
(BD Biosciences, Oxford, UK) and kept on ice until transplantation. For 
BT474 and MDA-MB-231 cell transplants, 8-12 week old Athymic Nude 
and NOD/SCID/Balbc mice were used respectively. Before surgery, 
mice were anaesthetized using a vaporizer to deliver 5% isoflurane 
(Abbot, Maidenhead, UK) with oxygen at a flow rate of 0.8 l/min and 
nitrous oxide at a flow rate of 0.4l/min in an induction chamber. 
Isofluorane was subsequently delivered at 2.5% through an 
anaesthetic mask to maintain the animal unconscious throughout 
surgical procedures. Consequently, a small patch of fur that is dorsal 
to the fourth abdominal mammary gland was removed and cleaned 
with Betadine (povidone-iodine) surgical scrub. Then, a small 
superficial incision was made to expose the abdominal mammary gland 
and cells were injected directly into the mammary fat pad with a 
Hamilton or insulin needle syringe (BD Micro-Fine). The lymph nodes 
in the fourth abdominal gland were used to orientate the point of 
injections, where cells were transplanted dorsal to the lymph nodes. 
Wounds were then sealed with Vetbond Tissue Adhesive (3M). Animals 
were then allowed to recover in a temperature regulated chamber at 
30oC for 15 minutes. 
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2.1.3.2 Tumour monitoring and measurements 
Mice transplanted orthotopically with breast cancer cells were 
inspected at least twice weekly for tumours via palpation. The growth 
kinetics of tumours were documented by measuring the diameter of 
tumours using digital calipers (Fisher Scientific, Loughborough, UK). 
The size of tumours were calculated as volume in mm3 using the 
formula; Volume = (Length X [Width x 2])/2. 
 
2.2 Tissue sampling and processing 
 
2.2.1 Removal and fixation of tissues 
At appropriate experimental endpoints, animals were culled by 
cervical dislocation prior to necropsy. 
 
2.2.1.1 Mammary tissues for gestational studies 
Animals used for gestational studies were mated and animals 
sacrificed midway through gestation. Before extraction of mammary 
tissues, the lymph nodes in the fourth inguinal glands were excised 
and discarded. The left abdominal gland was then removed and fixed 
in 4% formalin for histological analysis. For protein and RNA analysis, 
the remaining abdominal and inguinal glands were snap frozen and 
stored at -80oC. 
 
2.2.1.2 Tissues for tumour studies 
Mice bearing tumours were excised when reaching their defined 
scientific endpoint (often either due to reaching maximal tumour size 
of 4000mm3 or showing signs of morbidity). Upon necropsy, the left 
abdominal mammary gland, liver, lung and a portion of tumour from 
experimental mice were fixed in 4% formalin for histological analysis. 
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The remainder of tumour and normal mammary gland tissues were 
snap frozen in liquid nitrogen and stored at -80oC until required for 
molecular analysis.  
 
2.2.2 Tissue processing and sectioning for histology 
After fixing tissues in 4% formaldehyde for 4-8 hours, tissue 
processing and sectioning was carried out by the Histology Unit in 
Cardiff School of Biosciences. 
 
2.2.2.1 Dehydration of tissues 
Paraffin emdedded sections were prepared by the School of 
Biosciences Histology Unit. With the aid of a Leica TP1050 automatic 
processor in the Histology Unit, tissues were dehydrated in a series of 
solvents; 70% ethanol for 1 hour, 95% ethanol for 1 hour, 100% 
ethanol for 1.5 hours twice, 100% ethanol for 2 hours, xylene for 1 
hour twice and paraffin for 2 hours twice. Following that, tissues were 
embedded in paraffin wax for sectioning into 5µm thick slices with the 
aid of a Leica RM2135 microtome cutter. Tissue sections were then 
immobilized onto poly-L-lysine (PLL) coated slides (Thermo Fisher, 
Loughborough, UK) and heated at 58oC for 24 hours. Slides were then 
stained with H&E or used for immunohistochemistry (IHC). 
 
2.3 Histological analysis of tissue sections 
 
2.3.1 Dewaxing and rehydration 
Paraffin was removed and tissues were rehydrated by incubating 
slides in a series of solvents; 100% ethanol for 2 minutes twice, 95% 
ethanol for 2 minutes, 70% ethanol for 2 minutes and a rinse in 
distilled water. 
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2.3.2 Haematoxylin and eosin (H&E) staining 
Slides were stained with H&E after dewaxing and rehydration. 
Initially by staining in Meyer’s Haemalum (Thermo Fisher, 
Loughborough, UK) for 5 minutes, followed by a wash under running 
tap water for 5 minutes. Subsequently, slides were counterstained in 
1% aqueous Eosin (Thermo Fisher, Loughborough, UK) for 5 minutes 
before being washed twice for 15 seconds with tap water. Finally, 
slides were dehydrated, cleared and mounted as described in section 
2.3.3.4. 
 
2.3.3 Visualisation and quantification of H&E stained sections 
 Visualisation and quantification of all histological sections were 
carried out using an Olympus BX41 Light Microscope (Olympus). All 
digital photos taken of sections were done so using a Colorview III (5 
megapixel, Soft Imaging Systems) camera using Analysis software 
package (Version 3.2, build 831, Soft Imaging Systems) 
 
2.3.3.1 Analysis of lung metastases 
 Photos were taken of all visible lung metastases and the average 
area of these metastases calculated using measurements taken by 
Image J software. 
 
2.4 Cell culture maintenance and procedures 
 
2.4.1 Experimental cell lines 
The human MDA-MB-231, MCF-7, SKBR3, XL, TAMR and FASR 
cell lines used in this study were a gift from Dr. Julia Gee (Breast 
Cancer Molecular Pharmacology (BCMP) group, Dept. of Pharmacy, 
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Cardiff University). The human BT474 cell line was purchased from 
ATCC (http://www.atcc.org). The human MDA-MB-231-luc-D3H2LN 
cell line was purchased from Caliper Life Siences (Hopkinton, MA, US). 
The mouse 4T1 cell line (Aslakson and Miller 1992) was obtained from 
Dr. Robin Anderson (University of Melbourne). Mouse N202.1A cells 
were a kind gift from Dr. Pier-Luigi Lollini (Sezione di Cancerologia, 
Italy). The EPH4 cell line was obtained from Dr. Christine Watson 
(Cambridge University). The MCF10A cell line was a kind gift from Dr. 
Hiscox of the BCMP group, Dep. Pharmacology, Cardiff University. 
 
2.4.1.1 MDA-MB-231 
 MDA-MB-231 is a highly metastatic, human basal epithelial cell 
line isolated from the pleural effusion of an adenocarcinoma. These 
cells are ‘triple negative’ as they lack oestrogen, progesterone and 
HER2 receptors (Neve, Chin et al., 2006) whereas they strongly over-
express EGFR. 
 
2.4.1.2 MCF-7 
The MCF-7 is an oestrogen dependant, poorly metastatic, human 
luminal epithelial cell line isolated from the pleural effusion of an 
adenocarcinoma. These cells are oestrogen and progesterone receptor 
positive but do not over-express HER2 receptor (Neve, Chin et al., 
2006) 
 
2.4.1.3 SKBR3 
 SKBR3 is a poorly metastatic human luminal epithelial cell line 
derived from a pleural effusion of an adenocarcinoma. These cells are 
oestrogen and progesterone receptor negative but over-express the 
HER2 receptor and have low levels of EGFR expression (Neve, Chin et 
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al., 2006) 
 
2.4.1.4 XL, TAMR, FASR 
 The XL, TAMR and FASR cell lines are sub-clone derivatives of 
the MCF-7 cell line. The XL cell line was cultured long-term in the 
absence of any estrogen or steroid such that the cells no longer 
require these for maintenance. The TAMR and FASR cell lines are 
acquired endocrine therapy resistant models of the MCF-7 cell line to 
tamoxifen and Faslodex respectively. Whilst TAMR cell lines retain their 
estrogen receptors the FASR cell line is completely estrogen receptor 
negative in culture. 
 
2.4.1.5 MDA-MB-231-luc-D3H2LN 
 The MDA-MB-231-luc-D3H2LN cell line was derived from the 
parental MDA-MB-231 cell line and isolated from a spontaneous lymph 
node metastasis of orthotopically mammary transplanted MDA-MB-
231-luc-D3H1 cell line. The D3H2LN cell line shows enhanced tumour 
take and metastatic potential by comparison to it’s parental lines. 
 
2.4.1.6 EPH4 
 The EPH4 cell line is a spontaneously immortalized non-
transformed murine mammary epithelial cell line. 
 
2.4.1.7 N202.1A 
 N202.1A is a murine tumour cell line isolated and immortalized 
from tumour driven by MMTV/Neu transgene on an FvB background 
that over-express the ErbB2 oncogene (Nanni et al., 2000) 
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2.4.1.8 4T1 
 The 4T1 cell line is an aggressive metastatic murine cell line 
isolated and immortalized from a spontaneous tumour arising in a 
wild-type Balb/c mouse. 
 
2.4.1.9 MCF10A 
 The MCF10A cell line is a human luminal epithelial non-
transformed, non-tumourigenic cell line isolated and immortalized from 
fibrocystic breast tissue.  
 
2.4.2 Maintenance of cell lines 
The 4T1, MCF-7, BT474, MDA-MB-231, MDA-MB-231-luc-
D3H2LN and SKBR3 cell lines were cultured in RPMI medium 
(Invitrogen, Paisley, UK) with 10% v/v fetal bovine serum (FBS; 
Sigma, Dorset, UK), 2mM L-glutamine (Invitrogen) and 50 units/ml 
penicillin-streptomycin (Invitrogen). TAMR and FASR cells were 
cultured in RPMI (phenol red free) with 5% charcoal stripped FBS 
(Sigma), 2mM L-glutamine, 50 units/ml penicillin-streptomycin and 
1x10-7 4-OH tamoxifen or Faslodex. Eph4 and N202.1A cells were 
cultured in DMEM medium (Invitrogen) that is supplemented with 2mM 
L-glutamine and 50units/ml penicillin-streptomycin. FBS was 
supplemented into Eph4 and N202.1A cell media at 10% and 15% v/v 
respectively. The MCF10A cell line was cultured in a 1:1 mix of 
DMEM/F12 (Invitrogen) medium supplemented with 5% v/v horse 
serum (Sigma), 50units/ml of penicillin-streptomycin, 100ng/ml 
cholera toxin (Sigma), 20ng/ml epidermal growth factor (EGF, Sigma), 
0.5mg/ml hydrocortisone and 10µg/ml insulin. 
Cells were maintained in a sterile, humidified 37oC incubator and 
CO2 levels were kept at 5%. All cell lines were routinely cultured in 
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T25 tissue culture flasks (Nunc, Leics, UK). When cells reached a 
confluency of 80-90%, they were passaged on at a split ratio of 1:6-
1:12 every two days or at appropriate times. Cell passaging was 
carried out by completely removing used medium, followed by a rinse 
with PBS. This was followed by the addition of 2mls of 0.05% 
Trypsin/EDTA (Invitrogen, Paisley, UK) to each flask and left to 
incubate at 37oC for 5-10 minutes. Following this incubation period, 
cells were checked under the microscope to ensure that all cells had 
detached and were then diluted with culture medium according to 
appropriate splitting ratios. All cell lines were not maintained for any 
more than 30 recorded passages. 
 
2.4.3 Cell counting 
To aid the seeding of cells in assays, cells were counted using a 
haemocytometer counting chamber (Hawksley, Lancing, UK). For this, 
cells were detached with trypsin/EDTA as described in Section 2.5.2. 
Once detached cells were transferred to a 15ml Falcon tube (BD 
Biosciences) and re-suspended 10mls of growth media. Cells were 
then pelleted by centrifugation at 1100rpm for 5 minutes and 
resuspended in a known appropriate volume of growth media. 10µl of 
cell suspension was loaded into the counting chamber of the 
haemocytometer and the number of cells in four 1mm2 squares was 
quantified. The four counts were averaged and multiplied by the 
conversion factor of 1x104 to give the number of cells/ml. 
 
2.4.4 Long-term cell storage 
In order to maintain a low passage number for the experimental 
cell lines, cells were frozen and cryo-stored in liquid nitrogen. For that, 
a confluent T75 flask (Nunc, Leics, UK) of each cell line was detached 
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and resuspended in 10mls of culture medium in a 15ml falcon tube. 
Cells were then pelleted by centrifugation at 1100rpm for 5 minutes. 
The pellet was re-suspended in freezing medium (culture medium with 
10% v/v dimethyl sulfoxide [DMSO; Sigma, Dorset, UK]) and 1ml 
aliqouts placed in 1.5ml cryo-tubes (Nunc, Leics, UK). The tubes were 
then placed in a container containing isopropanol to facilitate gradual 
freezing at -80oC overnight. After that, cell aliquots were transferred 
into the liquid nitrogen storage container. For retrieval of cells from 
cryo-storage, cells were quickly defrosted at 37oC in a waterbath, 
resuspended in 10mls of complete growth culture medium in a 15ml 
falcon tube and pelleted by centrifugation at 1100rpm for 5 minutes. 
The resulting pellet was then resuspended in 7mls of culture medium 
and cultured in T25 flasks. 
 
2.4.5 TRAIL treatment of target cells  
Cells were treated with soluble human recombinant TRAIL 
(SuperKillerTRAIL, Enzo Life Sciences) at a concentration of 20ng/ml 
for 18 hours at 37oC in 5% CO2. For mouse target cells, soluble mouse 
recombinant TRAIL (Enzo Life Sciences) was added at a concentration 
of 100ng/ml for 18 hours. 
 
2.4.6 Transient siRNA transfection 
 STEALTH small interfering RNA (siRNA) duplexes targeting an 
irrelevant scrambled control, c-FLIP, c-FLIPs and c-FLIPL RNA were 
purchased from Invitrogen (Table 2.4). Each siRNA was custom 
designed to target the entire c-FLIP gene (mouse and human) or the 
c-FLIP-short and c-FLIP-long splice forms (human only). Cells were 
transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturers protocols to give a final siRNA 
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concentration of 10nM. Volumes and concentrations of each of the 
reagents used are outlined in Table 2.5. In brief, the appropriate 
amount of siRNA was diluted in additive free Opti-MEM 1 culture media 
(Invitrogen) and added to the desired well in the culture dish. An 
appropriate amount of Lipofectamine RNAiMAX was then added to each 
well containing siRNA. This was then mixed and left at room 
temperature for 20 minutes to allow siRNA-Lipofectamine complexes 
to form. Meanwhile, cells were diluted in complete growth media free 
of antibiotics to a density that would give 30-50% confluency 24 hours 
post-seeding (Table 2.6). Following the 20minute incubation of siRNA-
Lipofectamine, cells were gently added such that the final 
concentration of siRNA in each well was 10nM. Cells were then 
incubated at 37oC in 5% CO2. The optimal transfection period for each 
cell line was optimized to give maximum gene knockdown.  
 
siRNA Target sequence (5’-3’) Final Conc Source 
c-FLIP GGAUAAAUCUGAUGUGUCCUCAUUA 10nM Invitrogen 
c-FLIP 2 GAGUGAGGCGAUUUGACCUGCUCAA 10nM Invitrogen 
c-FLIP-long CCCUAGGAAUCUGCCUGAUAAUCGA 10nM Invitrogen 
c-FLIP-short CCCAGGCUACGUGUCAUAUAUACGA 10nM Invitrogen 
Scrambled Control GGACUAAUAGUUGUGCUCCAAUUUA 10nM Invitrogen 
 Table 2.4: siRNA reagents and concentrations 
Table 2.5: Volumes and concentrations for siRNA transfections 
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2.4.7 Lentiviral transduction of cell lines 
Prior to transduction with lentivirus, MCF-7 and MDA-MB-231 cell 
lines were seeded in 24-well plates at a density of 100,000 cells per ml 
to give 30-50% confluency after 24 hours. One day later the complete 
culture media was removed from the cells and 1ml of fresh complete 
media containing 7µg/ml Polybrene (Millipore, MA, US) was added to 
the wells. Lentivirus was then added to each well in a range of 
volumes (0, 1, 2, 5, 10 and 20µl). Following 24 hours of lentiviral 
infection the culture medium was removed and replaced with fresh 
complete culture media without polybrene to allow cells to expand. 
 
2.4.7.1 Generation of cell lines deficient of c-FLIP 
In order to generate cell lines deficient of c-FLIP gene products, MCF-7 
and MDA-MB-231 cells were transduced with lentivirus encoding 
shRNA against the c-FLIP gene (Open Biosystems, CO, US). MCF-7 and 
MDA-MB-231 cells were transduced with 2 shRNA sequences (Fwd 5’-
No. of cells seeded for siRNA transfection  Tissue Culture 
vessel MDA-MB-231 MCF-7 BT474 SKBR3 
96-well 6 x 103 8 x 103 1.5 x 104 1 x 104 
48-well 1.2 x 104 1.6 x 104 3 x 104 2 x 104 
12-well 3 x 104 3.5 x 104 8 x 104 5 x 104 
6-well 1.5 x 105 1.5 x 105 2.5 x 105 2 x 105 
Table 2.6: Cell line seeding densities for siRNA transfection  
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3’,GATCTCCGGGGATAAATCTGATGTGTCCTCATTACTCGAGTAATGAGGAC
ACATCAGATTTATCCTTTTTA; Rev 5’-3’,AGCTTAAAAAGGATAAATCTGAT 
GTGTCCTCATTACTCGAGTAATGAGGACACATCAGATTTATCCCCGGA) 
targeting the c-FLIP gene and cells were then cultured in 4µg/ml 
(MDA-MB-231) or 2µg/ml (MCF-7) puromycin to select for stably 
transduced cells. Cells transduced with lentivirus containing the empty 
vector pLKO1 (Open Biosystems, CO, US) were used as a control. The 
levels of knockdown achieved by different shRNA sequences were 
compared with cells transduced with non-target empty vector (NT) 
shRNA by western blot and qRT-PCR.  
 
2.4.8 CellTiter Blue (CTB) viability assays 
The CellTiter Blue assay (Promega, Southampton, UK) provides a 
homogenous, fluorometric method for the number of viable cells 
present.  This reagent measures metabolic capacity of cells using 
resazurin as an indicator dye. Viable cells have the ability to convert 
resazurin into resofurin, a highly fluorescent derivative. Any non-viable 
cells will lack the metabolic capability to make this conversion and thus 
fail to produce a fluorescent signal. 
Before use, CellTiter Blue reagent was thawed to room 
temperature. 20µl of CellTiter Blue reagent was added per 100µl of 
culture media and incubated at 37oC with 5% CO2 for 1 hour. The 
resulting fluorescence was then measured by setting 
excitation/emission wavelengths to 560/590nm on a Fluostar Optima 
plate reader (BMG Labtech, Bucks, UK). 
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2.4.9 Tryphan blue exclusion cell viability counts 
In order to estimate the number of cells present in a culture, 
cells were lifted from plates by 0.05% trpsin/EDTA incubation at 37oC 
for 5-10 minutes. The cells were then resuspended in a known volume 
of culture media. Tryphan blue dye was then added to 10ul of cell 
suspension at a 1:1 ratio and this was loaded onto a haemocytometer 
cell counting chamber. Only viable cells without blue stain were 
counted and the number of cells in a ml of suspension can be 
calculated by the average number of cells per square multiplied by 
2x104.  
 
2.4.9.1 Proliferation assay 
For proliferation assays, cells were seeded at a density of 10,000 
cells/well in 6-well plates (Nunc, Leics, UK). For each cell line, nine 
wells were seeded to represent triplicates of three timepoints. After 24 
hours, cells from triplicate wells for the first time point were 
trypsinized and individually counted as described in Section 2.4.3. The 
same was done for each cell line at 48 hours and 72 hours post-
seeding. The average cell counts for respective cell lines were then 
plotted on a log scale, normalized against the number of cells present 
at 24 hours. 
 
2.4.10 Flow cytometry  
Transfected cells were removed from tissue culture plates using 
1mM EDTA (Sigma) and centrifuged at 1100rpm for 5 minutes. The 
pellet was washed twice in Fluorescence activated cell sorting (FACS) 
buffer (PBS supplemented with 2% v/v FBS). Cells were resuspended 
at a density of 4x106 cells /ml and 100µl of this suspension was 
aliquoted into the appropriate wells of a 96 well plate before 
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centrifugation at 1100rpm for 5 minutes. The supernatant was 
removed and the pellet resuspended in 100µl of the fluorescently 
conjugated primary antibody (Table 2.6) and left on ice for 30 minutes 
in the dark. Cells were then centrifuged and the primary antibody 
removed. The pellet was washed twice in FACS buffer before being 
filtered through a 40µm cell strainer (BD Biosciences) into a FACS 
collection tube (BD Biosciences) to ensure a single cell suspension. 
FACS was performed on a FACS Canto I or Canto II Flow Cytometer 
(BD Biosciences) and analysis of results was performed using a FlowJo 
software package. Gates were set to exclude >99% of cells labelled 
with isoform-matched control antibodies conjugated with the 
corresponding fluorochromes.  
 
2.4.10.1 Aldefluor assay  
The aldefluor assay (Stemcell Technologies, Grenoble, France) is 
a method to identify stem cells on the basis of their high aldehyde 
dehydrogenase (ALDH) activity. A fluorescent aldefluor reagent 
diffuses into cells and is a substrate for ALDH. The amount of 
fluorescent ALDH reaction product is directly proportional to the ALDH 
activity in cells. Cells with high expression of ALDH are recognised by 
comparing the fluorescence of test cells with that of a control sample 
containing the specific ALDH inhibitor, diethylaminobenzaldehyde 
(DEAB).  
Aldefluor reagents were prepared according to manufacturer’s 
instructions. Transfected cells were removed from tissue culture plates 
using 1mM EDTA and centrifuged at 1100rpm for 5 minutes. The cells 
were washed twice in FACS buffer by resuspension and centrifugation. 
Cells were suspended in 1ml of aldefluor assay buffer and counted. 
The samples were adjusted to a concentration of 1x106 cells/ml with 
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aldefluor assay buffer. A ‘control’ and a ‘test’ tube were prepared for 
each sample to be tested and 1ml of the cell suspension was placed 
into each ‘test‘ tube. 5µl of DEAB reagent was added to the control 
tube and recapped immediately before 5µl of activated aldefluor 
substrate was added per ml of test suspension in the ‘test’ tube. The 
suspension was mixed and 0.5ml was immediately transferred to the 
‘control’ tube containing the DEAB substrate. The ‘test’ and ‘control’ 
tubes were incubated for 45 minutes at 37oC. The tubes were then 
centrifuged at 1100rpm for 5 minutes, the pellets resuspended in 
aldefluor buffer and placed on ice. The fluorescence of cells was 
measured in the green fluorescence channel of a FACS Canto flow 
cytometer (BD Biosciences). Analysis was performed using FlowJo 
software. Gates were set to exclude >99% of DEAB control cells
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2.4.11 Mammosphere assays  
Mammosphere assays can be used for the in vitro propagation of 
mammary epithelial cells in an undifferentiated state in non-adherent 
cell culture conditions. The resulting mammosphere colonies are 
enriched for mammary stem/early progenitor cells that are capable of 
self-renewal and form new colonies upon disaggregation and re-
seeding. This assay is therefore suitable for the functional identification 
of this cell population.  
Cells were removed from tissue culture plates using 0.25% w/v 
Trypsin/EDTA and centrifuged at 1100rpm for 5 minutes. Cells were 
then resuspended in mammosphere culture medium (serum-free 
epithelial growth medium [MEBM, Lonza], supplemented with B27 
[invitrogen], 20ng/ml Epidermal Growth Factor [EGF, Sigma], 5mg/ml 
Insulin [Sigma], 0.0008% v/v !-mercaptoethanol [Sigma] and 1mg/ml 
hydrocortisone [Sigma]) and disaggregated into single cell suspensions 
by mechanical agitation. Cells were counted and seeded into ultra-low 
attachment plates (Corning) at density of 4000 cells/ml (unless 
otherwise stated) before being incubated for 7 days at 37oC and 5% 
CO2 to allow the formation of mammosphere colonies. After this 
incubation period, the numbers of mammospheres per well were 
counted. In order to determine the self-renewal capacity of cells, 
mammospheres were collected by gentle centrifugation at 1100rpm 
and mechanically and enzymatically dissociated into single cells in 
0.25% w/v Trypsin/EDTA at 37oC. Cells were centrifuged at 1100rpm 
before being counted and re-seeded into ultra-low attachment plates 
at a density of 4000 cells/ml. Cells were then incubated for 7 days at 
37oC and 5% CO2 after which time the numbers of mammospheres per 
well were counted.  
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2.4.12 !" T cell isolation and stimulation from healthy human 
blood donors 
40mls of blood was removed from healthy human donors and 
added to 10ml of heparin/EDTA to prevent clotting. 30ml of this blood 
was then gently pippetted onto 20mls of Ficoll lymphoprep and then 
spun in a centrifuge for 20 minutes at 1800rpm with 0 deceleration at 
4oC. The interface, between Ficoll and plasma, of peripheral blood 
mononuclear cells (PBMCs) was collected and washed 3 times in MACS 
buffer, collecting cells by centrifugation at 1100rpm for 8 minutes 
between washes. From PBMCs !" T cells/monocytes were purified using 
2 methods. To isolate pure unstimulated populations, !" T 
cells/monocytes were isolated from PBMCs using MACs !" T cell/CD28 
magnetic purification kit (Miltenyi Biotec) and a 1:1 ratio of !" T 
cells:monocytes used at stimulation. Alternatively PBMCs were cutured 
in media containing the desired stimulatory compound for 2 weeks 
until the population of !" T cells was larger than 85% of the total cell 
population. In either case cells were stimulated using HMB-PP, 
zoledronate (Novartis) or ibandronate (Boniva). 
 
2.4.13 ELISA 
 To determine secreted concentrations of TRAIL and perforin, 
supernatants collected from culturing cells were collected and 
compared to standard concentrations of TRAIL and Perforin. ELISA kits 
for TRAIL and Perforin were obtained from R&D systems (DTRL00) and 
MabTech  (3465-1H-20) respectively and performed according to the 
manufacturers instructions.  
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2.4.14 Heterotypic cell death assay 
siRNA treated cells were treated with 0.25% trypsin for 10 mins, 
washed and stained with PKH67 or PKH26 cell linker kits according to 
the manufacturers protocol (Sigma). PKH67+ve FLIPi cells and 
PKH26+ve SCi cells were mixed 1:1 and cultured overnight with or 
without TRAIL or !" T cells and subsequently resuspended in 4µl (1 in 
10 dilution of stock solution) of 1:10 fixable near-IR live/dead stain 
(Invitrogen) and incubated for 15 mins at 4oC in the dark. Cells were 
then washed twice in PBS and analysed by flow cytometry. Gates were 
then set for PKH staining versus live/dead staining using a FACS Canto 
(Becton Dickinson) using untreated and unstained control cells.  
 
2.4.15 Annexin-V assay 
  siRNA treated cells were treated with 0.25% trypsin for 10 
mins, washed and stained with Annexin-V (APC) (eBioscience) for 15 
mins at 4oC in the dark. Cells were then washed twice in PBS and 
analysed by flow cytometry using a FACS Canto.  
 
2.5 Protein analysis by western blotting  
 
2.5.1 Protein extraction from cells  
Media was completely aspirated from cell culture flasks and the 
cells were washed twice in ice cold PBS. A further 12ml of PBS was 
added to the flask and cells were scraped using a cell scraper (Nunc) 
and transferred into 15ml falcon tubes. The cells were centrifuged at 
1100rpm for 5 minutes and the supernatant removed. Cell pellets were 
either stored at -80oC until required or immediately lysed by the 
addition of 100-300µl of RIPA buffer (150mM sodium chloride *Fisher 
Scientific+, 1% v/v Nonidet-P40 [Roche], 0.5% w/v sodium 
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deoxycholate [Sigma], 0.1% w/v sodium dodecyl sulphate [SDS; 
Sigma], 50mM Tris [Sigma], pH8) containing protease (Complete mini 
protease inhibitor tablets [Roche]) and phosphatase inhibitors (1mM 
sodium orthovanadate [Sigma], 10mM sodium fluoride [Fluka 
Biochemika], 10mM sodium pyrophosphate [Sigma]). The cell pellet 
was passed through a 23G needle 10 times to ensure complete cell 
lysis and incubated on ice for 30 minutes. Lysates were centrifuged at 
10,000rpm for 15 minutes at 4oC to pellet cell debris and the 
supernatant was aliquoted into fresh tubes and snap frozen in liquid 
nitrogen for storage at  -80oC until required.  
 
2.5.2 Determination of protein concentrations  
Protein concentrations were analysed using the BCA protein 
Assay kit (Pierce) according to manufacturer’s instructions. Protein 
samples were first diluted by 1:5 and 1:10 in RIPA Buffer (20mM Tris-
HCL [pH 7.5], 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% NF-40, 
1% sodium deoxycholate, 2.5mM sodium pyrophosphate, 1mM beta-
glycerophosphate, 1mM Na3VO4, 1µg/ml leupeptin) and 12.5µl of each 
diluted sample was added to a 96 well round bottomed plate (Nunc) in 
duplicate. BCA protein assay reagent A was added to BCA protein 
assay reagent B in a ratio of 50:1 and 100µl of this mix was added to 
each sample. Standard samples were also generated by diluting 
2mg/ml BSA in PBS to produce 4 known protein concentrations 
(2mg/ml, 1mg/ml, 0.5mg/ml, 0.25mg/ml) to which 100µl of BCA 
reagent mix was added. Samples were mixed well and incubated at 
37oC for 30 minutes to allow a purple colour to develop. Colour 
intensity of each sample was measured on a nanodrop 
spectrophotometer (ND-1000; Labtech International) at 562nm. The 
relative concentration of protein in each sample was extrapolated from 
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the standard curve generated using the standard samples.  
 
2.5.3 Western analysis  
 
2.5.3.1 Preparation of protein samples  
After protein concentrations were determined, 70µg of protein 
were diluted in RIPA buffer to produce a final volume of 10µl and 2.5µl 
of 5X laemmli buffer (0.125M Tris-HCL pH6.8, 4% w/v SDS, 40% v/v 
glycerol, 0.1% w/v bromophenol blue [Sigma], 6% v/v beta-
mercaptoethanol [Sigma] in ddH20) was added to each sample. Just 
before loading, the samples were heated to 95oC for 5 minutes to 
denature the proteins.  
 
2.5.3.2 Casting of polyacrylamide gels  
All Mini western SDS-PAGE gels were set in Mini-Protean III (Bio-
Rad) gel casting apparatus. Resolving gel mixtures composed of 
varying concentrations of Acrylamide/Bis (depending on target protein 
size) were prepared (Table 2.7), poured and left to set for 30 minutes. 
Once set, the 4% stacking gel mixture was prepared and poured over 
the resolving gel (Table 2.7). A clean 10 or 15-well comb was inserted 
immediately into the apparatus and the gel was left to set for 30 
minutes. Once set, the combs were removed and the wells rinsed with 
ddH20. 
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Table 2.7: Composition of polyacrylamide gels  
 
2.5.3.3 Gel electrophoresis  
Gels were placed in the Mini-Protean III (Bio-Rad) 
electrophoresis tank and immersed in 1 x Tris-Glycine running buffer 
(Table 2.8). Protein molecular weight marker (PageRuler Plus; 
Fermentas) was loaded into the first lane of each gel and prepared 
protein samples were loaded into the appropriate remaining wells. The 
samples were resolved down SDS-PAGE gels for approximately 45-60 
minutes at 150V until the dye front reached the bottom of the gel.  
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2.5.3.4 Transfer of proteins to PVDF membranes  
After separation of protein, gels were carefully removed from 
glass plates and soaked in 1 x Tris-Glycine transfer buffer (Table 2.8) 
for 10 minutes. Immobilon-P, Polyvinylidene difluoride (PVDF; 
Millipore) membrane was cut to size, pre-soaked in methanol (Fisher 
Scientific) for 10 seconds and washed in ddH20. The stacking gel was 
then cut away and discarded and the resolving gel was placed onto the 
membrane in a standard wet electroblotting system (BioRad). Air 
bubbles were carefully rolled out after the addition of each layer. An 
ice block was inserted into the transfer apparatus and proteins were 
transferred by electroblotting in 1 x Tris-Glycine transfer buffer (25mM 
Tris, 192mM glycine, pH8.3) at 100V for 1 hour. Blotting apparatus 
was then dismantled and membranes were washed for 5 minutes in 
PBS/T. 
 
2.5.3.5 Probing of membranes  
Following transfer, membranes were blocked in milk blocking 
solution (Table 2.8) under agitation for 1 hour at room temperature 
and then incubated in 5mls of primary antibody (Table 2.9) at 4oC on a 
roller mixer (Stuart, Merton, UK) overnight. The following morning the 
membrane was washed (3 x 5 minutes) in PBS/T before being 
incubated in 5mls of the appropriate horseradish-peroxidase (HRP)-
conjugated secondary antibody (Table 2.9) for 1 hour at room 
temperature on a roller mixer. Following this incubation, membranes 
were washed 3 x 5 minutes in PBS/T prior to protein detection by 
enhanced chemiluminesence.  
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2.5.3.6 Visualisation of protein bands  
The ECLprime reagent kit (GE Healthcare) was used to visualise 
the immobilised protein bands conjugated to HRP-labelled secondary 
antibodies according to manufacturer’s instructions. ECL solutions were 
mixed well and 2mls were immediately distributed evenly across the 
membrane and incubated in the dark for 1 minute (ECLprime). After 
removal of excess reagent, the membrane was placed in a light-proof 
cassette and exposed to light sensitive films (Amersham Hyperfilm 
ECL; GE Healthcare) under safelight conditions for varying lengths of 
time to give a range of exposure intensities. All films were developed 
on an automatic film processor (Xograph Compact X4 automatic X-ray 
film processor). Processed films were then realigned with the original 
membrane and the target protein was identified by comparison to the 
molecular weight marker.  
 
2.5.3.7 Stripping and re-probing of membranes  
In order to study more than one protein band from the same set 
of samples, membranes were stripped of their original antibodies and 
re-probed with a new one. The membrane was washed in PBS/T (3 x 5 
minutes) and incubated in stripping buffer (Table 2.8) at 55oC for 30 
minutes with gentle agitation. The stripping buffer was removed and 
the membrane was rinsed 5 times in dH20 before being incubated in 
PBS/T for 30 minutes at room temperature. After incubation for a 
further hour in milk blocking solution, the membrane was re-probed 
with the desired primary and secondary antibodies. Protein bands were 
then visualised using ECLprime reagent as described in section 
2.5.3.6. 
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2.5.3.8 Quantification of protein bands  
In some cases protein bands were semi-quantified. The intensity 
of protein bands was measured using a GelDoc (BioRad) and 
normalised to the band intensity of their corresponding loading control. 
 
Solution Composition 
10 x Electrophoresis Buffer 30.3g Tris base (Sigma), 144.4g Glycine 
(Sigma), Upto 1L dH20 
1 x Tris-Glycine SDS-PAGE 
Running Buffer (1L) 
890ml dH20, 100ml 10 x Electrophoresis 
Buffer, 10ml 10% w/v SDS 
1 xTris-Glycine Transfer Buffer 700ml dH20, 100ml 10 x Electrophoresis 
Buffer, 200ml Methanol 
Milk Blocking Solution 5% w/v non-fat milk powder (Marvel) in 
PBS/T 
Stripping Buffer 62.5mM Tris-Hcl (pH6.8), 2% w/v SDS, 
100mM 2-beta-mercaptoethanol 
Table 2.8: Composition of solutions used in western analysis
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2.6 Caspase assays  
 
Caspase-Glo 8 assay (Promega) is a luminescent assay that 
measures the activity of caspase-8 providing a measurable 
luminogenic substrate. Addition of the Caspase-Glo reagent to the 
sample results in cell lysis followed by caspase cleavage of the 
substrate and a resulting luminescent signal which is proportional to 
the amount of caspase activity present in the sample.  
 
2.6.1 Determination of caspase activity in cells 
Transfected or treated cells were removed from tissue culture 
plates using 0.25% w/v Trypsin/EDTA and centrifuged at 1100rpm for 
5 minutes before being resuspended in complete growth medium. Cells 
were counted and resuspended at a density of 2x105 cells/ml and 
100µl of this suspension was plated into appropriate wells of a black-
walled 96-well plate. At the same time, 100µl of complete media alone 
was plated into triplicate wells to serve as a ‘blank’ control. The plate 
was incubated at 37oC and 5% CO2 for an appropriate amount of time 
(as indicated in the results sections). After incubation, Caspase-Glo 
reagents were prepared according to manufacturer’s instructions, and 
plates were removed from the incubator and allowed to equilibrate to 
room temperature. To each well containing cells or ‘blank’ controls, 
100µl of Caspase-Glo reagent was added. The plate was then gently 
agitated on a plate shaker at 300-500rpm for 30 seconds before being 
incubated at room temperature 1 hour. The luminescence of each 
sample was then measured on a FLUOstar Optima plate reader and the 
‘blank’ control value was subtracted from all other values.  
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2.7 RNA analysis  
 
2.7.1 Isolation of RNA  
All bench work surfaces and equipment were treated with 
RNAseZAP (Ambion) before use and RNAse free H20 (Sigma) was used 
throughout.  
Purification of RNA from cells was achieved using the RNeasy 
Mini Kit according to manufacturer’s instructions. Concentration and 
quality of RNA was quantified on a NanoDrop spectrophotometer.  
 
2.7.2 Reverse transcription  
Reverse transcription was performed using RevertAID Premium 
Reverse Transcriptase (Fermentas). cDNA was synthesised from 500 – 
1000ng RNA samples diluted in 12.5µl of RNase free H20. A master 
reaction mix containing Random Primers and dNTPs (Table 2.10) was 
prepared in a nuclease free tube on ice and 2µl was added to each 
sample to make a total volume of 14.5µl. Samples were then mixed 
gently, centrifuged and heated to 65oC for 5 minutes before being 
returned immediately to ice. A second reaction mix containing the 
reverse transcriptase (Table 2.10) was prepared and 5.5µl was added 
to each sample to make a final volume of 20µl. Samples were then 
incubated for 10 minutes at 25oC, 30 minutes at 50oC and 5 minutes 
at 85oC before being returned to ice. For each experiment, controls 
were prepared in exactly the same way but with reaction mix lacking 
the reverse transcriptase enzyme. Samples were either used 
immediately or stored -70oC until required. 
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Reaction Mix 1 Component Volume Per 
Reaction 
dNTPs (10mM; dATP, dCTP, dGTP, dTTP; Promega) 1µl 
Random Primers (500ug/ml [Promega]) 1ul 
Reaction Mix 2 Component Volume Per 
Reaction 
5xRT Buffer (Fermentas) 4µl 
RNasin Plus (40u/µl; Promega) 0.5µl 
RevertAID Premium Reverse Transcriptase (200u/µl; 
Fermentas) 
1µl 
Table 2.10: Reaction mix components for reverse transcription  
 
2.7.3 Quantitative real-time polymerase chain reaction (qRT-
PCR) & semi-quantitative PCR  
 
2.7.3.1 Primer design  
All primer sets were designed across exon boundaries using the 
Primer3 web-based program http://frodo.wi.mit.edu/primer3/. To 
check for mis-priming, all sequences were verified by performing in 
silico PCR (http://genome.csdb.cn/cgi-bin/hgPcr). All primers were 
purchased from Sigma-Genosys and sequences can be found in Table 
2.12.  
 
2.7.3.2 qRT-PCR  
QRT-PCR was performed using Step One Plus Real-time PCR 
System (Applied Biosystems), in conjunction with StepOne (v2.1; 
Applied Biosystems) software. Each reaction was performed in 
triplicate and a minimum of 3 separate biological samples were 
analysed. One housekeeping gene (#-Actin) was always run as a 
reference.  
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An arbitrary standard curve was generated by pooling 5µl of 
cDNA from each sample to make a neat cDNA control which was then 
diluted 1:5 and 1:25 with PCR-grade water to make three cDNA 
standards. Appropriate volumes (Table 2.11) of cDNA test samples, 
cDNA standards or PCR-grade H20 (Sigma) control were loaded into 
separate wells of a 96 well reaction plate (MicroAmp Fast Optical 
0.1ml; Applied Biosystems).  
A PCR mastermix containing all other reaction components was 
then prepared according to Table 2.11. Mastermix (22.5µl) was added 
to each well and gently pipetted to ensure homogeneous mixing of 
cDNA and reaction mix. The PCR plate was then sealed with 
appropriate caps (MicroAmp Optical 8-capstrip; Applied Biosystems) 
before being loaded into the Realtime PCR machine.  
All reactions were run under the same cycling conditions of initial 
denaturation at 95oC for 10 minutes followed by 45 cycles of 95oC for 
15 seconds and 60oC for 1 minute (with a plate read after each cycle). 
A melting curve (95oC for 15 seconds, 60oC for 1 minute [optics off], 
60oC to 95oC at 0.2oC increments every 15 seconds [optics on]) was 
constructed at the end of the experiment and data was collected with. 
Step one plus software. 
Target Species Fwd Primer Seq (5’-3’) Rev Primer Seq (3’-5’) 
c-FLIP Human TGATGGCAGAGATTGGTGAG GATTTAGACCAACGGGGTCT 
#-actin Human CCCAGCACAATGAAGATCAA CAGGTGGAAGGTCGTCTACA 
Table 2.11: qRT-PCR primer sequences 
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2.7.3.3 Analysis of qRT-PCR data  
Data was initially examined using Step One Plus software. 
Melting curves were analysed to ensure that only one peak at the 
expected melting temperature was observed and that the H20 control 
samples produced no product.  Ct values for standards were plotted 
against relative amounts (neat cDNA = 1, 1:5 dilution = 0.2, 1:25 
dilution = 0.04) to generate a standard curve for each primer set. 
Relative mRNA expression in each sample was extrapolated by plotting 
Ct values on the standard curve. The differences between the amounts 
amplified in samples for a target gene and corresponding samples 
amplifying a reference gene was then calculated to get a normalised 
relative expression value. Generally, an average expression value 
across all biological replicates was taken and values were normalised 
back to the control samples.  
 
 
 
 
 
Table 2.12: qRT-PCR reaction components 
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2.8 Statistical analysis  
 
2.8.1 Kaplan-Meier survival analysis  
All tumour-free survival curves and statistical analysis of tumour-free 
survival times were performed using the Kaplan-Meier method with the 
aid of MedCalc statistical analysis software (Version 11.4.3.0, 
www.medcalc.org/).  
 
2.8.2 Kolmogorov-Smirnov analysis  
Differences in the distribution of data to determine whether data was 
parametric or non-parametric were tested for using the Kolmogorov-
Smirnov test. This test was performed using the Minitab statistics 
package (Version 14.20).  
 
2.8.3 Mann-Whitney U-test  
The Mann-Whitney U-test was used to determine statistical differences 
between non-parametric data sets. This was performed using the 
Minitab statistics package (Version 14.20).  
 
2.8.4 Student’s t-test  
The Student’s T-test was used to determine statistical differences 
between normally distributed data sets and between data sets with 
sample sizes of n=3. This test was performed using Excel 2007 
software.  
 
2.8.5 Chi-Squared test  
The Chi-Squared test was used to determine statistical differences 
between observed frequencies and expected frequencies of data.  
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3.1 Introduction 
 
 The realisation that breast cancer is a heterogenous disease has 
lead to great advancements in the way that we treat the disease, 
resulting in more targeted therapeutic strategies that have improved 
survival rates in discrete disease subgroups (Badve and Nakshatri 2009). 
This is demonstrated by the treatment of ER-positive and HER2-
positive breast cancers by agents such as tamoxifen and Herceptin 
respectively (Dean-Colomb and Esteva 2008; Yamashita 2008). However, 
despite these advances tumours still frequently relapse due to their 
innate or acquired resistance to therapeutic insult. The complexity of 
therapy due to inter-tumour heterogeneity is compounded further with 
the existence of intra-tumour heterogeneity that is defined by number 
of different cell types that can found within each tumour. Functionally 
one of the most important of these subsets of cells found within a 
breast tumour is the breast cancer stem cell (bCSC). It is these cells 
that are at the root of innate therapy resistance and provide the 
source for new tumour growth (Al-Hajj et al. 2003; Dontu et al. 
2003a; Visvader and Lindeman 2008; Zhou et al. 2009). 
Consequently, there is considerable interest in the targeting of this cell 
subset with cytotoxic agents across a broad range of breast cancer 
subtypes to benefit as wide a patient group as possible.  
 TRAIL is a promising anti-cancer agent that exhibits tumour 
specificity with almost no effect on normal cell populations in a wide 
range of different tissues. Currently, clinical trials are ongoing using 
TRAIL for treatment of colorectal cancer, non-small cell lung carcinoma 
and non-Hodgkins lymphoma (Ashkenazi et al. 1999; Kruyt 2008). 
However, its therapeutic potential in breast cancer is limited with most 
subtypes of disease displaying resistance (Kendrick et al. 2007; 
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Rahman et al. 2009b). Additionally, it has been documented that CSC 
subsets are also resistant to TRAIL therapy and thus patients receiving 
TRAIL therapy are still likely to incur relapse of disease (Capper et al. 
2009; Szegezdi et al. 2009). As a result, a prime focus of many 
studies has been to elucidate sensitising agents to TRAIL treatment 
and whilst this has been performed to varying degrees of success, 
most undermine the key attribute of TRAIL treatment that is the 
relative tumour specificity of the agent (Cuello et al. 2001; Keane et 
al. 1999; Ortiz-Ferron et al. 2008; Palacios et al. 2006; Sanchez-Perez 
et al. 2009). Common to many of these studies is the demonstration 
that the endogenous inhibitor of death receptor signalling c-FLIP is 
downregulated during the sensitisation process (Bijangi-Vishehsaraei 
et al. 2010; Ortiz-Ferron et al. 2008; Palacios et al. 2006; Sanchez-
Perez et al. 2009).  
 Whilst it is clear that c-FLIP, as a regulator of TRAIL instructive 
cell death, plays an important role in cancer cell resistance, the direct 
suppression of c-FLIP as a means of sensitisation to TRAIL has not 
been fully investigated.  
 In this chapter the potential of c-FLIP suppression to sensitise a 
broad range of breast cancer cell subtypes to TRAIL treatment was 
investigated with important focus on its capability in preventing 
disease relapse whilst maintaining tumour specificity of treatment.  
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3.2 Results 
 
3.2.1 Breast cancer cell line sensitivity to TRAIL is not 
determined by c-FLIP mRNA expression levels 
  Breast cancer cell line resistance to TRAIL has been previously 
documented (Rahman et al. 2009a). However, it is important to 
ascertain the specific sensitivity of cell lines ‘in-house’ as differing 
sources, culture conditions and passage time of cell lines may change 
their response to certain cytotoxic agents.  
  Here a panel of breast cancer cell lines representing a broad 
spectrum of disease was selected on the basis of their estrogen and 
herceptin receptor expression (Figure 3.1A) and their response to 
TRAIL ligand  (Figure 3.1B) assessed using assays detailing cell 
viability, apoptosis and cell death.  Additionally, mRNA was extracted 
from culturing cells and c-FLIP expression measured in each of the cell 
lines to determine the correlation between c-FLIP mRNA levels and 
TRAIL sensitivity. 
Using the selected four breast cancer cell lines representing all 
combinations of ER$ and HER2 expression, only the basal ER-
negative/HER2-negative MDA-MB-231 cell line gave a significant 
increase in apoptosis and cell death with a conferring reduction in cell 
viability (Figure 3.1, p<0.01) when treated with TRAIL.  The remaining 
luminal-like cell lines MCF-7 (ER-positive/HER2-negative), SKBR3 (ER-
negative/HER2-positive) and BT474 (ER-positive/HER2-positive) 
displayed resistance to TRAIL treatment with no significant increases 
in cell death or apoptosis and no significant reduction in cell viability 
(Figure 3.1).  The functional concentration of TRAIL capable of giving 
the maximum amount of caspase-8 activation was identified as 
20ng/ml by exposing the sensitive MDA-MB-231 cell line to increasing 
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TRAIL concentrations (Figure 3.1C).  Interestingly, c-FLIP mRNA levels 
did not determine sensitivity to TRAIL. SKBR3 cells expressed 
significantly less c-FLIP mRNA but still remained resistant to TRAIL 
treatment (Figure 3.1D). 
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Figure 3.2.1: Most breast cancer subtypes are resistant to TRAIL treatment. A) 
Western blot indicating breast cancer cell line protein levels of ErbB2 and ER$. Tubulin 
expression was used to determine equal loading. B) Cell lines were treated with 20ng/ml 
TRAIL for 18 hours and cell death, apoptosis and viability of breast cancer cell lines was 
measured by FACS (Live/dead assay and Annexin-V) or fluorescence (CTB assay) * 
p<0.01. C) MDA-MB-231 cells were treated with increasing concentrations of TRAIL and 
caspase-8 activation (CaspaseGlo assay) was measured. D) c-FLIP mRNA expression in 
BCCLs as measured by qRT-PCR relative to #-actin. Data shown is representative of 3 
experiments performed in triplicate ±SEM.  
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3.2.2 Optimisation of c-FLIP siRNA knockdown in breast cancer 
cell lines  
 To investigate the contribution of c-FLIP in breast cancer cell line 
resistance to TRAIL a number of in vitro experiments were performed. 
In these experiments a siRNA approach was adopted to efficiently 
suppress c-FLIP.  
 Initially the c-FLIP siRNA transfection technique was optimised 
on the basis of the manufacturer’s protocol.  Cells were plated into 
transfection medium containing 10nM of either c-FLIP (entire 
transcript, FLIPi) or scrambled control siRNA (SCi) for 24-72 hours. 
Triplicate wells of cells were then harvested at defined timepoints of 
24, 48 or 72 hours and cDNA prepared for qRT-PCR analysis with all 
results being normalised to a control internal housekeeping gene, #-
actin. Subsequently, protein levels of c-FLIPL and c-FLIPS were 
analysed by western blot in order to confirm the c-FLIP knockdown 
post-transcriptionally. 
 In the MDA-MB-231 and MCF-7 cell lines the optimum 
transfection period was identified at 48 hours. At this timepoint c-FLIP 
transcript levels had reduced to 27% and 19.6% of their constitutive 
controls respectively. In the SKBR3 and BT474 cell lines, the optimum 
transfection period was identified as 72 hours, during which time c-
FLIP transcript levels had reduced to 19.3% and 4% of their 
constitutive controls respectively. Although a reduction in c-FLIP 
transcript levels could be observed at other transfection period 
timepoints these were the timepoints at which the greatest knockdown 
could be achieved and thus for all subsequent siRNA experiments the 
MDA-MB-231 and MCF-7 cell lines were transfected for 48 hours and 
the SKBR3 and BT474 cell lines were transfected for 72 hours. 
Additionally, c-FLIP transcript levels were routinely checked across all 
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siRNA experiments to ensure a greater than 75% knockdown was 
being achieved.  
 Western blotting of protein extracted from scrambled control 
siRNA (SCi) and c-FLIP siRNA (FLIPi) treated cells showed that both 
the long and short isoforms of c-FLIP had been significantly reduced in 
all cell lines. Unfortunately after numerous attempts the suppression of 
c-FLIPS could not be confirmed at the protein level in the MCF-7 cell 
line treated with either SCi or FLIPi.  
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Figure 3.2.2: c-FLIP siRNA transfection results in significant reduction of c-
FLIP mRNA and proteins.  A) mRNA expression of c-FLIP in BCCLs following control 
or c-FLIP siRNA transfection, for different lengths of time, relative to #-actin. Data 
shown is representative of 3 experiments performed in triplicate ±SEM. B) c-FLIP short 
and long isoform protein levels in BCCLs following SCi of FLIPi treatment for 48 hours 
(MCF-7 and MDA-MB-231) or 72 hours (BT474 and SKBR3). 
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3.2.3 c-FLIP deficiency does not sensitise normal mouse cells 
to TRAIL 
 It has been reported that TRAIL preferentially targets tumour 
cells over normal cells (Ashkenazi 2002; Ashkenazi et al. 1999; 
Lawrence et al. 2001). To determine if the targeted inhibition of c-FLIP 
exhibited similar specificity for tumour cells, mammary epithelial cell 
viability was assessed in non-tumourgenic c-FLIP-deficient mouse 
mammary glands, non-tumourgenic murine cell lines and in the non-
tumourgenic human breast cell line MCF-10A.  c-FLIP was conditionally 
deleted from mammary epithelial cells of juvenile mice by crossing the 
BLG-Cre transgene (Selbert et al. 1998a, b) into the c-FLIPfl/fl line 
(Zhang and He 2005), and the mammary epithelial compartment 
subsequently assessed in adult virgin and pregnant animals.  
 Mammary epithelial morphogenesis and cell number in BLG-
Cre/c-FLIPfl/fl mammary glands was indistinguishable from wild-type 
controls, while isolated primary epithelial cells from both genetic 
backgrounds exhibited comparable cell viability either in the presence 
or absence of TRAIL in vitro  (Figure 3.2.3A, B).  Furthermore, 
inhibition of c-FLIP (FLIPi) using murine specific siRNA had no effect on 
a non-tumourgenic murine cell line’s response to TRAIL but 
significantly reduced viability in the tumourgenic, ErbB2 
overexpressing, N202.1A cell line (Figure 3.2.3C, p<0.00001). 
Similarly, in the human non-tumourgenic breast cell line, MCF-10A, 
cell viability was unaffected by c-FLIP inhibition (FLIPi) alone, nor did it 
increase sensitivity to TRAIL, although treatment with TRAIL induced a 
significant cell death response (Figure 3.2.3D, p= 0.0307). This 
confirms previous reports of partial TRAIL sensitivity in human 
transformed cell lines (Keane et al. 1999).  These data indicate that 
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the targeted inhibition of c-FLIP may exhibit tumour specific effects, 
similar to those observed with TRAIL, in other cancer types.   
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Figure 3.2.3: c-FLIP knockdown has no significant effect on normal mouse 
mammary epithelial cells and normal transformed cell lines. A) Representative 
H+E stained sections of the 4th inguinal mammary glands excised from c-FLIP+/+ (WT) 
and c-FLIPfl/fl (FF) mice. B) Viability of primary mammary epithelial cells isolated from 
WT or FF mammary glands following TRAIL treatment as measured by CTB assay. C) 
Cell death of normal (EPH4) and cancer (N202.1A) mouse mammary cell lines 
following SCi, FLIPi treatment alone or in combination with TRAIL as measured by 
fixable live/dead assay * p<0.01. D) MCF10A cell death following treatment with SCi 
or FLIPi alone or in combination with TRAIL. Data shown is representative of 3 
experiments performed in triplicate ±SEM.  
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3.2.4 c-FLIP knockdown increases basal apoptosis levels in 
breast cancer cell lines via caspase-8 and/or caspase-10 
activation. 
 As one of the key regulators of TRAIL induced apoptosis, c-FLIP 
acts by competing with caspase-8 to bind to FADD at the DISC. When 
c-FLIP is bound caspase-8 is unable to be activated and set off the 
caspase cascade that ultimately results in the onset of apoptosis. 
Despite c-FLIP having no apparent effect on the morphology or cell 
death of normal human and mouse cells it may inhibit the base rate of 
apoptosis in tumour cells. To investigate the effect of c-FLIP removal 
on tumour cell apoptosis and caspase activation, cells were treated 
with control or c-FLIP siRNA and incubated in the presence or absence 
of the cell permeable, non-reversible caspase inhibitors IETD (caspase-
8), LEHD (caspase-9) and AEVD (caspase-10) and apoptosis assessed 
by Annexin-V staining.   
 In each of the cell lines tested, c-FLIP knockdown (FLIPi) 
increased the base level of apoptosis between 10% and 15% over 
their corresponding SCi treated controls (Figure 3.2.4A). For the MDA-
MB-231 and BT474 cell lines, this increase in apoptosis from c-FLIP 
knockdown could be inhibited and returned to control base levels by 
the caspase-10 inhibitor, AEVD. The caspase-8 inhibitor, IETD, could 
prevent the increased apoptosis from c-FLIP knockdown observed in 
the MCF-7 and SKBR3 cell lines, although the caspase-9 and -10 
inhibitors also provided a similar inhibitory effect on the SKBR3 cells. 
These data suggest that c-FLIP regulates the base level of apoptosis 
seen in breast tumour cells by inhibiting the activation of capase-8, -9 
and -10 in a cell type dependant manner (Figure 3.2.4B).  
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Figure 3.2.4: c-FLIP knockdown induces a caspase dependant cell death 
in BCCLs. A) BCCL cell death following FLIPi treatment, normalised to SCi cell 
death as measured by fixable live/dead assay. B) Breast cancer cell death 
following FLIPi treatment normalised to SCi treated control cell death, in the 
presence or absence of IETD, LEHD and AEVD-FMK caspase inhibitors, * p<0.05. 
Data shown is representative of 3 experiments performed in triplicate ±SEM.  
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3.2.5 Suppression of c-FLIP (FLIPi) sensitized breast cancer 
cell lines to TRAIL induced apoptosis irrespective of 
hormone receptor status  
 Whilst most breast cancers are resistant to TRAIL induced 
apoptosis, it has recently been reported, and confirmed here, that 
mesenchymal breast cancer cell lines that lack hormone receptors 
(HER2 and ER$) partially respond to TRAIL treatment (Rahman et al. 
2009a). This is a clinically important subgroup of breast cancer, yet it 
represents only 15-20% of the breast cancer patient population.  In 
order to establish the extent to which c-FLIP might broaden the 
specificity of TRAIL-induced cytotoxicity, the relative sensitivity of 
different breast cancer subtypes to the combined effects of c-FLIP 
inhibition and TRAIL treatment was directly compared. To ensure 
treatment conditions between FLIPi and SCi cells were consistent the 
cell’s membranes were stained with PKH67 and PKH26 respectively, 
mixed at an equal ratio and treated in the same well as outlined in the 
‘heterotypic culture’ materials and methods section. The FLIPi and SCi 
cell populations were then separated and analysed for cell death as 
represented in Figure 3.2.5A (unstained control Appendix I).  
When c-FLIP inhibition (FLIPi) was combined with TRAIL 
administration, a significant TRAIL-dependent kill over their 
corresponding SCi cell death was observed for all of the breast cancer 
cell lines tested (Figure 3.2.5B, green bars, p<0.01). This 
demonstrated a marked sensitization to TRAIL in resistant cell lines, 
but no more than an additive effect of FLIPi in the TRAIL-sensitive 
MDA-MB-231 cell line (p=0.22). Thus FLIPi/TRAIL treatment 
significantly reduced breast cancer cell viability irrespective of 
hormone receptor status. Despite this sensitization to TRAIL, between 
8% (MDA-MB-231) and 33% (MCF-7) of the cell populations survived 
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the combined (TRAIL/FLIPi) treatment (Figure 3.2.5C), which 
suggested a differential response to this apoptotic insult by these 
heterogeneous cell populations. 
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Figure 3.2.5: c-FLIP knockdown 
sensitises resistant breast cancer 
cell lines to TRAIL A) Schematic 
demonstrating the heterotypic culture 
approach. PKH26 stained SCi cells 
and PKH67 stained FLIPi cells were 
cultured in the same well and treated 
with or without 20ng/ml TRAIL for 18 
hours before assessing cell death of 
each of these populations based on 
their plasma membrane stains by 
fixable live/dead assay. B) 
Percentage cell death of FLIPi cells 
untreated or treated with TRAIL, 
normalised to their respective SCi 
controls (i.e. red = percentage cell 
death increase as a result of FLIPi 
over SCi cell death and green = 
percentage increase in cell death as a 
result of FLIPi/TRAIL over SCi/TRAIL 
treatment) * p<0.01. C) Percentage 
of live breast cancer cells following 
FLIPi/TRAIL treatment. Data shown is 
representative of 3 experiments 
performed in triplicate ±SEM.  
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3.2.6 FLIPi sensitises breast cancer stem cells (bCSCs) to 
TRAIL  
 Breast tumours and breast cancer cell lines, contain a small sub-
population (up to 2%) of tumour-initiating (cancer stem) cells (Dontu 
et al. 2003a). These cells have been shown to be resistant to existing 
chemotherapeutic agents (Liu and Wicha 2010). To establish whether 
the cells surviving the FLIPi/TRAIL treatment within each cell line 
(Figure 3.2.5C) included a resistant sub-population of breast cancer 
stem cells (bCSCs), the functional mammosphere formation assay was 
used as previously described (Charafe-Jauffret et al. 2009; Dontu et 
al. 2003a; Harrison et al. 2010). Each of the cell lines was subjected to 
c-FLIP siRNA prior to transfer of viable cells to non-adherent low 
serum conditions, whereupon cells were treated with TRAIL. 
 Each of the untreated cell lines formed mammospheres of 
distinct size and morphology with the ER+ve lines, BT474 and MCF-7, 
forming the largest, most uniform colonies (Figure 3.2.6A) and the ER-
ve lines, SKBR3 and MDA-MB-231 forming loose, irregular colonies, as 
previously demonstrated (Harrison et al. 2010). Suppression of c-FLIP 
alone had no discernable effect on mammosphere integrity while 
TRAIL treatment alone partially impaired MCF-7 and MDA-MB-231 
mammosphere morphology. Combined treatment however severely 
disrupted mammosphere formation in all four cell lines. This was 
confirmed by quantitation of mammosphere forming units (MFUs) in 
short-term culture and serial passage (Figure 3.2.6B), whereby all 
self-renewing MFUs were deleted from the cell populations. 
 The frequency of mammosphere forming cells in the untreated 
cell lines ranged from 0.4% to 1.4% of the total cell populations.  
SKBR3 and MCF-7 MFUs were partially sensitive to TRAIL induced 
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anoikis, as less than a quarter of the mammospheres formed in the 
presence of TRAIL alone during the first passage compared to 
untreated controls (Figure 3.2.6B, Passage 1).   Similarly SKBR3, but 
not MCF-7, MFUs were significantly depleted with FLIPi treatment 
alone whilst MDA-MB-231 and BT474 MFUs were completely resistant 
to either FLIPi or TRAIL treament alone. In all cases however 
sensitivity to anoikis was dramatically enhanced with combined 
treatment. From starting populations of 12,000 cells, no 
mammospheres survived in MDA-MB-231 and BT474 cultures, while 2 
and 1 loose-forming colonies, respectively, were evident in SKBR3 and 
MCF-7 cells.  
Serial passaging of mammospheres in the absence of TRAIL 
and/or FLIPi revealed enrichment of MFUs in all cell cultures except 
those pre-treated with both TRAIL and FLIPi (Figure 3.2.6B, Passage 
2). MFU enrichment is indicative of stem cell self-renewal due to 
symmetric cell division (Dontu et al. 2003a). The complete loss of 
mammospheres from FLIPi/TRAIL treated cultures in subsequent 
passages suggests that the few surviving cancer-initiating cells from 
18 hours combined treatment were severely compromised and unable 
to undergo additional symmetric cell divisions.  
This complete ablation of functional MFUs represents a 
preferential sensitisation of bCSCs to TRAIL compared to the rest of 
the tumour cell population.  
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Figure 3.2.6: combined FLIPi/TRAIL treatment ablates the self-renewing cell 
population in BCCLs. A) Representative phase contrast images of SCi or FLIPi BCCL 
mammosphere morphology with or without 20ng/ml TRAIL treatment. B) BCCLs were 
treated with SCi or FLIPi and plated into mammosphere culture conditions in the presence or 
absence of 20ng/ml TRAIL. Percentage MFU from total cells plated was calculated following 7 
days in culture (Passage 1). Spheres from Passage 1 were dissociated by trypsin and re-
plated in mammosphere culture conditions for Passage 2 and %MFU re-calculated, * p<0.01. 
Data shown is representative of 3 experiments performed in triplicate ±SEM.  
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3.2.7 Confirmation of c-FLIP knockdown sensitisation 
In order to eliminate the possibility of any off-target effects of 
the siRNA a second oligo was designed to confirm the observed 
results. BT474 cells were transfected with this alternate siRNA oligo 
designed to suppress both c-FLIPL and c-FLIPs transcripts (knockdown 
confirmed by qRT-PCR and western blot, data not shown) and the 
sensitisation of both bulk tumour cells and CSC’s to TRAIL assessed 
under the same experimental protocol as Figure 3.2.6.  
The alternate siRNA sequence sensitised both the bulk and 
cancer stem cells to TRAIL in an almost identical manner to previous 
experiments. A significant increase in cell death In the FLIPi/TRAIL 
treated cells was observed over its corresponding SCi control (Figure 
3.2.7A, p=0.0075). Furthermore, the BT474 mammosphere forming 
capability was only marginally lower to that observed previously whilst 
the combined FLIPi/TRAIL treatment successfully abolished the anoikis 
resistant cancer stem cells with no mammospheres forming from the 
total 12,000 cells seeded (Figure 3.2.7B and C, p<0.00001).  
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Figure 3.2.7: c-FLIP knockdown using a different siRNA oligo confirms previous 
sensitisation observed A) Increase in BT474 cell death following FLIPi (red) or FLIPi/TRAIL 
(green) treatment over SCi and SCi/TRAIL cell death respectively, * p<0.01. B) Percentage 
MFU following SCi or FLIPi treatment alone or in combination with 20ng/ml TRAIL for 18 hour, 
* p<0.01. C) Representative phase contrast images of mammospheres formed in B. Data 
shown is representative of 3 experiments performed in triplicate ±SEM.  
 
100µmm 
  Chapter 3: Results 
L Piggott  Cardiff University 116 
3.2.8 c-FLIP knockdown reduces the ALDH1 expressing cancer 
cell population 
 Aldehyde dehydrogenase 1 (ALDH1) is a detoxifying enzyme 
responsible for the oxidation of intracellular aldehydes and has been 
shown to be particularly active in the stem/progenitor cell population 
of both the normal human mammary gland and mammary carcinomas 
(Ginestier et al. 2007). Moreover, it has been detailed that 
overexpression of HER2 leads to an increase in stem/progenitor cell 
population as characterised by both the mammosphere and ALDH1 
assays (Korkaya et al. 2008). Thus the enzymatic activity of ALDH1 
presents itself as a suitable surrogate marker for the bCSCs, especially 
in tumour cells that overexpress HER2.   
 The HER2 overexpressing cell lines SKBR3 and BT474 were 
treated with FLIPi/TRAIL and knockdown was confirmed by qRT-PCR. 
The population of cells with high ALDH1 activity was assessed using 
the aldefluor assay as described in materials and methods. Briefly, this 
assay functions by determining the ability of cells to convert the 
ALDH1 substrate, BAAA, into the bright fluorescent product, BAA-, that 
is retained in cells expressing high levels of ALDH1 and is subsequently 
detected by flow cytometry.  
 As an ALDH1 enzyme inhibitor, DEAB treated cells were used as 
a negative control such that a gate can be set for less than 1.5% 
positive cells. Using this gate a population of ALDH1-high (+ve) was 
identifiable in both the SKBR3 and BT474 cell lines (Figure 3.2.8A), 
with both the SCi controls averaging approximately 20% ALDH1+ve 
cell populations (Figure 3.2.8B). This positive population was 
significantly reduced in the surviving cells following FLIPi/TRAIL 
treatment of the SKBR3 and BT474 cell lines (SKBR3, p=0.027; 
BT474, p=0.037). In these cells the ALDH1+ve population was 
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reduced to 2.1% and 4.7% in the SKBR3 and BT474 cell lines 
respectively, supporting the previous observation in the functional 
mammosphere assay.  
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Figure 3.2.8: FLIPi/TRAIL treatment reduces the ALDH1 expressing population 
in BCCLs. A) Representative FACS plots of ALDH1 expression in the surviving cell 
populations of SCi or FLIPi/TRAIL treated BT474 and SKBR3 cell lines. B) Percentage of 
ALDH1+ve cells in BT474 and SKBR3 surviving cell populations after SCi or FLIPi/TRAIL 
treatment, * p<0.05. Data shown is representative of 3 experiments performed in 
triplicate ±SEM.  
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3.2.9 c-FLIP suppression sensitises bCSCs to TRAIL under 
adherent conditions 
The mammosphere formation assay primarily tests the ability of 
cells to resist anoikis, which is an important characteristic of tumour-
initiating (cancer stem) cells.  As c-FLIP has previously been reported 
to be an inhibitor of anoikis in other tumour cell types (Mawji et al. 
2007), it was necessary to test whether the MFU sensitization to TRAIL 
was dependent on the additional stresses imparted by the non-
adherent conditions. Each of the cell lines was subjected to c-FLIP 
siRNA and then incubated with TRAIL for 18 hours in adherent culture, 
as previously performed in the viability assays (Figure 3.2.5B).  Viable 
cells were subsequently washed and plated in non-adherent, 
mammosphere culture for 7 days, in the absence of TRAIL, and the 
number of mammospheres counted.  
The self-renewing capacity of MFUs was once again abolished in 
MCF7, MDA-MB-231 and BT474 cell lines, although SKBR3 cells 
exhibited a residual MFU self-renewal capacity.  Thus while some cell 
lines exhibited reduced sensitivity to combined treatment when 
maintained in adherent conditions, all continued to display a significant 
reduction in CSCs.  
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Figure 3.2.9: c-FLIP knockdown sensitises bCSCs to TRAIL under 
adherent conditions. BCCLs were treated with SCi or FLIPi alone or in 
combination with 20ng/ml of TRAIL for 18 hours. Surviving cells were then plated 
into mammosphere culture conditions  (Passage 1) and % MFU calculated from 
the total number of cells plated. Spheres from Passage 1 were dissociated by 
trypsin and cells re-plated in mammosphere culture conditions for Passage 2 and 
%MFU re-calculated, * p<0.03. Data shown is representative of 3 experiments 
performed in triplicate ±SEM. 
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3.2.10 c-FLIP suppression senisitises bCSCs to sub-toxic TRAIL 
concentrations 
 Although the bulk tumour cell populations of the luminal-like cell 
lines are resistant to TRAIL it was noted that the mammosphere 
forming potential of SKBR3 and MCF-7 cell lines was slightly abrogated 
when treated with TRAIL alone. To determine the contribution of TRAIL 
alone in the combined FLIPi/TRAIL treatment of bCSCs, a lower non-
toxic dose of TRAIL was used in the mammosphere assay.  
 Suppression of c-FLIP also sensitized cancer stem cells to sub-
toxic levels of TRAIL (Figure 3.2.9). TRAIL concentrations were 
reduced from 20ng/ml to 1ng/ml, levels that failed to activate a cell 
death response in the TRAIL-sensitive MDA-MB-231 cell line (Figure 
3.2.1C), and mammosphere cultures were performed as described 
above.  TRAIL addition alone had reduced effects on mammosphere 
integrity, yet combined treatment abrogated MFUs in BT474, SKBR3 
and MDA-MB-231 cell cultures, as previously observed with higher 
concentrations of TRAIL. The poorest responding cells to combined 
treatment, MCF-7 (Figure 3.2.6B), developed self-renewing MFUs at a 
very low frequency (1/12,000 cells seeded) in reduced TRAIL 
conditions (Figure 3.2.9). 
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Figure 3.2.10: c-FLIP knockdown sensitises bCSCs to sub-toxic TRAIL 
concentrations. BCCLs were treated with SCi or FLIPi alone or in combination 
with 1ng/ml of TRAIL for 18 hours. Surviving cells were then plated into 
mammosphere culture conditions  (Passage 1) and % MFU calculated from the 
total number of cells plated. Spheres from Passage 1 were dissociated by trypsin 
and cells re-plated in mammosphere culture conditions for Passage 2 and %MFU 
re-calculated, * p<0.01. Data shown is representative of 3 experiments 
performed in triplicate ±SEM. 
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3.11 Suppression of the c-FLIPL isoform is responsible for bCSC 
sensitisation to TRAIL 
 In order to address which c-FLIP isoform was responsible for the 
ablation of the self-renewing activity of the cancer stem cell 
population, siRNA sequences specific for cFLIP-short (c-FLIPS) and c-
FLIP-long (c-FLIPL) transcripts were used prior to TRAIL treatment and 
mammosphere assay.  
 In BT474 cells, silencing of c-FLIPL, but not c-FLIPS, followed by 
TRAIL treatment mimicked the effects previously observed when 
suppressing the entire c-FLIP transcript with no mammospheres 
forming from the total 12,000 cells seeded (Figure 3.2.11B). 
Interestingly, the silencing of c-FLIPS actually increased the 
mammosphere forming units, opening the possibility that c-FLIPS may 
play some role in the maintenance of cancer stem cells in the BT474 
cells (Figure 3.2.11A, Passage 1). In the MDA-MB-231 cells the 
combined knockdown of c-FLIPL and TRAIL treatment significantly 
reduced the mammosphere forming capability of the cells compared to 
SCi control or either treatment alone. In addition, c-FLIPS silencing 
combined with TRAIL treatment also resulted in a significant reduction 
of mammosphere forming units (Figure 3.2.11A, Passage 1). 
Importantly, however, mammospheres forming after c-FLIPL were not 
capable of self-renewal with the same proportion of mammosphere 
forming units in passage 2 being counted (Figure 3.2.11A, Passage 2). 
Contrastingly, this was not the case for c-FLIPS/TRAIL combined 
treatment. In this instance, the number of mammosphere forming 
units increased from 0.3% to 2% showing a significant capability to 
self-renew. Taken together these data indicate it is the c-FLIPL isoform 
that is responsible for determining bCSC sensitivity to TRAIL.  
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 To investigate which isoform of c-FLIP was responsible for 
sensitising bulk tumour cells, the BT474 cell line was treated with 
isoform specific siRNA and treated with TRAIL before cell death was 
assessed. Whilst suppressing the c-FLIPS, but not c-FLIPL, isoform of c-
FLIP gave a significant increase in cell death in combination with TRAIL 
(Figure 3.2.11C: Short, p=0.005; Long, p=0.133), this sensitization 
was not of the same scale as previously observed when suppressing 
the entire c-FLIP transcript (Figure 3.2.5B). This may suggest that 
both c-FLIPS and c-FLIPL both contribute to bulk tumour sensitization 
to TRAIL.  
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culture conditions for Passage 2 and %MFU re-calculated. B) Representative phase 
contrast images of BT474 mammospheres formed in A. C) BT474 cells were treated 
with c-FLIP-long and -short siRNA and treated with 20ng/ml TRAIL for 18 hours. 
Increased cell death of FLIPi and FLIPi/TRAILtreated BT474 cells, over SCi and 
SCi/TRAIL treated BT474 celss respectively, was then assessed by live/dead FACS. 
Data shown is representative of 3 experiments performed in triplicate ±SEM. 
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Figure 3.2.11: c-FLIPL but not c-
FLIPS knockdown sensitises 
bCSCs to TRAIL.  
A) BCCLs were treated with SCi or 
FLIPi, specific for the long and short 
isoforms, alone or in combination 
with 20ng/ml of TRAIL for 18 hours. 
Live cells were then plated into 
mammosphere culture conditions  
(Passage 1) and % MFU calculated 
from the total number of cells 
plated. Spheres from Passage 1 
were dissociated by trypsin and 
cells re-plated in mammosphere 
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3.2.12 Tumour initiation and metastasis formation are severely 
compromised following combined FLIPi/TRAIL treatment 
 BT474 cells formed the most well defined mammospheres in 
vitro and thus were used to further characterise previous observations 
in vivo. In order to confirm that the loss of MFUs was consistent with a 
reduction in tumour initiating capacity, adherent cultures of BT474 
cells were treated with c-FLIP siRNA and 106 viable cells orthotopically 
transplanted into the 4th inguinal mammary glands of severe combined 
immune-deficient (SCID) mice in the presence or absence of TRAIL 
(Figure 3.2.12A + B). Injected cells were also cultured under 
mammosphere conditions to assess the mammosphere forming 
capability of the transplanted cells in vitro. The occurrence of palpable 
tumours was then monitored for up to 16 weeks after transplantation.  
Tumours arose at the site of transplantation within 8 weeks 
(Figure 3.2.12C) of surgery in all mice transplanted with either 
untreated BT474 or FLIPi-treated BT474 cells, while 3 out of 5 mice 
with TRAIL-treated BT474 transplants acquired tumours in the same 
time-frame. However, 4 out of 5 transplants co-treated with FLIPi and 
TRAIL failed to acquire tumours within 16 weeks of surgery (Figure 
3.2.12A + C).  Tumour growth and histology (Figure 3.2.12B) was 
unaffected in all conditions. This residual tumour initiating capacity 
following combined treatment occurred despite complete loss of self-
renewing mammosphere forming potential in vitro (Figure 3.2.12D). 
Cancer stem cells are thought to be responsible for the seeding 
of new tumour growth at distal sights, which is central to the 
progression of metastatic disease – the major cause of mortality in 
breast cancer patients.  An established in vivo model of breast cancer 
metastasis, intravenous transplantation of MDA-MB-231 cells, was 
used to determine the effect of FLIPi/TRAIL on disease progression. 
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Adherent cultures of MDA-MB-231 cells were treated with c-FLIP siRNA 
(or control) and 106 viable cells transplanted intravenously into SCID 
mice in the presence or absence of TRAIL (Figure 3.2.12E).  After 6 
weeks, the number of lung metastases was determined by dissection 
and serial section of lung tissues from recipient mice (Figure 3.2.12F).  
An average of 23 secondary tumours per mouse were found in animals 
transplanted with control cells, compared to an average of 0.4 tumours 
(a total of 2 micrometastases from 5 mice) in transplants subjected to 
FLIPi and TRAIL.  This represented a 98% reduction in tumour burden 
and a significant sensitization to TRAIL-mediated suppression of 
metastatic disease (Figure 3.2.12E, p=0.0154). Significant reductions, 
up to 95%, were also observed in animals transplanted with FLIPi 
(FLIPi, p=0.028) or TRAIL (SCi + TRAIL, p=0.028) treated cells, 
however neither single treatment was as effective as FLIPi/TRAIL 
treatment in the prevention of metastasis.  
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Figure 3.2.12: FLIPi/TRAIL treatment reduces tumour initiation and metastasis in 
animal models. A) 1x107 SCi or FLIPi BT474 cells were xenografted, with or without 20ng/ml 
TRAIL, into the 4th inguinal mammary gland of athymic nu/nu mice. Tumour penetrance was 
then determined by the number of tumours formed per cohort. B) Representative image of H+E 
stained tumour and adjacent mammary gland excised from a SCi tumour-bearing animal. C) 
Kaplan-Meier survival curve of xenografted tumours in A. D) Representative phase contrast 
images of mammospheres formed from excess cells not transplanted in A. E) 1x106 MDA-MB-
231 cells were treated, as in A, and injected into SCID mice tail veins. Lungs from these animals 
were excised 6 weeks post-injection and metastases observed in H+E 50µm serial sections were 
counted, * p<0.03 compared to SCi, + p<0.05 compared to SCi + TRAIL. F) Representative H+E 
stained metastasis and surrounding lung tissue excised from SCi transplanted MDA-MB-231 
cells. Data shown is representative of 3 experiments performed in triplicate ±SEM 
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3.2.13 Re-acquired stem cells remain sensitive to repeat 
combined FLIPi/TRAIL treatment.  
 Despite no MFUs forming from the residual transplanted cells 
when cultured in vitro (Figure 3.2.12D), a tumour-initiating capacity 
was still observed in 1 out of 5 FLIPi/TRAIL treated BT474 in vivo 
transplants (Figure 3.2.12A). In order to determine whether this 
tumour-initiating potential was re-acquired from the surviving (post-
treatment) cell population, FLIPi/TRAIL treated cultures - with no 
residual mammosphere forming ability (Figure 3.2.13, Treatment 1) - 
were maintained in adherent culture for four weeks then transferred to 
mammosphere culture or re-treated with TRAIL/FLIPi (Figure 3.2.13A, 
Treatment 2).  
The surviving population slowly re-populated under the adherent 
culture conditions (Figure 3.2.13B) and re-acquired an equivalent 
proportion of mammospheres to the original untreated population 
(compare SCi samples, Figure 3.2.13A, Treatments 1 and 2). However, 
this subset of self-renewing cells was still exquisitely sensitive to 
FLIPi/TRAIL, as combined treatment of the re-established adherent 
cultures once again eradicated MFUs from the cell population (Figure 
3.2.13A, Treatment 2). Identical results were generated using the 
MDA-MB-231 cells, however in this instance the re-acquisition of MFUs 
was quicker taking only 2 weeks for the population to return.  
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shown is representative of 3 experiments performed in triplicate ±SEM. 
Figure 3.1.13: Re-acquired 
bCSCs remain sensitive to 
repeated FLIPi/TRAIL 
treatment. A) BT474 cells were 
treated with SCi or FLIPi/TRAIL 
and % MFU calculated. Surviving 
cells were then also plated into 
normal adherent culture 
conditions for 4 weeks prior to a 
second SCi or FLIPi/TRAIL 
treatment. Treated cells were 
then once again plated in 
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3.2.14 Maintaining c-FLIP suppression prevents the re-
acquisition of MFUs in breast cancer cell lines 
 Repetitive treatment of FLIPi/TRAIL upon tumour relapse may 
prove useful therapeutic approach to treating breast cancer, however, 
a far more robust therapeutic strategy has and always will be the 
prevention of tumour relapse in the first place. Hitherto we have 
demonstrated an important role for the anti-apoptotic factor c-FLIP in 
regulating death receptor-induced apoptosis but it is also clear that c-
FLIP has alternative functions in regulating other signalling pathways 
within the cell beyond its anti-apoptotic property. As such, it has been 
shown to regulate NF-%B (Fang et al. 2004; Kataoka et al. 2000; 
Kataoka and Tschopp 2004), Wnt (Katayama et al. 2010; Naito et al. 
2004) and Akt (Quintavalle et al. 2010) signalling, each of which have 
themselves been demonstrated to regulate cancer stem cell 
maintenance (Hinohara et al. 2012; Korkaya et al. 2009; Lu and 
Carson 2011; Shostak and Chariot 2011; Takahashi-Yanaga and Kahn 
2010).  
To investigate the role of c-FLIP in cancer stem cell maintenance 
a lentiviral vector containing c-FLIP shRNA was used to stably suppress 
c-FLIP long-term in breast cancer cell lines and the mammosphere re-
acquisition potential of cells surviving FLIPi/TRAIL treatment was 
assessed in the same manner as, and in tandem with, the previous 
siRNA methodology (Figure 3.2.13A).  
 Cells infected with c-FLIP shRNA (shFLIPi) successfully 
suppressed both c-FLIP mRNA and protein levels in the MCF-7 cell line 
(Figure 3.2.14A). The shFLIPi cells maintained a similar number of 
MFUs to the FLIPi treated cells and the mammospheres formed had the 
same morphology and also self-renewed in a similar proportion (Figure 
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3.2.14B, white bars). Furthermore, these cells responded to TRAIL 
treatment in a manner consistent with cells receiving FLIPi/TRAIL 
treatment, with no MFUs with self-renewal capacity forming (Figure 
3.2.14B, green bars). Conversely, when the surviving population of 
both FLIPi/TRAIL and shFLIPi/TRAIL treated MCF-7 cells was re-plated, 
as in Figure 3.2.13A, only the FLIPi/TRAIL treated cells were capable of 
mammosphere re-acquisition and adherent cell growth (Figure 
3.2.14C). After 2 weeks of culture the shFLIPi/TRAIL treated cells did 
not proliferate in adherence and subsequent mammosphere assays 
demonstrated no MFUs were re-acquired. These results were then 
replicated using a separate c-FLIP shRNA sequence at a different viral 
titre in the MCF-7 cells (data not shown). These data suggest that c-
FLIP may regulate the re-acquisition of bCSCs following their ablation 
from the tumour bulk and thus may play some part in tumour cell 
plasticity. 
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Figure 3.2.14: Maintaining suppression of c-FLIP prevents re-acquisition of 
bCSCs. A) c-FLIP mRNA expression and protein levels in shFLIPi MCF-7 cells. B) 
Percentage MFU in the live cell population of untreated and 20ng/ml TRAIL treated (18 
hours) shFLIPi cells, * p<0.01. C) Surviving FLIPi/TRAIL and shFLIPi/TRAIL cell 
populations were cultured in adherent conditions and checked for re-acquistion of MFUs 
at regular intervals. Data shown is representative of 3 experiments performed in 
triplicate ±SEM 
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3.3 Discussion 
 
 Tumour heterogeneity is a major obstacle to therapy. Recent 
insights into the hierarchical organisation of tumour cell populations 
highlight the potential importance of targeting the minority tumour-
initiating (cancer stem) cell population associated with cancers in order 
to radically improve patient outcome. However, cancer stem cells have 
been shown to be inherently resistant to chemotherapeutic challenge. 
TRAIL receptor agonists have shown much promise as a cancer 
therapeutic, exerting a cytotoxic effect on cancer cells whilst sparing 
normal cells (Ashkenazi et al. 1999; Kruyt 2008). Hitherto it has been 
demonstrated that the majority of breast cancer subtypes display 
resistance to TRAIL agonists and cell death is only achieved when used 
in combination other agents (Dyer et al. 2007; Rahman et al. 2009a). 
Previous studies have indicated that c-FLIP expression levels correlate 
with resistance/sensitivity to TRAIL-induced cell death (Frew et al. 
2008; Jonsson et al. 2003; Katayama et al. 2010; Palacios et al. 2006; 
Shankar et al. 2009). The main role for c-FLIP is as a direct repressor 
of caspase-8 activation, however it has also been shown to regulate 
cell fate via alternate signalling pathways such as Akt, NF%B and Wnt 
(Kataoka et al. 2000; Naito et al. 2004; Quintavalle et al. 2010). 
Despite all this evidence, no studies have previously been performed 
to fully evaluate the efficacy of suppressing c-FLIP protein levels as a 
sensitization method for TRAIL on a broad range of both inter- and 
intra-tumorally heterogeneic breast cancer subtypes and on metastatic 
disease. The aim of this chapter was to address this by assessing 
FLIPi/TRAIL treatment both in vitro and in vivo with particular focus on 
its efficiency to target both tumour heterogeneity and metastasis. 
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3.3.1 c-FLIP knockdown selectively sensitises bCSCs to TRAIL 
mediated cell death without effecting normal epithelium 
 Before investigation of c-FLIP suppression as a broad 
sensitising agent to TRAIL in breast cancer, it was important to first 
assess the effect of c-FLIP suppression both individually and in 
combination with TRAIL on normal epithelium. The apoptosis observed 
following c-FLIP inhibition is, like TRAIL, a phenomenon that is cancer-
specific. At present this observation has not been extended beyond 
non-tumourgenic cell lines, it will be imperative to assess the effects of 
FLIPi on normal cells both in vivo and in normal primary human cells 
before identifying FLIPi as a viable therapeutic strategy. Analysis of 
non-transformed mammary tissues from c-FLIP-deficient mice 
indicated that the absence of c-FLIP was not detrimental to normal 
tissue and did not sensitise normal tissue cells to TRAIL induced 
apoptosis (Figure 3.2.3). Currently there is no available means (in 
Cardiff) for testing normal human epithelial cell susceptibility to 
FLIPi/TRAIL, thus it has not been established whether normal stem 
cells of the breast are affected by either intervention. However, the 
non-tumourgenic transformed human epithelial cell line MCF10A also 
showed this same resistance to FLIPi/TRAIL treatment despite being a 
TRAIL-sensitive cell line. Interestingly, neural progenitor cells are 
resistant to TRAIL in a c-FLIP independent manner (Peng et al. 2005) 
and future investigation whether murine mammary stem cells are 
similarly refractory is of great interest.  
Significantly, mouse breast cancer cell lines did show sensitivity 
to TRAIL when treated with c-FLIP siRNA (FLIPi) and TRAIL as 
demonstrated by the ErbB2 positive N202.1A cell line (Figure 3.2.3). 
This sensitisation effect was then subsequently demonstrated in a 
panel of human bCCLs representing different subtypes of disease 
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(Figure 3.2.5).  Interestingly, knockdown of c-FLIP alone resulted in a 
10-15% increase in apoptosis that was shown to be a caspase-
dependant process (Figure 3.2.4). This result was consistent with a 
previous study that has shown FLIPi as an anti-tumour monotherapy 
both in vitro and in vivo (Day et al. 2008; Day et al. 2009). These 
results both confirm and broaden the scope for c-FLIP as a therapeutic 
target in breast cancer. 
 Recent studies demonstrating the importance of CSCs in cancer 
recurrence and metastatic progression identify them as a key target 
cell population in new therapy design. Here it is established both in 
vitro and in vivo that FLIPi selectively sensitizes this population to 
TRAIL-mediated killing independent of hormone status (Figure 3.2.6). 
This was demonstrated when combined FLIPi/TRAIL treatment resulted 
in the complete ablation of self-renewing MFUs and reduction in ALDH1 
expressing population, both of which are assays frequently used for in 
vitro identification of bCSCs. More specifically, the suppression of c-
FLIPL was responsible for the sensitisation of both the bulk tumour 
cells and the bCSCs (Figure 3.2.11). This supports other studies that 
have also revealed that c-FLIPL isoform plays an important role in 
sensitivity to TRAIL (Rosato et al. 2007; Yerbes et al. 2012). 
Confirmation of this bCSC ablation was demonstrated by transplanting 
ex vivo FLIPi/TRAIL treated cells into mice. The marked reduction in 
both tumour initiation and metastasis that followed showed the real 
therapeutic potential FLIPi/TRAIL treatment (Figure 3.2.12). 
Importantly, these results were acquired by a single treatment of 
TRAIL co-injected with the FLIPi cells. TRAIL sensitization has not 
previously been described in solid tumour stem cells. Thus, these 
results are the first demonstration of TRAIL-mediated loss of functional 
stem cell activity in a solid tumour cell type and the first indication 
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that CSC activity is directly influenced by c-FLIP. It did however raise 
further questions as to the therapeutic efficiency of the combined 
treatment, as one out of five xenografts still managed to form a 
primary tumour and two lung metastases were observed in the 
FLIPi/TRAIL tail vein injection experiments. The residual 
tumourgenicity observed in vivo was recapitulated in vitro by 
continued culture of the FLIPi/TRAIL surviving cell population in 
adherent culture condition. Following weeks of culture under these 
conditions, the MFU population returned (Figure 3.2.13). Crucially, 
however, Figure 3.2.13 shows that the newly acquired MFU activity 
remained responsive to re-administration of FLIPi/TRAIL. A similar 
sensitivity to repeat treatments has previously been observed for the 
Akt inhibitor perifosine, in a xenograft model of Sum159 cells (Korkaya 
et al. 2009). These observations have important implications for the 
future prevention of disease relapse in the clinical setting as they 
demonstrate that the tumourgenic cell population may be targeted 
without selecting for resistant cells. Given the inferences that c-FLIP 
may also play a role in signalling pathways regulating CSC population 
maintenance, it was satisfying to discover that the long-term 
suppression of c-FLIP prevented this re-acquisition of the bCSC 
population. This may have cost implications by indicating that 
repetitive combined FLIPi/TRAIL treatment may not be necessary but 
instead FLIPi must be maintained following a complete FLIPi/TRAIL 
regime.  
 
3.3.2 Therapeutic implications of combined FLIPi/TRAIL 
treatment 
It has been suggested that tumour cells in their natural context 
do not necessarily exhibit the sensitivity to TRAIL monotherapy as 
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observed in vitro, implying that a combined therapy would be required 
to re-sensitize to TRAIL (Dyer et al. 2007). RNAi was used to 
demonstrate the proof of principle that suppression of c-FLIP 
expression is sufficient to sensitize breast cancer cells to TRAIL. In 
light of this, a key future objective is to establish whether long-term 
suppression of c-FLIP in vivo, following the cessation of TRAIL 
treatment, might help prevent the recurrence of tumours as 
demonstrated in vitro (Figure 3.2.14). Despite limitations in drug 
design due to structural homology between c-FLIP and caspases, 
agents with broad specificity for c-FLIP have been described, each with 
anti-tumour properties (Bijangi-Vishehsaraei et al. 2010; Frew et al. 
2008; Hyer et al. 2005; Lee et al. 2009; Palacios et al. 2006; Tazzari 
et al. 2008). It remains to be determined if these agents exhibit 
selective targeting of cancer stem cells and whether this too can be 
recapitulated in vivo in the absence of off-target effects.  
The breadth of the breast tumour cell types affected here raises 
the question of the potential ubiquity of FLIPi/TRAIL treatment in 
targeting other cancer types in vivo. Of the few studies that have 
addressed the sensitivity of cancer stem cells to TRAIL (Kruyt 2008), 
the majority, including medulloblastoma (Yu et al. 2010a), 
glioblastoma (Capper et al. 2009) and lymphoma (Zobalova et al. 
2008) -derived stem cells, are resistant, with the exception of 
colorectal cancer cell lines in which a FACS sorted side-population was 
shown to be TRAIL responsive (Sussman et al. 2007). Sensitization of 
cancer stem cells to TRAIL has only previously been demonstrated in 
haematological cancers, including AML (Tazzari et al. 2008) and T cell 
lymphoma cells (Zobalova et al. 2008), both of which have implicated, 
but not functionally proven, a role for c-FLIP in the process. Other 
mechanisms for targeting breast cancer stem cells have been 
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described. Notably, a recent study demonstrated reduced stem cell 
activity in response to Notch1 or Notch4 suppression using the same 
breast cancer cell lines described here (Harrison et al. 2010), which 
supports the use of gamma-secretase inhibitors in clinical trials (Liu 
and Wicha 2010). The Akt/Wnt pathway inhibitor, perifosine, reduces 
breast cancer stem cell numbers (Korkaya et al. 2009) and incidentally 
is responsible for the reduction in c-FLIP levels in AML stem cells 
(Tazzari et al. 2008). Furthermore, it has been suggested that breast 
cancer stem cells may selectively express HER2 (Magnifico et al. 2009) 
and that inhibition of this pathway could have beneficial consequences 
for breast cancer patients with both HER2-positive and HER2-negative 
disease (Korkaya et al. 2008; Liu and Wicha 2010). As significant 
responses of CSCs to combined FLIPi/TRAIL were seen, independent of 
HER2 receptor status, it will be of interest in the future to establish 
whether primary human tumour stem cell populations are equally 
susceptible and whether this is due to amplification of a DISC-related 
mechanism.  
3.4 Summary 
 In summary, work detailed in this chapter has demonstrated 
that c-FLIP suppression acts as a sensitiser to TRAIL in a broad range 
of breast cancer subtypes but more importantly, c-FLIP suppression in 
combination with TRAIL selectively ablates the self-renewing bCSC 
population in vitro in all different subtypes of disease investigated 
whilst also successfully reduced tumour initiation and metastasis in 
vivo. Significantly, this treatment combination appears to have almost 
no effect on the normal cell populations tested making it a very 
attractive potential therapy for development into the clinical setting.
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4.1 Introduction 
  
 Breast cancer is well recognised as a hormone-dependant 
tumour and with nearly 70% of breast tumours expressing estrogen 
receptor (ER) it is clear that estrogen itself plays a vital role in tumour 
development and progression (Anderson et al. 2002). This was first 
confirmed by George Beatson in 1896 where studies showed that 
oopherectomy gave tumour remission in women with metastatic breast 
cancer by depriving tumours of circulating estrogen (Beatson 1896). 
This indicated that endocrine therapy would be beneficial to patients 
with tumours being driven by estrogen as it provides anti-tumour 
properties without the adverse side effects connected with 
chemotherapeutic intervention (Pritchard et al. 1997; Robertson 
1996). As such, the selective ER modulator tamoxifen has become the 
standard anti-estrogen therapy over the last 25-30 years giving 
improved survival and quality of life in early and advanced ER+ve 
disease sufferers (EBCTCG 1998; Jaiyesimi et al. 1995). Since the 
discovery of tamoxifen, further endocrine agents have been developed 
to either directly target estrogen production itself, for example 
aromatase inhibitors (AIs) (Osborne 1999) (Johnston and Cheung 
2010), or degrade ER, such as fulvestrant (Wakeling et al. 1991). 
These agents abrogate ER signalling in a different manner to 
tamoxifen and have also been shown to be clinically successful, with 
AIs now the gold standard endocrine agent in ER+ve postmenopausal 
women (Buzdar 2003). Collectively, these agents have dramatically 
improved the outcome and quality of life of ER-positive breast cancer 
sufferers by providing a relatively non-toxic anti-tumour therapy.  
 Unfortunately, one major pitfall of endocrine therapy is that a 
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resistance to this form of treatment following initial responsiveness 
and in some cases the endocrine agent itself may even begin to drive 
tumour growth and progression (Musgrove and Sutherland 2009; 
Schiff et al. 2003). For example, most patients with metastatic 
disease, and up to 40% of ER+ve patients, receiving adjuvant 
tamoxifen will acquire resistance to its inhibitory effects on breast 
cancer cell proliferation (Musgrove and Sutherland 2009; Schiff et al. 
2003). Unfortunately, resistance also equates with tumour 
aggressiveness and poorer prognosis (Hiscox et al. 2006). Acquired 
resistance is therefore a hurdle that must be overcome to maintain the 
beneficial effects of endocrine therapy. 
 It is suggested ER expression remains a stable phenotype for 
many acquired resistance tumours that initially responded to endocrine 
agents (Staka et al. 2005) and this is further corroborated by data 
showing that a proportion of acquired resistance tumours remain 
sensitive to additional endocrine treatment, however, as a therapeutic 
avenue this too has its limitations as response to additional endocrine 
therapies declines over time and tumours act more and more 
independent of ER (Johnston et al. 1995; Kuukasjarvi et al. 1996; 
Osborne et al. 1994). A further cohort is also believed to lose ER 
entirely during endocrine treatment. Recent model systems studies 
have also elucidated that endocrine agents upregulate various growth 
factor signalling pathways whilst the cells are still responding. 
Subsequently, these growth factors have been attributed to promoting 
tumour growth once cells have acquired resistance (Arpino et al. 2008; 
Beeram et al. 2007; Nicholson et al. 2004b). Thus many attempts to 
overcome endocrine resistance by targeting these signalling pathways 
have been made alongside endocrine agents (Johnston et al. 2008). 
Whilst there have been great advances in understanding and 
  Chapter 4: Results 
L Piggott  Cardiff University 143 
treatment of endocrine resistant tumours, it still remains a difficult 
hurdle to overcome in the management and prevention of long-term 
disease since many AE-resistant patients are also resistant to anti-
growth factor treatment. 
 In this chapter the efficacy of TRAIL as a novel anti-tumour 
agent for endocrine resistant breast cancer was investigated. Using in 
vitro models developed by the breast cancer molecular pharmacology 
group to mimic acquired endocrine resistance, where ER-positive cell 
lines (e.g. MCF-7) are cultured long-term (up to 2 years) in low dose 
4-hydroxy-tamoxifen or Faslodex and following initial responses 
eventually become resistant, the effectiveness of TRAIL treatment on 
these acquired resistance cell lines was then addressed in vitro and in 
in vivo transplantation models.  
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4.2 Results 
 
4.2.1 Acquired endocrine-resistant MCF-7-derived cell lines are 
hypersensitive to TRAIL induced cell death 
 A great advantage of combined FLIPi/TRAIL treatment in the 
context of breast cancer is the breadth of response seen across models 
representing many different disease subtypes. Importantly a marked 
response was seen in the reduction of metastasis (Figure 3.2.12), 
targeting the key process responsible for fatality. Another important 
therapeutic group with poor prognosis is endocrine therapy-resistant 
patients. These patients no longer respond to typical adjuvant first-line 
therapies, show an increased rate of metastasis and there is a great 
need for, and hence much research in the development of, novel 
therapeutic strategies in the adjuvant and advanced setting for these 
patients.  
 Using MCF-7-derived acquired endocrine resistant cell lines, the 
efficacy of TRAIL as a potential remedy was investigated. Treating 
long-term tamoxifen and Faslodex acquired resistant MCF-7 cell lines 
(TAMR and FASR respectively) with TRAIL resulted in a significant 
reduction in cell viability and an increase in cell death contrasting the 
parental MCF-7 model (Figure 4.2.1: TAMR, p<0.001; FASR, 
p=0.001). TAMR cells responded particularly well with very few 
surviving cells visible by microscopy following treatment (Figure 
4.2.1C). Furthermore both TAMR and FASR cells gave significant cell 
death at a ten times lower concentration of TRAIL than TRAIL-sensitive 
breast cancer cell line MDA-MB-231 (Figure 3.2.1C: TAMR, p=0.001; 
FASR, p=0.002), indicating that endocrine resistant cell lines display a 
hypersensitivity to TRAIL (Figure 4.2.1D).  
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Figure 4.2.1: MCF-7-derived AE resistant cell lines are hypersensitive to TRAIL A) Cell 
lines were incubated with 20ng/ml soluble TRAIL for 18 hours and cell viability assessed by 
cellTiter Blue viability assay,* p<0.01. B) Cell lines were incubated for 18 hours +/-20ng/ml 
TRAIL, and assessed by FACS for live/dead cells as described in methods, * p<0.01. C) Phase 
contrast images of cell lines following TRAIL treatment. D) TAMR and FASR cell lines were 
treated with increasing concentrations of TRAIL for 18 hours and viability assessed by cellTiter 
Blue assay. 
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4.2.2 TRAIL treatment of acquired endocrine resistant cell line 
targets bCSC population 
 As previously stated, within each tumour there exists different 
subsets of tumour cells, with one of the most functionally important 
being the cancer stem cell. This small subset of cells have been shown 
to be particularly resistant to radio- and chemo-therapeutic challenge 
(Phillips et al. 2006; Tanei et al. 2009) and as already shown targeting 
this subset has profound effects on tumour initiation and metastatic 
capability of cells (Chapter 3). Therefore for TRAIL to maintain a 
significant long-term preventative effect the CSCs must be targeted.  
  The effect of TRAIL treatment on stem-like activity in the 
endocrine resistant cell lines was analysed by treating TAMR and FASR 
cells in mammosphere culture conditions and, additionally, by treating 
adherent cultures of TAMR and FASR cells prior to plating the surviving 
cell population into mammosphere culture conditions in the absence of 
TRAIL.  
 Both TAMR and FASR cell lines were capable of forming 
mammospheres similar in morphology and size to their parental MCF-7 
cell line (Figure 4.2.2C). A small difference was observed in the FASR 
mammospheres that appeared to form more of a lumen in the centre 
of their spheres, which is normally occupied by cells in the MCF-7 
spheres (Figure 4.2.2C). These hollow spheres more closely resemble 
the morphology seen in primary breast cancer mammospheres, 
however, the reason for this is unknown and further research may 
provide further insight into FASR cell behaviour. Spheres formed from 
untreated endocrine-resistant TAMR and FASR cells showed that they 
contained a larger population of MFUs in passage 1 than their parental 
MCF-7 cells, signifying that these cell lines may contain a larger pool of 
anoikis-resistant cells. A single residual mammosphere was observed 
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in the TRAIL treated FASR cells (Figure 4.2.2C), however, there was 
no increase in MFU formation from this mammosphere in passage 2 
(Figure 4.2.2A). No MFUs were identifiable in the TRAIL treated TAMR 
cells. Surviving cell populations from adherent treated cells also failed 
to form any MFUs for both FASR and TAMR cells (Figure 4.2.2B) which 
contrasted the more modest reduction in MFU forming capability of 
MCF-7 cells (Figure 3.2.10), albeit mammospheres which maintained 
the capacity to self-renew (Figure 4.2.2B, passage 2).  
 These data show that both bulk tumour cells and CSCs are 
hypersensitive to TRAIL, implying long-term benefits and providing 
further support for TRAIL as a treatment for endocrine-resistant 
tumours.  
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Figure 4.2.2: bCSCs of AE resistant 
MCF-7 cell lines are also 
hypersensitive to TRAIL A) Cell lines 
were plated in low-serum non-adherent 
(mammosphere) culture conditions in the 
presence or absence of 20ng/ml TRAIL at a 
density of 4,000 cells per well (20,000 
cells/ml) (ND = Not Detected). 
Mammospheres from 3 replicate wells per 
condition were counted following 7 days 
culture (Passage 1). Mammospheres were 
dissociated using trypsin, passaged at a 
density of 2,000 cells/well (10,000 
cells/ml) in the absence of TRAIL and 
counted after 7 days culture (Passage 2). 
B) Cell lines were treated in adherent 
conditions with 20ng/ml TRAIL and then 
surviving cells plated in mammosphere 
conditions, as described in (A). As in (A), 
graphs represent the percentage of 
mammospheres formed following 7 days 
culture (Passage 1) and 7 days after 
trypsinisation and re-seeding (Passage 2). 
C) Representative phase/contrast images 
of mammospheres formed in (A). Data 
shown is representative of 3 experiments 
performed in triplicate ±SEM, * p<0.05. 
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4.2.3 TAMR and FASR hypersensitivity to TRAIL is a result of 
acquired resistance  
 As most breast cancers display resistance to TRAIL-induced cell 
death many attempts have been made to sensitise these resistant cells 
by combination therapies, some of which have been successful, 
including histone deacetylase inhibitors (HDACs) and cyclin dependant 
kinase (CDK) inhibitors (Ortiz-Ferron et al. 2008; Palacios et al. 2006; 
Shankar et al. 2009). To date there has been no evidence to suggest 
that either tamoxifen or Faslodex act as sensitising agents for TRAIL.  
 In order to determine if the hypersensitivity to TRAIL observed 
in the TAMR and FASR cell lines was a result of sensitisation by 
combination treatment with endocrine agents or changes to the cells 
as a consequence of long-term acquisition of endocrine resistance, the 
parental MCF-7 cells were treated with TRAIL in combination with 
tamoxifen and Faslodex respectively. Additionally MCF-7 cells were 
treated short-term with tamoxifen and Faslodex for 7 days, prior to 
TRAIL treatment, a standard timeframe for ER blockade. Furthermore, 
tamoxifen was also withdrawn from TAMR cell cultures for 1 week 
(TAMR-W), prior to TRAIL challenge, in order to determine if the 
response to TRAIL was due to irreversible cellular changes from long-
term acquired resistance. 
  Treating MCF-7 cells for 18 hours with either endocrine agent 
alone or in combination with TRAIL resulted in no significant reduction 
of cell viability (Figure 4.2.3A), confirming the sensitivity of the TAMR 
and FASR cells to TRAIL as a long-term acquired resistance phenotype. 
Furthermore, treating MCF-7 cells with tamoxifen and Faslodex for 7 
days prior to TRAIL treatment had no significant effect on cell viability 
suggesting that only long-term acquired resistance precipitated 
sensitivity to TRAIL (Figure 4.2.3B). Moreover, removing the influence 
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of tamoxifen on cell growth (TAMR-W) prior to TRAIL treatment also 
had no effect on the sensitivity of TAMR cells to TRAIL with an almost 
identical profile of sensitivity to a range of TRAIL concentrations being 
portrayed between the TAMR and TAMR-W cells (Figure 4.2.3C). This 
suggests that the TAMR sensitivity to TRAIL was due to irreversible 
cellular changes resulting from the prolonged effects of tamoxifen 
treatment. Some small differences in TRAIL sensitivity were observed 
at lower doses so, to confirm that this was not a specific effect on the 
CSCs, surviving cells were plated into mammosphere conditions where 
both TAMR and TAMR-W untreated MFUs were both identical in size 
and equally targeted by TRAIL treatment (Figure 4.2.3D).  
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Figure 4.2.3: AEs do not sensitise MCF-7 cell lines to TRAIL A) MCF-7 cells 
were treated with Faslodex or tamoxifen alone or in combination with 20ng/ml 
TRAIL for 18 hours and cell viability assessed by cellTiter Blue assay. B) MCF-7 
cells were treated for 7 days with either tamoxifen or Faslodex prior to 20ng/ml 
TRAIL treatment for 18 hours and cell viability assessed by cellTiter Blue assay. C) 
tamoxifen was withdrawn from culturing TAMR cells for 7 days (TAMR-W) and 
treated with increasing concentrations of TRAIL for 18 hours and cell viability 
assessed by cellTiter Blue assay. D) TAMR and TAMR-W cells were treated as in 
Figure 4.2.2A and %MFU calculated. Representative phase contrast images of 
mammospheres formed in untreated TAMR and TAMR-W cells. Data shown is 
representative of 3 experiments performed in triplicate ±SEM 
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4.2.4 Acquired tamoxifen-resistant EFM19 cells display similar 
hypersensitivity to TRAIL as MCF-7-derived cell lines 
 Although both TAMR and FASR cells showed hypersensitivity to 
TRAIL treatment both these endocrine resistant cell lines were derived 
from the hormone responsive ER+ve parental MCF-7 cell line. To 
ensure the observed hypersensitivity was not a cell line specific effect 
of acquired resistance an EFM19-derived tamoxifen-resistant line (~1 
year tamoxifen treated), developed in the same manner as the TAMR 
cells by the BCMP group from ER+ve, hormone responsive, EFM19 
cells (Westley and May 1988), was cultured in the presence of TRAIL.  
 The sensitivity to TRAIL of the parental EFM19 cell line has not 
been previously reported. EFM19 cells demonstrated some sensitivity 
to TRAIL, even at a low dosage of 5ng/ml, reducing cell viability by 
40%. Cell viability was reduced by up to 60% when treated at 20ng/ml 
TRAIL. However, the acquired tamoxifen-resistant derivative of the 
EFM19 cell line (EFM-TAMR) again showed increased sensitivity to 
TRAIL over their parental counterpart with 40% more cell death at 
5ng/ml TRAIL and viability being reduced down to as low as 10% when 
treated at 20ng/ml (Figure 4.2.4A). From phase contrast microscopy 
pictures following TRAIL treatment it is clear that 20ng/ml treatment 
of EFM19-TAMR cells leaves almost no detectable surviving cells 
whereas the parental EFM19 cells appear to still have a population of 
adherent surviving cells (Figure 4.2.4B). This increased cell death over 
the parental cell line confirms the hypersensitivity of tamoxifen-
resistant cells in multiple cell lines. 
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Figure 4.2.4: EFM19-derived AE resistant cell lines are more sensitive to TRAIL 
than parental EFM19 cells. A) Cell lines were incubated with 20ng/ml soluble TRAIL 
for 18 hours and cell viability assessed by cellTiter Blue viability assay, * p<0.01 
compared to EFM 5ng/ml, +p<0.01 compared to EFM untreated. B) Representative 
phase contrast images of cell lines after treatment outlined in (A). Data shown is 
representative of 3 experiments performed in triplicate ±SEM 
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4.2.5 TRAIL hypersensitivity of TAMR and FASR cells is not a 
result of estrogen deprivation. 
  During long-term culture and acquisition of resistance of MCF-7 
cells to tamoxifen or Faslodex the cells lose their reliance on estrogen 
for cell growth. It is possible therefore that this loss of estrogen 
dependence may be responsible for the sensitivity to TRAIL observed 
in the TAMR and FASR cell lines. To determine if lack of estrogen-
dependent signalling is responsible for TAMR/FASR hypersensitivity to 
TRAIL a third MCF-7 derived model of estrogen deprivation was used. 
These cells (MCF-7-XL (Staka et al. 2005)) were developed by up to 2 
years maintenance in the absence of estrogen and hence their cell 
growth no longer relies on estrogen-induced signalling. The MCF-7-XL 
cells were treated with TRAIL in both adherent and mammosphere 
culture conditions to ascertain their sensitivity. 
 Treating the XL cells with TRAIL under adherent culture 
conditions gave no significant reduction in cell viability with the cells 
demonstrating almost identical resistance to TRAIL as their parental 
MCF-7 cells (Figure 4.2.5A). This effect was then mimicked in the 
EFM19 estrogen deprivation model, where EFM19-XL cells were also 
resistant to TRAIL (Figure 4.2.5F). Previously it was shown that 
tamoxifen or Faslodex as a combination therapy with TRAIL, did not 
cause any significant cell death in MCF-7 cells (Figure 4.2.3A) and it 
was explored if this was also true for such AE ER blockade in XL cells. 
The XL cells were treated with each endocrine drug alone and also in 
combination with TRAIL. The resulting response of the XL cells was the 
same as the MCF-7 cells with no significant cell death observed by 
combination endocrine/TRAIL treatment (Figure 4.2.5B). In the 
context of bCSCs, the XL cells appear to have a larger mammosphere 
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forming population, similar to the TAMR and FASR cells (Figure 4.2.5C, 
white bars). Interestingly this increase in MFUs was not consistent in 
passage 2 where the percentage of MCF-7 MFUs increased more than 
that of the XL cells suggesting the XL cells have a reduced self-renewal 
capacity. Previous data showed that MCF-7 mammosphere formation 
capability was reduced by treatment of adherent cultures with TRAIL, 
although MFUs with self-renewal capacity did still form. The XL cells on 
the other hand did not demonstrate any reduction in mammosphere 
forming capacity when treated with TRAIL under adherent conditions, 
indicating that the XL MFUs are more resistant to TRAIL (Figure 
4.2.5D). However, the mammospheres formed by the XL cells showed 
no difference in morphology or size in comparison to their parental 
MCF-7 cells (Figure 4.2.5D, 4.2.5E). Interestingly, the estrogen-
deprived EFM19-XL cells also demonstrated increased resistance to 
TRAIL compared to their parental EFM19 cells, further supporting the 
TRAIL resistance of the MCF-7-derived XL cell line.   
 Collectively these data confirm that ER signalling is not a 
determinant for sensitivity to TRAIL in MCF-7-derived acquired AE-
resistant models. XL cells still maintain their ER signalling, in the 
absence of estrogen, in a similar fashion to TAMR cells, however, the 
FASR cells are an ubiquitously ER-ve cell line and TRAIL response 
between each of these cell lines differs greatly. This indicates that the 
sensitivity to TRAIL demonstrated in the TAMR and FASR cell lines is a 
result of the prolonged exposure, and acquisition of resistance, to anti-
estrogens and is not dependant on ER signalling.  
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Figure 4.2.5: Estrogen deprived breast cancer cell lines are resistant to TRAIL A) Cell 
lines were treated with TRAIL and cell viability assessed by CTB viability assay. B) XL cells 
were treated with Faslodex or tamoxifen alone or in combination with TRAIL and cell viability 
assessed by CTB assay. C) Cell lines were plated in mammosphere culture conditions in the 
presence or absence of 20ng/ml TRAIL. Mammospheres from 3 replicate wells per condition 
were counted following 7 days culture (Passage 1). Mammospheres were dissociated using 
trypsin and passaged in the absence of TRAIL and counted after 7 days culture (Passage 2), * 
p<0.05 compared to MCF-7 untreated. D) Cell lines were treated with 20ng/ml TRAIL and then 
plated in mammosphere conditions, as described in (C) and MFUs calculated as in (C) E) 
Representative phase contrast images of mammospheres formed in (C). F) Representative phase 
contrast images of mammospheres formed in untreated and TRAIL treated XL cells. F) EFM19 cell 
lines were incubated with increasing concentrations of TRAIL for 18 hours and cell viability 
assessed by CTB viability assay, * p<0.05 compared to EFM-X untreated, + p<0.01 compared 
to EFM 10ng/ml. Data shown is representative of 3 experiments performed in triplicate ±SEM. 
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4.2.6 TAMR and FASR cells maintain similar levels of death 
receptor expression as parental MCF-7 cells 
 There is some evidence to suggest that DR4 and DR5 cell surface 
expression may contribute to TRAIL sensitivity in some cancer cells 
(Mitsiades et al. 2001; van Geelen et al. 2011; Wu 2009) and as 
previously stated (Chapter 3), c-FLIP is clearly an important regulator 
of TRAIL-induced cell death. The expression of c-FLIP, DR4 and DR5 
proteins and cell surface expression of DR4 and DR5 were assessed by 
western blot and FACS analysis in TAMR FASR and XL cells to uncover 
any contribution each may have in the hypersensitivity to TRAIL 
observed in AE-resistant models.  
 Flow cytometry showed that MCF-7, TAMR and FASR cells all had 
similar expression of DR5 on their cell surface with 60-80% of the cells 
expressing equivalent levels of surface DR5 (Figure 4.2.6B). Positive 
staining was gated on the basis of corresponding isoform controls. 
Average expression levels of DR5 in each cell line as determined by 
mean antibody labelling were also similar (Figure 4.2.6A). While mean 
expression levels between cell lines were also similar for DR4, the 
relative proportion of MCF-7 and TAMR cells expressing surface DR4 
was significantly less than that for FASR cells (5% compared to 20%, 
p=0.004). Total protein levels of DR5, as determined by pooled sample 
western blot, were also similar across most the cell lines with just the 
FASR cells having increased amount of DR5 protein (Figure 4.2.6C).  
DR4 expression was confirmed to be very low in the MCF-7 and TAMR 
relative to the FASR and XL cells. This data suggests that death 
receptor expression is not determinant of AE-resistant cell sensitivity 
to TRAIL. As shown in the previous chapter, reducing levels of c-FLIP 
protein can sensitise cells to TRAIL-mediated cell death so it was 
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interesting to discover that the most TRAIL-sensitive MCF-7-derived 
cell line expressed much lower levels of both short and long c-FLIP 
protein (Figure 4.2.6C).  This was then confirmed using a different c-
FLIP antibody against only the c-FLIP-long isoform, also showing no 
expression in the stable knockdown MCF-7 shFLIPi cell line (Figure 
4.2.6D). Contrastingly c-FLIP protein levels in the FASR cells remained 
comparatively high, thus c-FLIP protein expression is not the sole 
determining factor in endocrine-resistant breast cancer sensitivity to 
TRAIL. Co-operatively these data suggest that TRAIL hypersensitivity 
of endocrine-resistant cell lines is dependant on the endocrine agent 
used and does not correlate with one specific mechanism of 
sensitisation as neither DR4, DR5 nor c-FLIP were consistently altered 
across all endocrine-resistant cell lines.  
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Figure 4.2.6: Endocrine resistant cell lines differentially express regulators of 
TRAIL signalling. A) Representative FACS plots of cell lines stained with conjugated 
antibodies to surface death receptors DR4 and DR5. Data shown is representative of 
experiments performed in triplicate ±SEM B) Average percentage expression of cell 
surface death receptors on cell lines, * p<0.01. C) Western blot analysis of DR4, DR5 
and c-FLIP isoform (NF6 antibody) total protein levels in cell lines. D) c-FLIPL (5D8 
antibody) protein levels in cell lines. Western data is representative of single 
experiments. 
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4.2.7 Systematic TRAIL administration eliminates TAMR and 
FASR tumours in vivo 
 Hypersensitivity of AE-resistant cells to TRAIL identifies it as a 
promising treatment for patients who are no longer responding to 
these agents in the clinic. To test TRAIL’s therapeutic potential in a 
preclinical setting NOD-SCID mice were transplanted with 107 MCF-7, 
TAMR or FASR tumour cells and the orthotopic tumours allowed to 
reach 10mm in diameter before receiving 4 daily injections of 0.4mg of 
TRAIL. This treatment regime was then repeated 10 days later and 
tumour size monitored weekly.  
 Tumour initiation for both MCF-7 and TAMR was 100%, with all 
transplantations resulting in tumour growth. Hitherto an in vivo model 
for the BCMP group FASR cells has not been previously described; here 
2 out of 8 transplants successfully resulted in tumour initiation. 
Following the two TRAIL treatments described, the MCF-7 cells 
demonstrated a small but significant regression in tumour growth. 
Following this small regression, MCF-7 tumours then continued to grow 
at the same rate as the untreated cohort of animals (Figure 4.2.7). 
This response was consistent with the in vitro findings for MCF-7 cells 
where a small reduction in overall viability and MFU integrity was 
observed (Figure 4.2.2B). Treatment of the TAMR cells with TRAIL 
resulted in complete regression of the tumours and no subsequent re-
growth was observed for up to 14 weeks following TRAIL treatment 
(Figure 4.2.7). Again this regression correlated with the in vitro data 
where TAMR cells were killed by TRAIL treatment in adherent 
conditions. Additionally the maintenance of this complete regression 
was consistent with the ablation of MFUs witnessed in vitro (Figure 
4.2.2). Similar effects were seen in FASR transplants where complete 
regression was observed in the tumour treated with TRAIL, however 
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this tumour then relapsed 6 weeks later. Importantly the resulting 
tumour, following relapse, remained sensitive to subsequent TRAIL 
dosages, completely regressing the tumour following two additional 
TRAIL dose regimes administered 4 weeks apart (Figure 4.2.7). Taken 
together these data support the in vitro findings in this chapter and 
indicate that systematic TRAIL administration, either singly or 
repetitively, may prove beneficial as a treatment for endocrine-
resistant patients.  
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Figure 4.2.7: Systemic TRAIL treatment completely regresses AE resistant 
tumours in vivo. 1x107 MCF-7, TAMR and FASR cells were xenografted into the 4th 
inguinal mammary glands of Balb/c NOD/SCID and tumour growth monitored 
weekly. Once tumours had established animals were given 4 daily injections of 
0.4mg of TRAIL or PBS (untreated). 10 days later this dose was repeated a second 
time. Further 4 daily doses of TRAIL were administered to FASR animals upon 
disease relapse. MCF-7 animals were pre-implanted with a 90-day release 0.75mg 
17#-estradiol pellet. TAMR animals were pre-implanted with 90-day release 
Tamoxifen (Free base) pellet. 
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4.2.8 Cells surviving TRAIL treatment are capable of re-
acquiring MFUs in FASR but not TAMR cells 
 Transplantation experiments of FASR cells showed that despite 
complete tumour remission, after a period of time without TRAIL 
treatment the tumours would re-grow. This was in spite of the 
complete abrogation of mammospheres with self-renewal capacity 
observed in vitro (Figure 4.2.2). In an attempt to recapitulate this 
tumour relapse in vitro, post TRAIL treated surviving cells were 
replated following complete removal of MFUs, as previously described 
in chapter 3 (section 3.2.13).  
 TRAIL treatment successfully removed all MFUs from TAMR and 
FASR cell populations (Figure 4.2.8A) and residual surviving cells were 
plated into adherent culture conditions. Following 2 weeks culture, 
replacing culture media when necessary, cells were once again plated 
in mammosphere conditions. The FASR cells re-acquired their 
mammosphere forming capacity back to an almost identical 
percentage as their untreated counterparts (Figure 4.2.9B). 
Interestingly the TAMR cells were unable to re-acquire any MFUs 
following their time in adherent culture (Figure 4.2.8B). Taken 
together these data support previous observations (Figure 3.2.13) that 
tumour cell populations containing no MFUs are capable of re-acquiring 
stem-like characteristics if cultured for a period of time in adherent 
conditions. Additionally these data indicate that resistance to specific 
endocrine agents may alter their cellular plasticity. Extrapolation of 
this data from the in vitro to in vivo context suggests that targeting 
the CSCs in tamoxifen-resistant patients may have long-term 
beneficial effects. 
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Figure 4.2.8: FASR but not TAMR cells are capable of re-acquiring MFUs 
following TRAIL treatment. A) Cell lines were treated with 100ng/ml TRAIL 
for 18 hours and live cells plated into mammosphere culture conditions as 
previously described. B) Live cells from (A) were also plated back into adherent 
culture conditions for 2 weeks. Following 2 weeks culture, MFU re-acquisition 
was then assessed by plating these cells in mammosphere conditions and MFU 
calculated as previously described. Data shown is representative of 3 
experiments performed in triplicate ±SEM 
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4.2.9 TRAIL reduces viability of a multiple endocrine drug 
resistant patient sample 
 Having seen clear benefits of TRAIL treatment in preclinical AE-
resistant cell models both in vitro and in vivo, the efficacy of TRAIL-
induced cell death on clinical samples would confirm it as a prime 
candidate for therapy in this patient cohort. The clinical potential of 
TRAIL was assessed by collecting breast cancer cells from ascites in a 
patient with advanced resistant disease having received multiple 
endocrine, including AEs, and chemotherapy agents (Appendix II) and 
were plated into adherent culture conditions for 72 hours prior to 
treatment with TRAIL. 
 Patient sample BB3RC50 showed a significant reduction in cell 
viability when treated with TRAIL (Figure 4.2.9A, p=0.0425) and the 
amount of cell death determined by phase contrast microscopy of the 
adherent monolayers was visibly increased (Figure 4.2.9B). 
Furthermore, when cell death was analysed by flow cytometry using a 
live/dead fixable stain a relatively small, yet significant, increase in cell 
death was observed (Figure 4.2.9C, p=0.0219). The difference in the 
magnitude of cell death between assays may be related to the loss of 
adhesion and metabolic activity occurring more rapidly than the 
compromisation of cell membrane.  Experiments over a timecourse 
and including annexin-V staining may confirm the TRAIL cytotoxicity 
observed. Notwithstanding these data support the hypothesis, based 
on in vitro cell lines, that TRAIL may be a beneficial treatment for AE-
resistant patients. 
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A 
B 
C 
Untreated TRAIL 
Figure 4.2.9: TRAIL reduces the viability of a multiple endocrine drug 
resistant patient sample. A) Primary human breast cancer cells collected from 
ascites were plated in adherent conditions for 48 hours prior to treatment with 
100ng/ml TRAIL for 18 hours and cell viability assessed by cellTiter Blue assay. B) 
Representative phase contrast images of cells treated in (A), * p<0.05. C) Cells were 
treated as in (A) and assessed for live/dead cells by FACS, * p<0.03. Data shown is 
representative of single experiments performed in triplicate ±SEM 
 
 * 
* 
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4.3 Discussion 
 
 Despite recent advances in the treatment of breast cancer, 
disease recurrence remains a major obstacle to curative therapy. 
Currently around 40% of all initially responsive breast cancer patients 
relapse, with 60-70% of these recurrences being distant metastases 
(Gerber et al. 2010; Normanno et al. 2005). There are many reasons 
for this disease recurrence following resistance, including under-
treatment of disease, local sites of tumour growth missed during 
surgery or the prior development of micrometastases (Gerber et al. 
2010). In addition to these therapeutic deficiencies, intrinsic properties 
of breast cancer stem cells (bCSCs) predispose to tumour relapse 
during conventional therapy (Dontu et al. 2003b; Polyak and Weinberg 
2009). Consequently there is much interest in identifying new 
therapeutic strategies to overcome resistance of tumour cells and 
more specifically CSCs in breast and other cancers.  
 Estrogen receptor-positive breast cancer represents over 70% of 
all breast cancers diagnosed worldwide (www.breastcancer.org), this 
led to the discovery of various agents to inhibit estrogen signaling in 
cancer cells such as tamoxifen, Faslodex (Fulvestrant) and AIs. 
Endocrine agents then became the standard treatment for ER+ve 
breast cancer and indeed they provide much benefit to these patients 
(Davies et al. 2011; Perey et al. 2007). Unfortunately, a large 
percentage of patients will eventually become resistant to these anti-
estrogen therapies and additionally to second-line anti-hormone 
therapies resulting in anti-estrogen or multihormone-resistant 
phenotypes (Henderson and Canellos 1980; Yano et al. 1992). Clinical 
relapse on these agents has been linked to a more aggressive 
phenotype and increased metastastic capacity of the tumour cells 
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(Hiscox et al. 2006). Further research then elucidated that these 
tumours may have increased growth factor signaling, in some 
instances promoted by endocrine agents, and although this 
upregulation is acquired during the drug responsive phase of 
treatment, it is not until the drug resistant phase that they actually 
promote tumour growth and metastasis (Arpino et al. 2008; Nicholson 
et al. 2004b). It is suspected that cross-talk from signaling pathways 
such as EGFR, HER2, HER3 and IGF1R with ER signaling contribute to 
endocrine resistance and even sustain tumour cell growth through 
their independent pathway activation (Britton et al. 2006; Hutcheson 
et al. 2003; Knowlden et al. 2003; Kurokawa and Arteaga 2001; 
Parisot et al. 1999). Furthermore, it has been hypothesized that within 
ER+ve breast cancers there may be a small population of ER-ve bCSCs 
that would not respond to endocrine therapies, these cells would then 
remain and maintain the capacity for tumour cells to grow and 
metastasise (O'Brien et al. 2011). Additionally bCSCs have been 
described as having a basal/mesenchymal phenotype similar to that 
seen in cells having undergone EMT (Hiscox et al. 2006), coincidentally 
ER signaling can also negatively regulate key factors in the EMT 
process (Dhasarathy et al. 2007). Together this provides some 
evidence that CSCs may play a role in endocrine resistance and the 
progression of endocrine-resistant tumours. The aim of this chapter 
was to extend the potential of TRAIL treatment, on bulk tumour and 
cancer stem cells, elucidated in chapter 3, to endocrine-resistant 
breast cancer models.  
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4.3.1 Endocrine resistant breast cancers are hypersensitive to 
TRAIL treatment   
 The FLIPi/TRAIL treatment has thus far shown promise across a 
broad range of breast cancer subtypes, however, one key subtype of 
breast cancer patients are those who have received therapy but have 
become resistant to it. As ER+ve breast cancer is the most common 
form of breast cancer the endocrine-resistant subset was investigated, 
using MCF-7-derived cell lines that have acquired resistance to the 
common endocrine drugs tamoxifen (TAMR) and Faslodex (FASR). 
Surprisingly the TAMR and FASR cell lines displayed significant 
sensitivity to TRAIL treatment alone, without the need for c-FLIP 
inhibition, despite their parental MCF-7 cells showing no sensitivity to 
TRAIL (Figure 4.2.1). Further investigation revealed that this 
sensitivity was not a result of endocrine agents working cooperatively 
with TRAIL as a sensitising agent but that the sensitivity was a result 
of acquired resistance to prolonged endocrine agent treatment. 
Furthermore this sensitivity was observed at very low concentrations 
of TRAIL that previous ‘sensitive’ cell lines would not respond to. This 
sensitivity was true for both the bulk tumour cells and also the bCSC 
subset such that no self-renewing cells remained in TAMR and FASR 
cell lines following TRAIL treatment. Notably the TAMR and FASR cell 
lines both appear to have a larger stem cell pool (Figure 4.2.2A) than 
the MCF-7 cells. It has been demonstrated that the TAMR (Kurokawa 
and Arteaga 2001) have increased EGFR signalling including detectable 
HER2 whilst other research has also shown that HER2 regulates the 
stem cell pool in cancer cells (Korkaya et al. 2008). Estrogen 
deprivation resistance has also been shown to increase growth factor 
signalling (Nicholson et al. 2004b; Staka et al. 2005), here estrogen 
deprivation represented in vitro by the XL cells also shows an increase 
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in the stem cell pool (Figure 4.2.5C), further corroborating with the 
endocrine-resistant models. Interestingly sensitivity to TRAIL was not 
a consequence of cell dependance on estrogen signalling, as XL cell 
resistance to TRAIL confirms. Nor could the sensitivity be attributed to 
the combination of either tamoxifen or Faslodex with TRAIL, 
irrespective of their dependence on estrogen (Figure 4.2.5). 
Significantly, estrogen ablation therapy using aromatase inhibitors 
(AIs) is frequently used in postmenopausal women. Patients that 
become resistant to AIs may have some phenotypic similarities to the 
XL cells and as a consequence may also be resistant to TRAIL in a 
similar manner. Further investigation into TRAIL sensitivity of AI-
resistant breast cancer would be appreciably aided by the development 
of in vitro (including clinical ex vivo) and in vivo models. Collectively 
these data then suggest that the AE-resistant-dependent sensitivity to 
TRAIL is mediated through an as-of-yet undetermined mechanism 
associated with long-term acquired resistance to AEs. 
 
4.3.2 Acquired resistance to endocrine agents may alter 
regulation of c-FLIP  
 In an attempt to uncover the mechanism by which endocrine-
resistant cells become sensitive to TRAIL, death receptor and c-FLIP 
protein levels were assessed by western blot. Western data indicates 
TAMR cells have reduced c-FLIP protein levels compared to FASR cells 
and their parental MCF-7s (Figure 4.2.6C). As demonstrated in chapter 
3, c-FLIP reduction gives very significant sensitisation of bulk tumour 
cells and bCSCs to TRAIL correlating with the extremely sensitive 
TAMR cells. Importantly Figure 3.2.14 suggested that c-FLIP may also 
be important for cellular plasticity in re-acquisition of stem cells after 
ablation. Here the TAMR cells were not capable of re-acquiring MFUs 
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after TRAIL treatment and culture in adherence (Figure 4.2.8) whereas 
the FASR cells, that have comparatively higher c-FLIP protein levels, 
did, with MFUs returning to original levels after just 1 week in 
adherent culture. This was consistent with the observations of tumour 
kinetics in vivo where the FASR tumour treated with TRAIL re-grew 5 
weeks following complete tumour regression while in contrast TAMR 
tumours treated with TRAIL did not re-grow, even 14 weeks after 
complete regression (Figure 4.2.7). In this set of in vivo experiments 
TRAIL was administered systemically over 4 days. Although the results 
from the in vivo experiments were very promising, in the clinical 
setting a more systematic TRAIL regime may prove more 
therapeutically beneficial. Additionally, FASR in vivo results are based 
on n=1 as many of the transplants did not initiate a tumour. FASR 
cells in vitro become ubiquitously ER-ve (Nicholson et al. 2004a; 
Nicholson et al. 2004b), however this was not observed in vivo. 
Nonetheless this is the first time that a human Faslodex-resistant cell 
line has been described in vivo and additional transplants are currently 
ongoing within the lab to develop a better in vivo model of Faslodex 
resistance by maintaining Faslodex levels with injections.  
In contrast to the c-FLIP protein expression data presented here, 
mRNA expression data (Affymetrix microarray) collected on TAMR and 
FASR cells indicated that c-FLIP transcript levels were actually slightly 
elevated in the TAMR and FASR cells (BCMP group, School of 
Pharmacy, Appendix IV). This suggests that c-FLIP in the TAMR cells 
may be regulated post-transcriptionally and the reduction in c-FLIP 
protein may be responsible for TAMR hypersensitivity to TRAIL. 
Previous studies have shown c-myc as a major regulator of c-FLIP 
protein (Ricci et al. 2004) and a key determinant in sensitivity to 
TRAIL, however, TAMR and FASR cells showed no increase in c-myc 
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transcript levels (BCMP group, School of Pharmacy, affymetrix data not 
shown) The mechanism underlying the decline in c-FLIP levels in TAMR 
cells remains undetermined; a hypothesis of this mechanism is 
discussed in chapter 6.    
 
4.4 Summary 
 
 To summarize, work in this chapter suggests that TRAIL may 
prove to be a beneficial treatment for AE-resistant disease by killing 
both bulk tumour cells and bCSCs in long-term endocrine-resistant 
tumour cells. Furthermore in TAMR cells c-FLIP was once again 
implicated as a key regulator in this increased sensitivity to TRAIL, 
however, there was no correlation between c-FLIP expression and 
TRAIL sensitivity. Therefore endocrine-resistant cell line sensitivity to 
TRAIL is dependant on the agent to which the cells have become 
resistant to. Cell line models of endocrine resistance, such as TAMR 
and FASR, can be criticised on the basis that they have been 
developed from a single parental ER+ve cell line; attempts to address 
this have been made within this thesis by the inclusion of the EFM19 
cell line and its tamoxifen-resistant counterpart, however, 
development and use of additional cell line models together with 
primary endocrine-resistant patient samples will help to uncover new 
therapeutic methods to overcome resistance. However, the data in this 
chapter extends and supports that of chapter 3, identifying TRAIL as a 
potential therapy in a broad range of breast cancer subtypes. Without 
the need for additional targeting of c-FLIP (and the associated 
complications of identifying pharmacological c-FLIP inhibitors) and in 
light of the fact that TRAIL is already progressing in clinical trials, 
TRAIL would seem more likely to be of immediate benefit to endocrine-
  Chapter 4: Results 
L Piggott  Cardiff University 173 
resistant patients, if confirmed in vivo. This represents a large cohort 
of patients, as AEs are still the mainstay therapy in premenopausal 
women and the understanding of TRAIL resistance in estrogen-
deprived disease may also help to reveal future therapeutic strategies.  
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CHAPTER 5: 
 
TRAIL’s Role in !" T cell 
Cytotoxicity to Tumour 
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5.1 Introduction 
 
 The human immune system has evolved in order to provide the 
body with its own internal defence mechanism that responds to foreign 
agents or stressed tissue that occurs on a daily basis. The immune 
system can be separated into two major subdivisions, the innate 
immune system and the adaptive immune system. In brief, the innate 
immune system is capable of a rapid response against foreign agents 
that gain access into the body and the adaptive immune system 
comprises of T and B lymphocytes, with antigen-specific receptors that 
recognise threats and produce a slower immune response but also 
expand and form memory cells capable of recognising and responding 
to the same antigen upon its next encounter.  
 There is evidence to show that the immune system naturally 
controls tumours (Smyth et al. 2006) and there are many strategies 
for immunotherapy, most of which target the adaptive responses of B 
cells and MHC-restricted $# CD8+ T cells (Chhabra 2011). However 
sustainable responses are not common and as of yet immunotherapy 
of tumours is not fully established. One common escape mechanism 
used by tumour cells is the downregulation of MHC antigens (Bubenik 
2003). There is a small subset of T cells carrying the !" T cell receptor 
(TCR) that make up approximately 1-5% of CD3+ T cells which are not 
MHC-restricted and thus most !" T cells do not express CD4 or CD8. In 
a healthy individual, up to 90% of !" T cells typically use the TCR pair 
V!9V"2 expressing the V"2 gene that pairs with the V!9 chain (Hayday 
2000). Originally !" T cells were shown to be activated by bacteria and 
parasites by non-peptidic phosphorylated intermediates of the non-
melavonate pathway of bacterial isoprenoid biosynthesis such as (E)-
4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMB-PP) and in 
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mammalian cells by phosphoantigens produced by the mevalonate 
pathway for isoprenoid biosynthesis such as isopentenyl 
pyrophosphate (IPP) (Viey et al. 2005). These intermediates stimulate 
the lytic activity of the cells whilst they also expand and release pro-
inflammatory cytokines. Importantly, certain models have shown that 
non-transformed cells are incapable of producing high enough 
physiological concentrations of IPP to activate !" T cells whereas 
tumour cells are (Gober et al. 2003). Furthermore synthetic 
aminobisphosphonate compounds, used in the treatment of 
osteoporosis and metastatic bone disease, are also capable of 
activating !" T cells as they inhibit the IPP-processing enzyme farnesyl 
pyrophosphate synthase resulting in IPP accumulation (Kunzmann et 
al. 2000).  
 The relative specificity of cytotoxic activity of !" T cells towards 
tumour cells and the potential use of already licensed 
aminobisphosphonates as their activators sparked interest in !" T cells 
as a potential immunotherapy for cancer. The presence of !" T cells in 
tumour infiltrating lymphocytes (TILs) (Chen et al. 2001) suggested 
these cells also home to tumour sites and prompted further 
investigation into their anti-tumour efficacy and indeed these cells are 
capable of inducing cell death in a broad range of tumours (Bank et al. 
1993; Corvaisier et al. 2005; Groh et al. 1999; Maeurer et al. 1996). 
Additionally, the cytotoxic effects of !" T cell immunotherapy have 
been shown in a range of cancers both in vitro and in vivo (Bank et al. 
1993; Kabelitz et al. 2004; Liu et al. 2005). Correlations between 
patient survival and absolute number of blood circulating !" T cells 
further support the evidence for !" T cells and their anti-tumour 
activity.  
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 Recently a study demonstrated that activated !" T cells express 
TRAIL (Dieli et al. 2007), microarray studies within the Eberl group 
then supported this finding by identifying TRAIL as a gene that is 
differentially regulated between activated !" T cells and activated CD8+ 
cells (unpublished data). These studies suggest that TRAIL may 
contribute to the tumour cell cytotoxicity effects of !" T cells. Therefore 
it is possible that !" T cells express TRAIL at tumour sites in order to 
specifically target them for cell death without harming normal cells in 
the surrounding tissue. 
 In this chapter the ability of activated !" T cells to produce TRAIL 
and their use as a targeted immunotherapy for breast cancer was 
addressed. 
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5.2 Results 
 
5.2.1 Activation and expansion of human !" T cells from healthy 
human donors. 
 As with many lymphocyte subsets for the !" T cells to perform 
their cytotoxic function they must first be stimulated to do so. It is well 
accepted that one key activator is HMB-PP, produced during bacterial 
isoprenoid biosynthesis (Viey et al. 2005). Additionally, 
aminobisphosphonates (NBPs) have been shown to activate !" T cells, 
these provide further therapeutic benefits and are already approved 
drugs in the clinic, thus NBPs are more desirable activators of the !" T 
cells. To compare the activation capabilities of aminobisphosphonates 
to the natural stimulator HMB-PP, blood was drawn from healthy 
donors and !" T cells were isolated as described in the Materials and 
Methods. The activation of !" T cells was then assessed by flow 
cytometry for surface marker expression indicative of T cell activation.  
 As the natural stimulator of !" T cells, HMB-PP stimulated 100% 
of the cells to express CD25 at concentrations as low as 10nM (Figure 
5.2.1A). This level of expression could also be achieved using the 
aminobisphosphonates zoledronate and ibandronate at a concentration 
of 10µM but was only capable of achieving 80% CD25 expression. The 
weaker stimulation ability of aminobisphosphonates was then 
confirmed using a second marker for activation, HLA-DR; again a 
1000-fold increase in zoledronate and ibandronate concentration was 
required to achieve similar levels of HLA-DR to HMB-PP stimulated !" T 
cells (Figure 5.2.1B). Once stimulated, !" T cells produced common T 
cell cytokines and cytolytic proteins. Increases in expression of both 
interferon-! (IFN!) and perforin were detected when !" T cells became 
activated (Figure 5.2.1C), both of which are important for !" T cell 
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cytotoxic function.  Taken together these data successfully replicate 
that of other researchers in the field confirming that !" T cells can be 
activated by aminobisphosphonates in order to carry out their 
cytotoxic functions.  
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Figure 5.2.1: !" T cells can be 
activated by HMB-PP and 
NBPs. !" T cells isolated from 
healthy blood donors were 
cultured with increasing 
concentrations of HMB-PP 
zoledronate or ibandronate for 7 
days and A) CD25 B) HLA-DR 
measured by flow cytometry. C) 
Representative FACS plots 
comparing unactivated and 10nM 
HMB-PP activated intracellular !" T 
cell expression of IFN! and 
perforin. Results are 
representative of 3 experiments 
performed in triplicate, using cells 
from 2 separate donors. 
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 5.2.2 Activated !" T cells have increased surface and 
intracellular TRAIL and secrete it into the surrounding 
supernatant 
As previously mentioned, a recent study revealed TRAIL as being 
differentially expressed by activated V!9+ve cells in response to 
zoledronate (Dieli et al. 2007). To better understand this increase in 
TRAIL expression flow cytometry was used to assess intracellular and 
surface TRAIL expression in resting and activated !" T cells. 
Additionally, TRAIL secretion was analysed by removing culture 
supernatants from resting and activated !" T cells and measuring 
TRAIL and perforin by ELISA.  
Activating !" T cells using HMB-PP resulted in increased 
intracellular TRAIL expression, where almost all CD25+ cells also 
expressed surface TRAIL compared to the resting !" T cells in which 
less than 1% of the cells expressed TRAIL (Figure 5.2.2A). This TRAIL 
expression could also be achieved when activating !" T cells using 
aminobisphosphonates but as previously demonstrated, much higher 
concentrations were required to achieve the same level of expression 
seen in HMB-PP activated !" T cells (Figure 5.2.2B). Similarly, surface 
TRAIL levels also increased upon stimulation with HMB-PP (Figure 
5.2.2C). Finally, culturing !" T cells in HMB-PP or zoledronate increased 
the amount of TRAIL secreted into the culture supernatant (Figure 
5.2.2D). However, this increase was only pico-molar, a far higher 
concentration than is typically required to induce cell death in TRAIL 
sensitive cells. Interestingly the amount of perforin secreted by 
activated !" T cells was far greater, with concentrations of up to 
40ng/ml being achieved when stimulated with HMB-PP. Collectively 
these data demonstrate that activating !" T cells results in increased 
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TRAIL production in 3 different ways; intracellularly, on the cell surface 
and secretion.  
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Figure 5.2.2: Activated !" T cells express TRAIL and secrete perforin and 
TRAIL. A) Representative FACS plot of intracellular CD25 and TRAIL expression in 
unactivated and 10nM HMB-PP activated !" T cells, isolated from healthy donors, 
permeabilised by brefeldin. B) Intracellular TRAIL expression in !" T cells at increasing 
concentrations of HMB-PP, zoledronate and ibandronate. C) Representative cell surface 
expression of TRAIL in unactivated and 10nM HMB-PP activated !" T cells. D) 
Unactivated (Media) and activated (either by 10nM HMB-PP or 100µM zoledronate) !" T 
cell supernatant concentration of TRAIL and perforin. Results shown are representative 
of 2 individual experiments using cells from 2 independent donors. 
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5.2.3 Activated !" T cell supernatants are cytotoxic to breast 
cancer cell lines 
 The cytotoxic effects of both TRAIL and perforin are well known 
and thus the secretion of these factors into the surrounding 
environment of the !" T cells may contribute to tumour cell killing. The 
cytotoxicity of activated !" T cell supernatants was assessed by adding 
them to breast cancer cell lines. Blocking antibodies/compounds 
targeted to TRAIL (RIK-2), perforin (concanamycin [CMA]) and 
caspase-8 (C8i) were then used to assess their contribution to any cell 
death observed.  
 Initially culture of breast cancer cell lines in activated !" T cell 
supernatant (conditioned media) was performed. This resulted in 
significant reductions in cell viability in each of the cell lines 
irrespective of ER or HER2 status (Figure 5.2.3A, p<0.05). Using the 
MDA-MB-231 cell line for further investigation, it was clear that this 
cell death was, at least in part, through an apoptotic mechanism 
resulting in caspase-3/7 activation (Figure 5.2.3B). Significantly this 
apoptosis was also activated using conditioned medium (CM) from 
zoledronate-activated !" T cells, in fact zoledronate CM resulted in 
similar levels of caspase-3/7 activation as the HMB-PP-activated 
supernatants. The reduction in viability seen in the MDA-MB-231 cells 
following CM treatment (Figure 5.2.3A) was then shown to be 
predominantly perforin mediated, as blocking perforin action in the CM 
using CMA returned cell viability back to that of cells cultured in media 
from unactivated cells. Perforin is capable of inducing cell death both 
using caspases or independently of caspases (Voskoboinik et al. 2006), 
blocking caspase-8 in activated !" T cell CM, using IETD-FMK, also 
resulted in the recovery of cell viability back to control levels (Figure 
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5.2.3C) suggesting that the apoptosis initiated in these cells was 
caspase-8 mediated. It should be noted however that this family of 
caspase inhibitors exhibit some cross-reactivity with other caspases, 
and therefore it is possible that other caspase pathways may be 
involved in this process. A series of controls were also used to confirm 
that the perforin blocking compound CMA was not inhibiting any 
apoptosis induced by TRAIL. Here, the efficient blocking of TRAIL by 
the RIK-2 antibody, but not by CMA, was observed (Figure 5.2.3D). 
Additionally, a small amount of caspase-3/7 activation was observed 
from unactivated supernatants compared to cells cultured in normal 
complete media, signifying a resting secretion of apoptosis-inducing 
factors by !" T cells. Together these results indicate that activated CM 
induces cell death in breast cancer cells predominantly by a perforin 
and/or a caspase-8-mediated apoptosis and TRAIL may only contribute 
in small part to this cell death, consistent with the significant 
difference in concentrations observed in activated !" T cell 
supernatants in Figure 5.2.2D. 
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Activated Supernatant Unactivated Supernatant 
MDA-MB-231 cells 
A 
B 
C 
D 
* * * 
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* 
Figure 5.2.3: Supernatants from 
activated !" T cells are cytotoxic to 
BCCLs. A) Breast cancer cell line viability, 
as measured by CTB assay, after 
treatment with unactivated or 10nM HMB-
PP activated !" T cell CM and 
representative phase contrast image of the 
visible cell death in MDA-MB-231 cells, * 
p<0.05. B) Caspase-3/7 activity in MDA-
MB-231 cells following treatment with !" T 
cell, activated with either 10nM HMB-PP or 
100µM zoledronate, supernatants. C) MDA-
MB-231 cell viability following 10nM HMB-
PP activated !" T cell supernatant pre-
treated with blocking compounds, * 
p<0.01. D) Caspase-3/7 activation in MDA-
MB-231 cells treated by unactivated !" T 
cell CM, media or TRAIL in the presence 
RIK-2 or CMA blocking compounds. Data 
shown from 3 independently performed 
experiments performed in triplicate ± SEM 
using cells from 2 individual donors. 
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5.2.4 Co-culturing !" T cells with breast cancer cell lines  
 Secreted factors from activated !" T cell cultures appear to 
induce apoptosis in breast cancer cells but much of T cell function is 
mediated through cell to cell contact (Janeway 2001). Thus activated 
!" T cells were co-cultured together with bCCLs at different 
effector:target cell ratios and cell death assessed in the MDA-MB-231 
and MCF-7 cell lines by flow cytometry. 
 A significant increase in cell death was observed for both the 
MDA-MB-231 and MCF-7 cell lines when cultured at an effector:target 
cell ratio of 1:1 with !" T cells (Figure 5.2.4A). Not surprisingly this cell 
death induced by the !" T cells increased as effector:target cell ratio 
increased, with up to 45% cell death being observed in both cell lines 
at the 25:1 ratio (Figure 5.2.4A, Donor 1). Using !" T cells taken from 
a different donor a similar cell death profile was observed in the MCF-7 
cell line and, whilst still a significant cell death, a lesser effect was 
seen in the MDA-MB-231 cell line (Figure 5.2.4B, Donor 2). Although it 
seems !" T cells from different sources are consistently cytotoxic to 
breast cancer cells, this implies different !" T cell subsets between 
patients may display different cytotoxic efficiency on different subtypes 
of breast cancer.  The contribution of TRAIL, perforin and caspase-8 
activation to the co-culture induced cell death was then assessed by 
the use of different blocking antibodies/compounds. The results 
demonstrate that little to none of the killing of the TRAIL-sensitive 
MDA-MB-231 cell line was actually induced by TRAIL itself (Figure 
5.2.4B), despite the significant expression of TRAIL on !" T cell surface 
after activation (Figure 5.2.2). It appears that the majority of cell 
death observed in these co-cultures is a result of perforin 
expression/production as blocking perforin with CMA resulted in a 
significant reduction of cell death in the 5:1 and 25:1 effector:target 
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ratios (Figure 5.2.4C). Notably, inhibiting caspase-8 at these ratios 
also significantly reduced cancer cell death, suggesting caspase-8 
activation is important in the !" T cell induction of cancer cell death.  
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A 
B 
Figure 5.2.4: Activated !"  T cells are cytotoxic to BCCLs in co-cultures 
A) Percentage cell death, as measured by fixable live/dead assay, of MDA-MB-
231 and MCF-7 cell lines co-cultured for 18 hours with expanded !" T cells at 
increasing effector:target ratios from two separate donors. B) Percentage cell 
death of MDA-MB-231 cells, as measured by fixable live/dead assay, after co-
culture with expanded !" T cells in the presence of blocking compounds. Data 
shown is representative of triplicate experiments ± SEM. 
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4.2.5 c-FLIP suppression increases !" T cell induced cell death 
 As demonstrated in previous chapters and many other published 
studies, c-FLIP is a key regulator of TRAIL cell death and a major 
determinant of cancer cell sensitivity to TRAIL (Lee et al. 2006; 
Palacios et al. 2006; Ricci et al. 2004).  Hitherto it has been 
demonstrated that TRAIL secretion and expression by activated !" T 
cells plays a very minor role in their cytotoxic effects on bCCLs (Figure 
5.2.3 + 5.2.4). Thus the approach adopted in Chapter 3 was adopted 
in an attempt to increase TRAIL’s participation in !" T cell cytotoxicity 
by suppressing c-FLIP in cancer cells using siRNA (FLIPi) and then co-
culturing these cells with !" T cells at different effector:target ratios. As 
in Figure 3.2.5A, MDA-MB-231 FLIPi and SCi cells were stained with 
PKH26 and PKH67, mixed at a 1:1 ratio and then !" T cells added to 
the culture at 1:1, 5:1 and 25:1 effector:total target cell ratios for 4 
hours (as shown in appendix III) and cell death of each cell population 
then assessed by fixable live/dead assay.  
 The knockdown of c-FLIP in FLIPi cells when cultured with !" T 
cells resulted in a significant increase in cancer cell death compared to 
the cancer cell death of the SCi cells (Figure 5.2.5A). Successful 
sensitisation of the MDA-MB-231 cells was demonstrated by treating 
SCi and FLIPi cells with TRAIL (Figure 5.2.5A, bar graph), however, 
over the 4 hours treatment, FLIPi gave no increase in cell death 
indicating the increase in cell death observed in co-cultures with !" T 
cells is due solely to their cytotoxic effect on the cells. This increased 
cytotoxic effect was then duplicated using !" T cells from a second 
donor (Figure 5.2.5B, red and blue lines). In the same experiment !" T 
cells were also pre-incubated with RIK-2, CMA and caspase-8 inhibitor 
to determine the contribution of TRAIL, perforin and caspase-8 
mediated apoptosis respectively. As previously demonstrated in Figure 
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5.4.4 blocking TRAIL had no significant effect on !" T cell killing of 
MDA-MB-231 cells (Figure 5.2.5B, Blue and green lines). TRAIL 
blocking also had no effect on the increased cell death seen in the 
FLIPi cells (Figure 5.2.5B, red and orange lines) signifying the increase 
observed was not due to a sensitisation to TRAIL. Similar results were 
obtained when using CMA to block perforin, a reduction in !" T cell 
killing was observed in the SCi cells, however, CMA did not block the 
additional death seen in the FLIPi cells. This suggested that the 
additional death incurred from loss of c-FLIP expression was not an 
increase in perforin-mediated killing from the !" T cells, nor from a 
TRAIL-mediated kill. Interestingly inhibiting caspase-8 was capable of 
reducing the additional cell death in the FLIPi cells, thus the additional 
cell death in the FLIPi cells may be via a TRAIL-independent caspase-
8-mediated apoptotic signal (Figure 5.2.5B). 
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A B 
Figure 5.2.5: FLIPi increases !"  
T cell cytotoxicity in co-cultures  
A) Percentage cell death of SCi and 
FLIPi MDA-MB-231 cells co-cultured 
with expanded !" T cells at 
increasing effector:target ratios for 
18 hours and SCi and FLIPi cells 
treated with or without TRAIL, as 
measured by fixable live/dead 
assay. B) Cells treated as in (A) in 
the presence of blocking 
compounds. Results shown are 
representative of triplicate 
experiments using cells from 1 
donor but separate donors were 
used for A and B. Error bars 
represent SEM of triplicate 
measurements. 
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5.2.6 !" T cells target the bCSC subset  
 A common theme throughout this study has been the importance 
of targeting the bCSC subset in therapeutic approaches as it can have 
significant implications in long-term disease management (Charafe-
Jauffret et al. 2009; Ginestier et al. 2007; Pardal et al. 2003; Phillips 
et al. 2006). Accordingly the cytotoxic effect of !" T cells on the bCSC 
subset was assessed using the mammosphere assay to determine the 
MFU capacity of cancer cells following co-culture with !" T cells.  
 MCF-7, TAMR, FASR and MDA-231 cells were co-cultured with !" 
T cells and the surviving cancer cell population then plated into non-
adherent low serum conditions. The MDA-MB-231 cells maintained 
their MFU capacity irrespective of the effector:target ratio used in 
treatment (Figure 5.2.6). Contrastingly the MFU capacity of MCF-7 
cells was halved after co-culturing with !" T cells and the MFU capacity 
of the endocrine-resistant cell lines TAMR and FASR was completely 
abolished following treatment at a 25:1 effector:target ratio (Figure 
5.2.6).  
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Figure 5.2.6: Activated !"  T cells are cytotoxic to the MFU 
population of some breast cancer cell lines. Breast cancer cell 
lines were treated with expanded !" T cells at different 
effector:target ratios and the surviving cancer cell population 
seeded into mammosphere culture conditions for 7 days and MFUs 
counted. Results shown are from a single experiment performed in 
triplicate using cells from a single donor, * p<0.05.  
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5.3 Discussion 
 
 The capacity of the immune system for specificity makes it an 
appealing therapeutic option for cancer. This was first demonstrated 
by the clinical success of mAbs in the treatment of breast cancer and 
lymphomas. This brought about the interest in T cell-based 
immunotherapy with their capability to recognise peptides derived 
from protein in any cellular compartment. There are now several 
clinical studies supporting immunotherapy as a realistic therapeutic 
approach and thus development and application of immunotherapy has 
attracted much attention over the last decade. Augmentation of 
immune response can be achieved in vivo by stimulatory compounds 
and ex vivo expansion of effector cells followed by adoptive transfer. 
The end result of each is a population of activated effector cells that 
recognise a target population of cells for destruction (reviewed in 
(Restifo et al. 2012)) of course, ex vivo stimulation of effector cells will 
ultimately result in behavioural differences in the cells as the in vivo 
environment could never be accurately recapitulated in vitro. Despite 
these differences each of these two modalities have their benefits and 
show some promise as a methodology for cancer treatment.  
 One particular subset of T cells that has shown promise as an 
immunotherapy for many different types of cancer is the !" T cells 
(Beck et al. 2010; Chargui et al. 2010; Dieli et al. 2007; Gomes et al. 
2010; Todaro et al. 2009). These T cells appear to expand and 
respond to cellular antigens frequently displayed on cells that have 
undergone malignant transformation, especially those of epithelial 
origin. Additionally, !" T cells have been documented as being present 
amongst tumour-infiltrating lymphocytes (TILs) (Kabelitz et al. 2007). 
The aim of this chapter was to build on existing studies that have 
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demonstrated the cancer cell cytotoxicity of !" T cells whilst also 
determining the contribution of TRAIL and other cytotoxic factors to 
this killing.  
 
5.3.1 !" T cells are cytotoxic to breast cancer cells 
 Culturing !" T cells with breast cancer cells has previously been 
demonstrated to induce cancer cell death, however, much focus of that 
research was surrounding the antigens recognised by the !" T cells and 
their activation. Data presented here supports these observations and 
elucidates the contribution of different cytotoxic molecules to the well-
documented cancer cell cytotoxicity of !" T cells. Primarily, the 
activation and expansion of !" T cells was shown to result in the 
increased expression of TRAIL, IFN! and perforin all of which are 
known to contribute to cancer cell death. IFN! itself is a key cytokine in 
anti-tumour immune responses; the immunostimulatory function of 
IFN! helps augment the correct immune response at the site of the 
tumour (Restifo et al. 2012). As shown in Figure 5.4.3, once !" T cells 
are activated they secrete soluble factors such as TRAIL and perforin. 
In breast cancer it would seem that the majority of the apoptosis 
induced by !" T cells is being induced by perforin (Figure 5.2.3C). Not 
surprisingly this is consistent with the fact that the activated !" T cells 
secreted far higher concentrations of perforin than TRAIL. Whilst 
inhibiting caspase-8 with the IETD-FMK compound also resulted in 
blocking !" T cell supernatant cancer cell death. Although it should be 
noted that this compound is also capable of inhibiting granzyme B. 
Accordingly, it’s inhibitory effect may be most likely explained through 
its role in preventing perforin-mediated killing, however, this does not 
mean the contribution of caspase-8 mediated cell death should be 
ignored, even though TRAIL appears to contribute little to the 
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supernatant cell death, effects of other death receptors, such as CD95, 
can not be discounted.  
 Despite the low concentrations of secreted TRAIL from activated 
!" T cells, the close proximity of these cells to their target cancer cells 
allows both cell contact with TRAIL expressed on the cell surface and a 
higher local concentration of TRAIL in the surrounding 
microenvironment. In spite of this, TRAIL appeared to play no 
significant role in cancer cell death induced in co-cultures with !" T 
cells (Figure 5.2.4B). Again the predominant killing mechanism 
seemed to be perforin-mediated. In chapter 3 it was demonstrated 
that suppression of c-FLIP protein gave significant sensitisation of 
breast cancer cell lines to TRAIL, both in bulk tumour cells and bCSCs. 
Therefore c-FLIP protein levels were also suppressed in MDA-MB-231 
cells in attempt to sensitise the cancer cells to TRAIL being delivered 
via !" T cells. Although a significant sensitisation to !" T cell killing was 
observed this was not as a result of TRAIL sensitisation (Figure 
5.2.5B). Even though CMA inhibited the !" T cell killing of SCi cells it 
was not capable of blocking the increased killing observed in FLIPi 
cells. Interestingly the only blocking agent capable of preventing the 
increased cell death in the FLIPi cells was the caspase-8 inhibitor. This 
may suggest that FLIPi sensitised the cancer cells to an alternative 
caspase-8 mediated cell death such as CD95. However, further work is 
required to confirm exactly what is responsible for the increased cell 
death detected in the FLIPi cells.  
 Significantly, the !" T cells could also be activated using 
aminobisphosphonates (NBPs). The concentration of zoledronate (ZOL) 
and ibandronate required for achieving similar stimulation as using 
HMB-PP is much higher, however there are several advantages of 
using NBPs as a stimulatory compound. NBPs inhibit bone resorption 
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by osteoclasts and are a common treatment for bone-loss disorders in 
postmenopausal osteoporosis (Delmas 2002) and cancer treatment 
induced bone loss (Clezardin 2011). In breast cancers a common site 
of metastasis is bone, consequently there is currently clinical trials 
being performed to assess the advantage of ZOL treatment in 
preventing bone metastasis in patients with advanced breast cancer. 
The results in this chapter appear to show TRAIL as a small/non-
contributor to activated !" T cell induced cell death, however these 
assays were performed using HMB-PP stimulated !" T cells. A recent 
study has shown that treatment of breast cancer cells with ZOL 
increased the TRAIL:OPG ratio in MDA-MB-231 cells (Rachner et al. 
2009). Thus such a pre-treatment may increase !" T cell killing, not 
only by increasing TRAIL expression but also chemotaxis of !" T cells 
to the cancer cells (Benzaid et al. 2011).  
 
5.3.2 Potential of !" T cells as a therapy for breast cancer 
 Ex vivo expansion and stimulation of !" T cells for adoptive 
transfer therapy has previously been demonstrated in mice (Beck et 
al. 2010). Here ex vivo expanded and labelled !" T cells were well 
tolerated by the recipient mice and readily localized to tumour sites, 
supporting previous observations of tumour homing in prostate cancer 
(Liu et al. 2008). Stimulating !" T cells ex vivo allows the use of 
compounds that may otherwise produce harmful side effects if given 
systemically, additionally, !" T cells may be labelled as described in 
Beck et al. 2009 to follow their chemotaxis and potentially aid tumour 
tracing. Thus the potential for ex vivo expanded !" T cell therapy may 
be a realistic target in human disease. There have now been a number 
reports of adoptively transferred !" T cells in humans to treat various 
forms of cancer (Bennouna et al. 2008; Kobayashi et al. 2011; 
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Kobayashi et al. 2007; Sakamoto et al. 2011). Overall these studies 
demonstrated adoptive transfer of ex vivo expanded !" T cells for 
systemic infusion is well tolerated but that objective responses are 
uncommon. In general the cohort size for these studies was small and 
thus further investigation is still required determine if adoptive transfer 
!" T cell immunotherapy is a realistic therapeutic modality.  
 In spite of TRAIL’s seemingly minimal contribution to !" T cell 
killing of breast cancer cells it is interesting that breast cancer cell line 
MFU forming capacity following !" T cell co-culture closely replicated 
that seen by treating these cell lines directly with TRAIL. As shown in 
chapter 4, TAMR and FASR MFUs are hypersensitive to TRAIL 
treatment with a partial response being observed in the MCF-7 cells. 
One explanation could be that although TRAIL production by !" T cells 
is not important in bulk tumour cell killing it may be contributing to the 
reduction in MFU capacity of these cell lines, however these results are 
very preliminary and further assessment of TRAIL’s contribution is 
required.  
 The importance of using currently approved drugs for disease 
treatment cannot be understated, in 2003 a survey by DiMasi et al 
revealed that the average cost of developing a drug to the point of 
marketing is approximately 802 million dollars (DiMasi et al. 2003). 
Using ZOL as a stimulatory compound for !" T cells is therefore 
extremely desirable as the patent for Zometa (zoledronic acid 
[Novartis]) expires in March 2013 and will ultimately result in a 
reduction in cost. Future prospects could even incorporate a 
combination of FLIPi, TRAIL and ZOL for breast cancer, attacking 
breast cancer cells from multiple angles whilst hopefully maintaining 
relatively minimal side effects.  
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5.4 Summary 
 
 In summary, activating !" T cells may be a beneficial therapeutic 
approach in breast cancer sufferers due to their apparent cytotoxic 
effect on, and recognition of, cancer cells. Stimulation of these cells 
using aminobisphosphonates may also have multiple benefits for 
patients. Although it would seem TRAIL contributes little to these 
cytotoxic effects and the majority of cancer cell death is being induced 
via a perforin-mediated mechanism, it is possible that TRAIL’s 
contribution is more significant in the reduction of bCSCs. Further work 
should focus on the !" T cell killing on the bCSC subset and the 
investigation of !" T cell adoptive transfer as a potential therapeutic 
approach for breast cancer patients. 
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6.1 General discussion 
 
 Over the past decade many advances have been made in breast 
cancer disease management. Significant improvements in survival 
rates clearly represent these advances with 90% of stage I, 70% of 
stage II, 50% of stage III and 13% of stage IV patients surviving at 
least five years following diagnosis (Cancer Research UK). Much of this 
can be attributed to improvements in surgical techniques and 
equipment. Subsequent therapy following surgery has remained fairly 
consistent with the main therapeutic interventions being Herceptin 
(trastuzumab), anti-hormones (tamoxifen, fulvestrant and aromatase 
inhibitors) and chemo/radio-therapy. Each of these therapies 
represents an important leap forward in breast cancer treatment, 
however, there are also pitfalls for each of these modalities including 
de novo resistance, acquired resistance and off-target toxicity. 
Herceptin has been shown to potentially have severe side effects on 
the heart, many patients develop resistance to endocrine therapies, 
and many patients see little to no clinical benefit whatsoever from 
radio- or chemo-therapy whilst experiencing the severe side effects 
that accompany the treatment (Goldhirsch et al. 2005; Mauri et al. 
2005; Shimizu et al. 2007).  Recently many studies focussing on the 
breast cancer stem cell subset have elucidated it as being responsible 
for tumour initiation and seeding of metastasis. Furthermore bCSCs 
have been shown to be particularly resistant to therapeutic, in 
particular radio- and chemo-therapy, challenge and thus remain 
following treatment, resulting in disease relapse (Eyler and Rich 2008; 
Li et al. 2008). TRAIL is a naturally existing death-inducing ligand that 
displays tumour specificity with almost no side effects on normal cells 
(Ashkenazi et al. 1999). However, TRAIL is currently not a suitable 
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therapy for breast cancer as most breast cancer cells are resistant to 
TRAIL treatment (Rahman et al. 2009a).  
 Clearly there are specific cohorts of patients that require novel 
therapeutic intervention techniques including those diagnosed with 
later stage disease and those that have become resistant to existing 
therapies. The key to controlling disease progression in these patients 
is prevention of metastasis. With this in mind, using cell lines as in 
vitro and in vivo models that represent the heterogeneic nature of 
breast cancers, the aims of this study were to (1) determine if TRAIL 
has potential as a treatment for breast cancer (2) Assess the extent of 
any treatment that proves successful on the inter- and intra-tumour 
heterogeneity that exists between breast cancers (3) uncover 
alternative delivery methods of TRAIL to breast tumours.  
 
6.1.1 Sensitising breast cancer cells to TRAIL  
 Previous studies have demonstrated a correlation between the 
regulation of c-FLIP expression and sensitivity to TRAIL. In one of 
these studies it was also shown that reducing c-FLIP expression using 
siRNA successfully sensitised certain breast cancer cell lines to TRAIL. 
However, the extent of this effect on the heterogeneity within breast 
cancer was not fully elucidated in this study (Palacios et al. 2010). This 
thesis revealed that suppressing c-FLIP by siRNA sensitises a range of 
breast cancer cell types to TRAIL whilst maintaining the tumour cell 
specificity of the treatment. The relative specificity of c-FLIP 
suppression in sensitising only tumour cells to TRAIL was limited to 
differences between normal mouse epithelial cells and cancer cell lines 
and thus was not fully investigated in this thesis. The fact that 
knocking out c-FLIP in animals is embryonic lethal suggests that it 
does play a key role at least in development, more specifically in 
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vascularisation (Varfolomeev et al. 1998; Yeh et al. 1998; Yeh et al. 
2000; Zhang et al. 1998). In chapter 3 of this thesis c-FLIP was 
conditionally deleted in luminal epithelial cells of the normal mouse 
mammary gland without sensitising them to additional TRAIL 
treatment, in support of this data the non-tumourgenic Eph4 normal 
mouse mammary epithelial cell line also did not respond to TRAIL 
following c-FLIP suppression. However, for clinical translation of 
combined FLIPi/TRAIL treatment a drug suppressing c-FLIP would need 
to be produced and evaluated for systemic toxicity in animal models. 
Such a drug would not specifically inhibit c-FLIP in mammary tissue 
and at present the effects of FLIPi/TRAIL on other normal tissues are 
unknown.  
 There are currently compounds that are capable of providing 
some c-FLIP suppression, however, these compounds are not c-FLIP-
specific inhibitors and come with a host of additional side effects. 
Despite this, the results observed in Figures 3.2.6, 3.2.12 and 3.2.13 
suggest that combining these compounds with TRAIL may be a valid 
therapeutic approach for targeting the bCSC subset. Whilst targeting 
bCSCs has been demonstrated in chapter 3 (Figure 3.2.12) and in 
other studies to drastically reduce tumour initiation and metastasis, 
cells outside the bCSC pool display cellular plasticity and acquire CSC 
attributes (Figure 3.2.13). Thus tumour relapse even following the 
ablation of the bCSCs would seem inevitable. Although subsequent 
bCSCs still remained sensitive to repeat FLIPi/TRAIL treatment (Figure 
3.2.13), from a clinical perspective it could be hypothesised that a 
continuous relapse/treatment cycle is only going to increase the 
likelihood of eventual resistance and disease progression. As a 
consequence a more pertinent therapeutic strategy would be to 
prevent this cellular plasticity displayed by surviving non-CSCs as 
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demonstrated by maintaining suppressed c-FLIP levels (Figure 3.2.14). 
Interestingly, c-FLIP has been shown to interact with various important 
signalling pathways outside of death receptor apoptosis. Interactions 
have been demonstrated with Akt, NF-%B and Wnt suggesting that c-
FLIP is not limited solely to its anti-apoptotic function but also cell 
survival, proliferation, differentiation and cell fate (Figure 6.1.1). 
Furthermore Akt, NF-%B and Wnt have all been implicated in cancer 
stem cell maintenance (Korkaya et al. 2009; Shostak and Chariot 
2011; Takahashi-Yanaga and Kahn 2010). In many cases, changing 
these signalling pathways also results in a reduction, but not the 
elimination, of MFUs. It is plausible, therefore, that by maintaining 
suppressed c-FLIP expression each of these signalling pathways is 
being regulated to cooperatively prevent cellular plasticity. Additional 
experiments using activators of each of these signalling pathways 
(such as the Wnt activator 6-bromoindirubin-3'-oxime [BIO] and 
the Akt activator 2-deoxyglucose [2-DG]) will help reveal the 
importance of their regulation by c-FLIP in cellular plasticity.  
Further characterisation of these observations in preclinical 
models will be key in realising the potential translation of FLIPi/TRAIL 
to the clinical setting. Using the bicistronic KRAB doxycycline inducible 
c-FLIP construct currently being developed in the lab would allow the 
switching on and off of c-FLIP expression in vivo. Thus tumour cells 
containing this construct could be transplanted into animals and 
following tumour establishment, c-FLIP could be suppressed and TRAIL 
subsequently administered systemically. This approach could also be 
applied to primary tissue collected from breast cancer patients, 
cancerous and normal, in vitro and in vivo. These models would help 
determine normal human cell and stem cell response to FLIPi/TRAIL 
and better mimic the clinical treatment regime, although more 
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selectively and may provide important insight into FLIPi/TRAIL as a 
therapeutic strategy.  
 
 
 
 
 Breast cancer is a heterogeneous disease and as such the 
efficacy of many current therapies is limited to specific subtypes of 
disease. It is therefore encouraging to see the breadth of response 
seen to FLIPi/TRAIL on disease subtypes. Although existing anti-
estrogen agents can give significant positive clinical responses in 
ER+ve breast cancer, acquired resistance to existing treatments limits 
the timeframe these agents are efficient for. Some response to 
Figure 6.1.1 – proposed c-FLIP regulation of CSCs by non-apoptotic 
intracellular signalling pathways. 
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alternate endocrine agents can be seen in anti-estrogen-resistant 
disease but ultimately in many cases further resistance occurs. As a 
result there is a desire to identify novel therapies to which these 
resistant cancers may respond. It was hypothesised that the effects of 
FLIPi/TRAIL treatment could be extended to endocrine-resistant breast 
cancer. Early observations revealed that the TAMR and FASR cells 
were hypersensitive to TRAIL treatment alone without the need for 
FLIPi (Figure 4.2.1). Further investigation revealed that this 
hypersensitivity was also seen in the self-renewing mammosphere 
forming population (Figure 4.2.2). This had significant implications 
during the in vivo treatments where complete regression of the TAMR 
and FASR cells was seen following systemic TRAIL treatment (Figure 
4.2.7). Importantly, in these experiments TRAIL was administered by 
intraperitoneal injection rather than co-injection with the tumour cells, 
as in chapter 3 (Figure 3.2.12), suggesting FLIPi/TRAIL as a 
combination treatment for breast cancer may also be successful using 
systemic injections. Furthermore the response seen in the human 
primary tumour cells tested in Figure 4.2.10 also suggest that TRAIL 
treatment of primary cancer cells may also result in significant cell 
death. Of course further experimentation would be required to confirm 
such observations in these preclinical models of anti-estrogen-resistant 
breast cancer. Advances are now being made at Cardiff University to 
obtain consecutive primary human tissue samples from endocrine-
resistant patients and the ex vivo use of this tissue in culture and in 
transplantation models will help to provide further insight. However, 
what would seem clear from the data collected thus far is that the 
hypersensitivity observed was a result of the long-term acquired 
resistance independent of ER status and not a sensitisation through 
combination treatment. Interestingly the most sensitive anti-estrogen-
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resistant cell line, the TAMR cells, but not the FASR cells, showed 
decreased c-FLIP protein levels. This may be the reason TAMR cells 
show sensitivity to TRAIL. This is not the first time drug resistant cells 
have been shown to display increased sensitivity to TRAIL (Kim et al. 
2011; Mitsiades et al. 2001). In a study of multi-drug resistant MCF-7 
(MCF-7-MDR) cells, c-myc was upregulated and c-myc has also been 
shown to regulate c-FLIP expression, although c-FLIP’s role in MCF-7-
MDR cell sensitivity to TRAIL was not addressed (Kim et al. 2011). 
Significantly, TAMR cells were incapable of MFU re-acquisition following 
TRAIL treatment and the reduced c-FLIP protein levels in TAMR cells 
(Figure 4.2.6) correlate with results seen in Figure 3.2.14 where low c-
FLIP protein levels prevent the re-acquisition of MFUs. Conversely the 
FASR cell line, where c-FLIP levels were not reduced, was capable of 
re-acquiring MFUs. Further investigation of c-FLIP’s role in cellular 
plasticity may help to uncover additional benefits of c-FLIP inhibition in 
breast cancer.  
 Affymetrix data collected from the Gee lab (School of 
Pharmacology, Cardiff University) (Appendix IV) revealed no reduction 
in c-FLIP transcript levels in either of the TAMR or FASR cells compared 
to their parental MCF-7 cells signifying c-FLIP protein levels may be 
being regulated by a post-transcriptional mechanism (Appendix IV). 
Previous studies have shown that c-FLIPL can be proteasomally 
degraded by Itchy E3-ligase (ITCH) following TNF$ activation of JNK 
(Chang et al. 2006). A hypothesis was formed on this basis of c-FLIP 
post-transcriptional regulation in TAMR cells and is summarised in 
Figure 6.1.2. Consultation of the Affymetrix data supported this 
hypothesis showing that ITCH, TNF$ and MEKK1 are overexpressed in 
TAMR cells but not in FASR cells and JNK expression was elevated in 
both TAMR and FASR cells (Appendix IV). This has lead to the 
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formulation of the hypothesis that c-FLIP protein may be regulated 
through TNF$ signalling that activates JNK, via MEKK1 activation, 
which in turn ubiquitinates c-FLIP through ITCH leading to its 
degradation as depicted in Figure 6.1.2.  
 
 
 
 
 
Although FASR cells also have increased JNK mRNA expression, the 
comparably low levels of TNF$ and MEKK1 could mean there is no 
observable increase in JNK activation. Additionally the FASR cells show 
a small decrease in ITCH expression, again inhibiting the hypothesised 
pathway from degrading c-FLIP in these cells. At this point this 
regulatory mechanism is speculation and does not explain FASR 
sensitivity to TRAIL. This is a testable hypothesis as future work will 
Figure 6.1.2: Hypothesised post-transcriptional regulation of c-FLIP in 
TAMR cells. TNF$ signalling results in MEKK1 mediated phosphorylation and 
subsequent activation of JNK. This activates Itch that ubiquitinated c-FLIP protein 
targeting it for degradation.  
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first focus on confirming the relative levels of phosphorylated and 
native forms of these constituent proteins, and if consistent with the 
model of regulation, the siRNA (or pharmacological) inhibition of each 
component of the pathway will be performed to functionally verify its 
role in c-FLIP degradation. FASR cells did show an increase in DR4 
expression (Figure 4.2.6), a mechanism that has been previously 
reported to increase TRAIL sensitivity (Gomez-Benito et al. 2007) and 
additionally DR4 has now been shown to be the functional TRAIL 
receptor in primary breast cancer samples (Twiddy D 2010). Although 
at this point the contribution of this increased expression of DR4 to 
FASR TRAIL sensitivity is unclear. The contribution of increased DR4 
expression in FASR cells to TRAIL sensitivity can be clarified in future 
experiments using siRNA to knockdown DR4 expression or antibodies 
to specifically block its binding to TRAIL. Future experiments will 
therefore be focussed on further characterisation of TAMR and FASR 
hypersensitivity. 
Uncovering the mechanism of AE-resistant cancer cell sensitivity 
to TRAIL and further extending this work to more models of endocrine 
resistance including additional primary samples from multi-drug-
resistant patients will be key in further evaluating TRAIL’s potential in 
the clinical setting. 
 
6.1.2 Using the immune system to deliver TRAIL to tumour 
cells 
 The capacity of the immune system for specificity makes it an 
appealing therapeutic option for cancer. This was first demonstrated 
by the clinical success of mAbs in the treatment of breast cancer and 
lymphomas. This brought about the interest in T cell-based 
immunotherapy with their capability to recognise peptides derived 
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from protein in any cellular compartment. There are now several 
clinical studies supporting immunotherapy as a realistic therapeutic 
approach and thus development and application of immunotherapy has 
attracted much attention over the last decade. Augmentation of 
immune response can be achieved in vivo by stimulatory compounds 
and ex vivo expansion of effector cells followed by adoptive transfer. 
The end result of each is a population of activated effector cells that 
recognise a target population of cells for destruction (reviewed in 
(Restifo et al. 2012)). Of course in vivo and ex vivo stimulation of 
effector cells will ultimately result in behavioural differences in the 
cells as the in vivo environment can not be accurately recapitulated in 
vitro. Despite these differences each of these two modalities have their 
benefits and show some promise as a methodology for cancer 
treatment.  
 Adoptive transfer of !" T cells is in the early stages of 
development and phase I clinical trials for treating renal and lung 
cancer are currently ongoing (Bennouna et al. 2008; Kobayashi et al. 
2011; Sakamoto et al. 2011). As of yet there are no active trials for 
breast cancer treatment with adoptively transferred !" T cells although 
there is strong evidence of their efficiency in killing breast cancer cells 
in preclinical models and additionally !" T cells have also been 
identified in breast tumour infiltrating lymphocytes (Beck et al. 2010; 
Capietto et al. 2011; Guo et al. 2005; Meraviglia et al. 2010). In 
another study where prostate cancer patients were treated with ZOL 
and IL-2, a transition of !" T cells toward an activated effector-
memory-like state was observed in conjunction with maintained serum 
TRAIL levels. This correlated with reduced prostate-specific antigen 
and improved clinical outcome (Dieli et al. 2007). Furthermore TRAIL 
has also been indicated to partly contribute to activated !" T cell killing 
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of chronic myelogenous leukaemia (D'Asaro et al. 2010). Data shown 
in Chapter 5 collectively suggests that breast cancer killing by 
activated !" T cells is predominantly a TRAIL-independent cytotoxicity. 
Similar results have also been seen in !" T cell treatment of solid 
tumour cells, where the killing observed was also predominantly 
perforin-mediated (Mattarollo et al. 2007). This is not to discount any 
role TRAIL may have in the cytoxicity that was observed in bCSC 
subset (Figure 5.2.6). In fact the cytotoxicity of activated !" T cells on 
the cancer stem cell subset has not been previously addressed. 
 Importantly the !" T cells could also be activated using 
zoledronate, producing similar expression of cytotoxic factors (Figures 
5.2.1, 5.2.2, 5.2.3). Zoledronate shows great promise in facilitating ex 
vivo expansion of !" T cells from cancer patients for adoptive transfer 
(Kondo et al. 2008). Zoledronate is generally non-toxic (Rosen et al. 
2001; Rosen et al. 2004) maintaining the tumour cell specificity of the 
!" T cells by limiting off-target effects. Coincidentally, zoledronate has 
also been demonstrated to improve endocrine therapy response in 
premenopausal breast cancer patients (Delea et al. 2010; Gnant et al. 
2009). Although the mechanism of this combination treatment benefit 
was not elucidated in the study, this combination therapy would allow 
the delivery of TRAIL to tumours by activation of !" T cells. The 
treatment regime was performed over three years during which time 
recurrence events were significantly reduced by combination 
treatment. Although individual contribution of immune responses, 
TRAIL and disease resistance were not investigated in this study, it is 
possible that in this timeframe some patients may have acquired 
resistance to the endocrine agent resulting in cellular changes that 
may sensitise the tumour cells to !" T cell treatment, similar to the 
effect observed in the bCSCs of the TAMR and FASR cells shown in 
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Figure 5.2.6. At present this is highly speculative and there are many 
other possible explanations for the cytotoxicity that was observed in 
Figure 5.2.6. The contribution of perforin and Fas to bCSC cell death in 
TAMR and FASR cells was not explored due to time constraints and 
cannot be ignored as possible inducers of cell death in these cells. 
Future work will focus on elucidating any bCSC cytotoxicity of 
activated !" T cells alone or also in combination with FLIPi. It is 
possible that FLIPi can sensitise bCSCs to activated !" T cell delivery of 
TRAIL. Furthermore it may be of interest to investigate activated !" T 
cell delivery of TRAIL to AE-resistant tumours. Importantly the 
efficiency of activated !" T cell cytotoxicity to breast cancer cells must 
be assessed in preclinical models including primary cancer cells and in 
vivo studies.   
 The work performed in this thesis collectively identifies potential 
therapies that may prove effective in combination, or in some cases 
individually, in the treatment of breast cancer by overcoming disease 
resistance and preventing distant metastasis. 
 
6.1.3 Future perspectives 
 
 Work in this thesis has touched upon creating and exploiting 
certain signalling pathways of tumour cells across the breadth of 
breast cancer sub-types. Existing therapies for breast cancer are 
generally sub-type specific and resistance is prevalent to these 
treatments resulting in the need for new or adjuvant therapies. On the 
basis of the data shown here, further investigation into the therapeutic 
efficacy of c-FLIP inhibition to sensitise breast tumours to TRAIL 
treatment is warranted. The feasibility of designing drugs to target c-
FLIP is at present unknown. It is clear from the homology c-FLIP 
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shares with caspase-8 that drug development will not be without 
difficulty. In addition it is also currently unclear as to what the overall 
effect on normal tissue homeostasis would be in response to systemic 
c-FLIP inhibition. Evaluation of toxicity of such compounds in both in 
vitro and in vivo models will help provide insight into the potential use 
of c-FLIP inhibition in future treatment of breast cancer.  
 Data presented in Chapter 4 of this thesis supports the potential 
use of TRAIL as an adjuvant therapy in patients who have become 
resistant to anti-estrogens. Continuation of this work will be primarily 
focussed on the completion of in vivo studies of AE-resistant cell line 
sensitivity to TRAIL and the treatment of additional primary samples 
obtained from AE-resistant patients. It may also prove beneficial to 
correlate primary sample response with c-FLIP expression potentially 
identifying it as a biomarker for AE-resistant patient response to 
TRAIL.  
 The use of adoptively transferred ex vivo expanded !" T cells as 
a therapeutic strategy for cancer patients is currently ongoing. Work 
performed in this thesis identifies c-FLIP inhibition as a potential 
sensitizer of breast cancer cells and further supports this therapeutic 
approach. Investigating CSC targeting and preclinical in vivo modelling 
of combined FLIPi/ activated !" T cell treatment will help to elucidate 
its potential benefit to breast cancer patients.  
In all cases, each one of these therapeutic approaches is 
particularly desirable in light of the tumour specificity implied by the 
data collected hitherto. 
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APPENDICES 
 
 
Appendix I – Heterotypic cultures unstained control 
 
Figure 7.1: Unstained control. Untreated breast cancer cells were stained 
with only fixable live/dead stain before analysis for background fluorescence in 
APC and FITC channels and background cell death. 
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Appendix II – Human primary sample details 
 
2004: Right WLE (wide local excision), Axilar node biopsy, 3/5 LN  
(Lymph node) positive 
 
Patient 
Details 
Collected 
Material 
Chemotherapy 
/Radiotherapy 
Date Endocrine 
Therapy 
Date Patient 
Status 
BB3RC50 
 
ER +++ 
PR +++ 
HER2 -ve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ascites 
01/2012 
8 x FEC60 
 
 
 
 
 
Paclitaxel  
 
 
Capecitabine 
 
 
 
 
Vinorelbine 
 
2005 
 
 
 
 
 
02/04/08-
23/06/08 
 
08/04/09-
01/08/09 
 
 
 
08/2009-
03/2010 
 
 
Tamoxifen 
 
 
 
 
 
 
 
 
Anastrazole 
 
 
 
 
 
 
Exemestrane 
 
 
Fulvestrant 
2005 
 
 
 
 
 
 
 
 
08/04/09-
01/08/09 
 
 
 
 
 
04/2010-
06/2011 
 
07/2011-
092011 
Bone, 
Liver, 
Ovarian 
Mets 2008 
 
 
PR 
 
PD 
 
 
 
 
SD 
 
 
SD 
 
 
PD 
 
 
Died 
03/2012 
 
Table 7.1 – Full details of primary human sample. ER- estrogen receptor, PR- 
progesterone receptor, PR (patient status) – partial remission, PD – progressive 
disease, SD – stable disease. 
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Appendix III – !" T cell treatment of heterotypic cultures  
 
Figure 7.2: Illustration of !" T cell treatment of heterotypic SCi and FLIPi 
cultures. 
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Appendix IV– Miccroarray heatmaps of gene expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Microarray heatmaps. Gene expression of TAMR, FASR and XL cells 
compared to parental WT MCF-7 cells. Red = upregulation Green = downregulation. 
  Bibliography 
L Piggott  Cardiff University 219 
Bibliography 
 
Adjei, A. A. et al. 2009. Novel designs and end points for phase II 
clinical trials. Clinical cancer research 15(6), pp. 1866-1872. 
 
Aggarwal, B. B. et al. 2005. Curcumin suppresses the paclitaxel-
induced nuclear factor-kappaB pathway in breast cancer cells and 
inhibits lung metastasis of human breast cancer in nude mice. Clinical 
cancer research 11(20), pp. 7490-7498. 
 
Aggarwal, B. B. et al. 2006. TNF blockade: an inflammatory issue. 
Ernst Schering Research Foundation workshop (56), pp. 161-186. 
 
Ahmadzadeh, M. et al. 2009. Tumor antigen-specific CD8 T cells 
infiltrating the tumor express high levels of PD-1 and are functionally 
impaired. Blood 114(8), pp. 1537-1544. 
 
Aktas, B. et al. 2009. Stem cell and epithelial-mesenchymal transition 
markers are frequently overexpressed in circulating tumor cells of 
metastatic breast cancer patients. Breast cancer research 11(4), p. 
R46. 
 
Al-Hajj, M. et al. 2003. Prospective identification of tumorigenic breast 
cancer cells. Proceedings of the National Academy of Sciences of the 
United States of America 100(7), pp. 3983-3988. 
 
Alimandi, M. et al. 1995. Cooperative signaling of ErbB3 and ErbB2 in 
neoplastic transformation and human mammary carcinomas. 
Oncogene 10(9), pp. 1813-1821. 
 
Allred, D. C. and Medina, D. 2008. The relevance of mouse models to 
understanding the development and progression of human breast 
cancer. Journal of mammary gland biology and neoplasia 13(3), pp. 
279-288. 
 
Anderson, W. F. et al. 2002. Estrogen receptor breast cancer 
phenotypes in the Surveillance, Epidemiology, and End Results 
database. Breast cancer research and treatment 76(1), pp. 27-36. 
 
  Bibliography 
L Piggott  Cardiff University 220 
Arpino, G. et al. 2008. Crosstalk between the estrogen receptor and 
the HER tyrosine kinase receptor family: molecular mechanism and 
clinical implications for endocrine therapy resistance. Endocrine 
reviews 29(2), pp. 217-233. 
 
Ashkenazi, A. 2002. Targeting death and decoy receptors of the 
tumour-necrosis factor superfamily. Nature reviews 2(6), pp. 420-430. 
 
Ashkenazi, A. and Dixit, V. M. 1998. Death receptors: signaling and 
modulation. Science (New York, N.Y 281(5381), pp. 1305-1308. 
 
Ashkenazi, A. and Dixit, V. M. 1999. Apoptosis control by death and 
decoy receptors. Current opinion in cell biology 11(2), pp. 255-260. 
 
Ashkenazi, A. et al. 1999. Safety and antitumor activity of 
recombinant soluble Apo2 ligand. The Journal of clinical investigation 
104(2), pp. 155-162. 
 
Asiedu, M. K. et al. 2011. TGFbeta/TNF(alpha)-mediated epithelial-
mesenchymal transition generates breast cancer stem cells with a 
claudin-low phenotype. Cancer research 71(13), pp. 4707-4719. 
 
Aslakson, C. J. and Miller, F. R. 1992. Selective events in the 
metastatic process defined by analysis of the sequential dissemination 
of subpopulations of a mouse mammary tumor. Cancer research 
52(6), pp. 1399-1405. 
 
Aydin, C. et al. 2007. Decoy receptor-2 small interfering RNA (siRNA) 
strategy employing three different siRNA constructs in combination 
defeats adenovirus-transferred tumor necrosis factor-related 
apoptosis-inducing ligand resistance in lung cancer cells. Human gene 
therapy 18(1), pp. 39-50. 
 
Badve, S. and Nakshatri, H. 2009. Oestrogen-receptor-positive breast 
cancer: towards bridging histopathological and molecular 
classifications. Journal of clinical pathology 62(1), pp. 6-12. 
 
Badve, S. et al. 2007. FOXA1 expression in breast cancer--correlation 
with luminal subtype A and survival. Clinical cancer research 13(15 Pt 
1), pp. 4415-4421. 
 
Bangert, A. et al. 2012. Histone deacetylase inhibitors sensitize 
glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated 
downregulation of cFLIP. Oncogene. 
  Bibliography 
L Piggott  Cardiff University 221 
 
Bank, I. et al. 1993. V delta 2+ gamma delta T lymphocytes are 
cytotoxic to the MCF 7 breast carcinoma cell line and can be detected 
among the T cells that infiltrate breast tumors. Clinical immunology 
and immunopathology 67(1), pp. 17-24. 
 
Baum, B. et al. 2008. Transitions between epithelial and mesenchymal 
states in development and disease. Seminars in cell & developmental 
biology 19(3), pp. 294-308. 
 
Beatson, G. 1896. On the treatment of inoperable cases of carcinoma 
of the mammary: suggestions for a new method of treatment with 
illustrative cases. Lancet 2, pp. 104-107, 162-165. 
 
Beck, B. H. et al. 2010. Adoptively transferred ex vivo expanded 
gammadelta-T cells mediate in vivo antitumor activity in preclinical 
mouse models of breast cancer. Breast cancer research and treatment 
122(1), pp. 135-144. 
 
Beeram, M. et al. 2007. Akt-induced endocrine therapy resistance is 
reversed by inhibition of mTOR signaling. Annals of oncology 18(8), 
pp. 1323-1328. 
 
Bennouna, J. et al. 2008. Phase-I study of Innacell gammadelta, an 
autologous cell-therapy product highly enriched in gamma9delta2 T 
lymphocytes, in combination with IL-2, in patients with metastatic 
renal cell carcinoma. Cancer immunology, immunotherapy 57(11), pp. 
1599-1609. 
 
Benz, C. C. et al. 1992. Estrogen-dependent, tamoxifen-resistant 
tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast 
cancer research and treatment 24(2), pp. 85-95. 
 
Benzaid, I. et al. 2011. High phosphoantigen levels in bisphosphonate-
treated human breast tumors promote Vgamma9Vdelta2 T-cell 
chemotaxis and cytotoxicity in vivo. Cancer research 71(13), pp. 
4562-4572. 
 
Berstein, L. M. et al. 2003. New approaches to the understanding of 
tamoxifen action and resistance. Endocrine-related cancer 10(2), pp. 
267-277. 
 
  Bibliography 
L Piggott  Cardiff University 222 
Bertucci, F. et al. 2004. Identification and validation of an ERBB2 gene 
expression signature in breast cancers. Oncogene 23(14), pp. 2564-
2575. 
 
Bhat-Nakshatri, P. et al. 2010. SLUG/SNAI2 and tumor necrosis factor 
generate breast cells with CD44+/CD24- phenotype. BMC cancer 10, 
p. 411. 
 
Bijangi-Vishehsaraei, K. et al. 2010. 4-(4-Chloro-2-methylphenoxy)-N-
hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and 
induces apoptosis in MCF-7 human breast cancer cells. Molecular and 
cellular biochemistry 342(1-2), pp. 133-142. 
 
Biswas, D. K. and Iglehart, J. D. 2006. Linkage between EGFR family 
receptors and nuclear factor kappaB (NF-kappaB) signaling in breast 
cancer. Journal of cellular physiology 209(3), pp. 645-652. 
 
Boatright, K. M. et al. 2004. Activation of caspases-8 and -10 by 
FLIP(L). The Biochemical journal 382(Pt 2), pp. 651-657. 
 
Body, J. J. et al. 2003. Intravenous ibandronate reduces the incidence 
of skeletal complications in patients with breast cancer and bone 
metastases. Annals of oncology 14(9), pp. 1399-1405. 
 
Boissier, S. et al. 2000. Bisphosphonates inhibit breast and prostate 
carcinoma cell invasion, an early event in the formation of bone 
metastases. Cancer research 60(11), pp. 2949-2954. 
 
Boissier, S. et al. 1997. Bisphosphonates inhibit prostate and breast 
carcinoma cell adhesion to unmineralized and mineralized bone 
extracellular matrices. Cancer research 57(18), pp. 3890-3894. 
 
Bombonati, A. and Sgroi, D. C. 2010. The molecular pathology of 
breast cancer progression. The Journal of pathology 223(2), pp. 307-
317. 
 
Bomken, S. et al. 2010. Understanding the cancer stem cell. British 
journal of cancer 103(4), pp. 439-445. 
 
Bonnet, D. and Dick, J. E. 1997. Human acute myeloid leukemia is 
organized as a hierarchy that originates from a primitive hematopoietic 
cell. Nature medicine 3(7), pp. 730-737. 
 
  Bibliography 
L Piggott  Cardiff University 223 
Bonneville, M. and Scotet, E. 2006. Human Vgamma9Vdelta2 T cells: 
promising new leads for immunotherapy of infections and tumors. 
Current opinion in immunology 18(5), pp. 539-546. 
 
Borges, J. et al. 2007. Erk5 nuclear location is independent on dual 
phosphorylation, and favours resistance to TRAIL-induced apoptosis. 
Cellular signalling 19(7), pp. 1473-1487. 
 
Borley, A. C. et al. 2008. Anti-oestrogens but not oestrogen 
deprivation promote cellular invasion in intercellular adhesion-deficient 
breast cancer cells. Breast cancer research 10(6), p. R103. 
 
Bos, R. et al. 2001. Levels of hypoxia-inducible factor-1 alpha during 
breast carcinogenesis. Journal of the National Cancer Institute 93(4), 
pp. 309-314. 
 
Britton, D. J. et al. 2006. Bidirectional cross talk between ERalpha and 
EGFR signalling pathways regulates tamoxifen-resistant growth. Breast 
cancer research and treatment 96(2), pp. 131-146. 
 
Brown, J. M. et al. 2001. Serum osteoprotegerin levels are increased in 
patients with advanced prostate cancer. Clinical cancer research 7(10), 
pp. 2977-2983. 
 
Brunner, N. et al. 1993. MCF7/LCC2: a 4-hydroxytamoxifen resistant 
human breast cancer variant that retains sensitivity to the steroidal 
antiestrogen ICI 182,780. Cancer research 53(14), pp. 3229-3232. 
 
Bubenik, J. 2003. Tumour MHC class I downregulation and 
immunotherapy (Review). Oncology reports 10(6), pp. 2005-2008. 
 
Bubenik, J. 2004. MHC class I down-regulation: tumour escape from 
immune surveillance? (review). International journal of oncology 
25(2), pp. 487-491. 
 
Bunone, G. et al. 1996. Activation of the unliganded estrogen receptor 
by EGF involves the MAP kinase pathway and direct phosphorylation. 
The EMBO journal 15(9), pp. 2174-2183. 
 
Buzdar, A. U. 2003. Advances in endocrine treatments for 
postmenopausal women with metastatic and early breast cancer. The 
oncologist 8(4), pp. 335-341. 
 
  Bibliography 
L Piggott  Cardiff University 224 
Caldas, C. and Aparicio, S. A. 2002. The molecular outlook. Nature 
415(6871), pp. 484-485. 
 
Camidge, D. R. 2008. Apomab: an agonist monoclonal antibody 
directed against Death Receptor 5/TRAIL-Receptor 2 for use in the 
treatment of solid tumors. Expert opinion on biological therapy 8(8), 
pp. 1167-1176. 
 
Camidge, D. R. et al. 2007. A phase I pharmacodynamic study of the 
effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle 
markers within the buccal mucosa, plucked scalp hairs and peripheral 
blood mononucleocytes of healthy male volunteers. Cancer 
chemotherapy and pharmacology 60(4), pp. 479-488. 
 
Campbell, R. A. et al. 2001. Phosphatidylinositol 3-kinase/AKT-
mediated activation of estrogen receptor alpha: a new model for anti-
estrogen resistance. The Journal of biological chemistry 276(13), pp. 
9817-9824. 
 
Cao, Y. et al. 2007. IkappaB kinase alpha kinase activity is required for 
self-renewal of ErbB2/Her2-transformed mammary tumor-initiating 
cells. Proceedings of the National Academy of Sciences of the United 
States of America 104(40), pp. 15852-15857. 
 
Capietto, A. H. et al. 2011. Stimulated gammadelta T cells increase 
the in vivo efficacy of trastuzumab in HER-2+ breast cancer. Journal of 
immunology (Baltimore, Md. 187(2), pp. 1031-1038. 
 
Capper, D. et al. 2009. Stem-cell-like glioma cells are resistant to 
TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter 
methylation. Acta neuropathologica 117(4), pp. 445-456. 
 
Carlisi, D. et al. 2009. The histone deacetylase inhibitor suberoylanilide 
hydroxamic acid sensitises human hepatocellular carcinoma cells to 
TRAIL-induced apoptosis by TRAIL-DISC activation. European Journal 
of Cancer 45(13), pp. 2425-2438. 
 
Carter, P. et al. 1992. Humanization of an anti-p185HER2 antibody for 
human cancer therapy. Proceedings of the National Academy of 
Sciences of the United States of America 89(10), pp. 4285-4289. 
 
Chaffer, C. L. et al. 2011. Normal and neoplastic nonstem cells can 
spontaneously convert to a stem-like state. Proceedings of the 
  Bibliography 
L Piggott  Cardiff University 225 
National Academy of Sciences of the United States of America 
108(19), pp. 7950-7955. 
 
Chan, C. M. et al. 2002. Molecular changes associated with the 
acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells 
on long-term oestrogen deprivation. The Journal of steroid 
biochemistry and molecular biology 81(4-5), pp. 333-341. 
 
Chang, L. et al. 2006. The E3 ubiquitin ligase itch couples JNK 
activation to TNFalpha-induced cell death by inducing c-FLIP(L) 
turnover. Cell 124(3), pp. 601-613. 
 
Chao, Y. L. et al. 2010. Breast carcinoma cells re-express E-cadherin 
during mesenchymal to epithelial reverting transition. Molecular cancer 
9, p. 179. 
 
Charafe-Jauffret, E. et al. 2009. Breast cancer cell lines contain 
functional cancer stem cells with metastatic capacity and a distinct 
molecular signature. Cancer research 69(4), pp. 1302-1313. 
 
Chargui, J. et al. 2010. Bromohydrin pyrophosphate-stimulated 
Vgamma9delta2 T cells expanded ex vivo from patients with poor-
prognosis neuroblastoma lyse autologous primary tumor cells. Journal 
of immunotherapy (Hagerstown, Md. 33(6), pp. 591-598. 
 
Chatterjee, D. et al. 2001. Induction of apoptosis in 9-
nitrocamptothecin-treated DU145 human prostate carcinoma cells 
correlates with de novo synthesis of CD95 and CD95 ligand and down-
regulation of c-FLIP(short). Cancer research 61(19), pp. 7148-7154. 
 
Cheang, M. C. et al. 2009. Ki67 index, HER2 status, and prognosis of 
patients with luminal B breast cancer. Journal of the National Cancer 
Institute 101(10), pp. 736-750. 
 
Chen, J. et al. 2001. Antitumor activity of expanded human tumor-
infiltrating gammadelta T lymphocytes. International archives of 
allergy and immunology 125(3), pp. 256-263. 
 
Chen, Q. et al. 2000. Distinct stages of cytochrome c release from 
mitochondria: evidence for a feedback amplification loop linking 
caspase activation to mitochondrial dysfunction in genotoxic stress 
induced apoptosis. Cell death and differentiation 7(2), pp. 227-233. 
 
  Bibliography 
L Piggott  Cardiff University 226 
Chen, Y. et al. 2008. NSOM/QD-based nanoscale immunofluorescence 
imaging of antigen-specific T-cell receptor responses during an in vivo 
clonal Vgamma2Vdelta2 T-cell expansion. Blood 111(8), pp. 4220-
4232. 
 
Cheng, J. et al. 2006. Multiple mechanisms underlie resistance of 
leukemia cells to Apo2 Ligand/TRAIL. Molecular cancer therapeutics 
5(7), pp. 1844-1853. 
 
Chhabra, A. 2011. TCR-engineered, customized, antitumor T cells for 
cancer immunotherapy: advantages and limitations. 
TheScientificWorldJournal 11, pp. 121-129. 
 
Christiansen, J. J. and Rajasekaran, A. K. 2006. Reassessing epithelial 
to mesenchymal transition as a prerequisite for carcinoma invasion 
and metastasis. Cancer research 66(17), pp. 8319-8326. 
 
Chung, C. T. and Carlson, R. W. 2003. The role of aromatase inhibitors 
in early breast cancer. Current treatment options in oncology 4(2), pp. 
133-140. 
 
Clezardin, P. 2011. Bisphosphonates' antitumor activity: an unravelled 
side of a multifaceted drug class. Bone 48(1), pp. 71-79. 
 
Connelly, L. et al. 2010. Inhibition of NF-kappa B activity in mammary 
epithelium increases tumor latency and decreases tumor burden. 
Oncogene 30(12), pp. 1402-1412. 
 
Correia, D. V. et al. 2009. Highly active microbial phosphoantigen 
induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal 
transduction in anti-tumor human gammadelta T-cells. PloS one 4(5), 
p. e5657. 
 
Corvaisier, M. et al. 2005. V gamma 9V delta 2 T cell response to colon 
carcinoma cells. Journal of immunology (Baltimore, Md. 175(8), pp. 
5481-5488. 
 
Costa, L. 2007. Bisphosphonates: reducing the risk of skeletal 
complications from bone metastasis. Breast (Edinburgh, Scotland) 16 
Suppl 3, pp. S16-20. 
 
Coutts, A. S. and Murphy, L. C. 1998. Elevated mitogen-activated 
protein kinase activity in estrogen-nonresponsive human breast cancer 
cells. Cancer research 58(18), pp. 4071-4074. 
  Bibliography 
L Piggott  Cardiff University 227 
 
Creighton, C. J. et al. 2009. Residual breast cancers after conventional 
therapy display mesenchymal as well as tumor-initiating features. 
Proceedings of the National Academy of Sciences of the United States 
of America 106(33), pp. 13820-13825. 
 
Cuello, M. et al. 2001. Down-regulation of the erbB-2 receptor by 
trastuzumab (herceptin) enhances tumor necrosis factor-related 
apoptosis-inducing ligand-mediated apoptosis in breast and ovarian 
cancer cell lines that overexpress erbB-2. Cancer research 61(12), pp. 
4892-4900. 
 
Curtis Hewitt, S. et al. 2000. Estrogen receptor transcription and 
transactivation: Estrogen receptor knockout mice: what their 
phenotypes reveal about mechanisms of estrogen action. Breast 
cancer research 2(5), pp. 345-352. 
 
D'Asaro, M. et al. 2010. V gamma 9V delta 2 T lymphocytes efficiently 
recognize and kill zoledronate-sensitized, imatinib-sensitive, and 
imatinib-resistant chronic myelogenous leukemia cells. Journal of 
immunology (Baltimore, Md. 184(6), pp. 3260-3268. 
 
Davies, C. et al. 2011. Relevance of breast cancer hormone receptors 
and other factors to the efficacy of adjuvant tamoxifen: patient-level 
meta-analysis of randomised trials. Lancet 378(9793), pp. 771-784. 
 
Day, T. W. et al. 2008. c-FLIP knockdown induces ligand-independent 
DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in 
breast cancer cells. Biochemical Pharmacology 76(12), pp. 1694-1704. 
 
Day, T. W. et al. 2009. c-FLIP gene silencing eliminates tumor cells in 
breast cancer xenografts without affecting stromal cells. Anticancer 
research 29(10), pp. 3883-3886. 
 
Dean-Colomb, W. and Esteva, F. J. 2008. Her2-positive breast cancer: 
herceptin and beyond. European journal of cancer (Oxford, England 
44(18), pp. 2806-2812. 
 
Degli-Esposti, M. A. et al. 1997. Cloning and characterization of TRAIL-
R3, a novel member of the emerging TRAIL receptor family. The 
Journal of experimental medicine 186(7), pp. 1165-1170. 
 
Degterev, A. et al. 2003. A decade of caspases. Oncogene 22(53), pp. 
8543-8567. 
  Bibliography 
L Piggott  Cardiff University 228 
 
Del Bufalo, D. et al. 1997. Bcl-2 overexpression enhances the 
metastatic potential of a human breast cancer line. FASEB journal 
11(12), pp. 947-953. 
 
Delea, T. E. et al. 2010. Cost-effectiveness of zoledronic acid plus 
endocrine therapy in premenopausal women with hormone-responsive 
early breast cancer. Clinical breast cancer 10(4), pp. 267-274. 
 
Delmas, P. D. 2002. Treatment of postmenopausal osteoporosis. 
Lancet 359(9322), pp. 2018-2026. 
 
Dhasarathy, A. et al. 2007. The transcription factor snail mediates 
epithelial to mesenchymal transitions by repression of estrogen 
receptor-alpha. Molecular endocrinology (Baltimore, Md 21(12), pp. 
2907-2918. 
 
Dieli, F. et al. 2007. Targeting human {gamma}delta} T cells with 
zoledronate and interleukin-2 for immunotherapy of hormone-
refractory prostate cancer. Cancer research 67(15), pp. 7450-7457. 
 
DiMasi, J. A. et al. 2003. The price of innovation: new estimates of 
drug development costs. Journal of health economics 22(2), pp. 151-
185. 
 
Dohrman, A. et al. 2005. Cellular FLIP long form augments caspase 
activity and death of T cells through heterodimerization with and 
activation of caspase-8. Journal of immunology (Baltimore, Md. 
175(1), pp. 311-318. 
 
Donovan, J. C. et al. 2001. Constitutive MEK/MAPK activation leads to 
p27(Kip1) deregulation and antiestrogen resistance in human breast 
cancer cells. The Journal of biological chemistry 276(44), pp. 40888-
40895. 
 
Dontu, G. et al. 2003a. In vitro propagation and transcriptional 
profiling of human mammary stem/progenitor cells. Genes & 
Development 17(10), pp. 1253-1270. 
 
Dontu, G. et al. 2003b. Stem cells in normal breast development and 
breast cancer. Cell proliferation 36 Suppl 1, pp. 59-72. 
 
  Bibliography 
L Piggott  Cardiff University 229 
Dontu, G. et al. 2004. Role of Notch signaling in cell-fate 
determination of human mammary stem/progenitor cells. Breast 
cancer research 6(6), pp. R605-615. 
 
Drasin, D. J. et al. 2011. Breast cancer epithelial-to-mesenchymal 
transition: examining the functional consequences of plasticity. Breast 
cancer research 13(6), p. 226. 
 
Duiker, E. W. et al. 2006. The clinical trail of TRAIL. European journal 
of cancer (Oxford, England 42(14), pp. 2233-2240. 
 
Dyer, M. J. et al. 2007. Barriers to effective TRAIL-targeted therapy of 
malignancy. Journal of clinical oncology 25(28), pp. 4505-4506. 
 
Dykxhoorn, D. M. et al. 2009. miR-200 enhances mouse breast cancer 
cell colonization to form distant metastases. PloS one 4(9), p. e7181. 
 
EBCTCG 1998. Tamoxifen for early breast cancer: an overview of 
randomised trials. Lancet 351, pp. 1451-1467. 
 
Eberl, M. et al. 2002. Differentiation of human gamma-delta T cells 
towards distinct memory phenotypes. Cellular immunology 218(1-2), 
pp. 1-6. 
 
Eisenhauer, E. A. et al. 2009. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). European journal of 
cancer (Oxford, England 45(2), pp. 228-247. 
 
El-Zawahry, A. et al. 2005. Doxorubicin increases the effectiveness of 
Apo2L/TRAIL for tumor growth inhibition of prostate cancer 
xenografts. BMC cancer 5, p. 2. 
 
Ellis, L. and Pili, R. 2010. Histone Deacetylase Inhibitors: Advancing 
Therapeutic Strategies in Hematological and Solid Malignancies. 
Pharmaceuticals (Basel, Switzerland) 3(8), pp. 2411-2469. 
 
Emery, J. G. et al. 1998. Osteoprotegerin is a receptor for the 
cytotoxic ligand TRAIL. The Journal of biological chemistry 273(23), 
pp. 14363-14367. 
 
Eyler, C. E. and Rich, J. N. 2008. Survival of the Fittest: Cancer Stem 
Cells in Therapeutic Resistance and Angiogenesis. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 
26(17), pp. 2839-2845. 
  Bibliography 
L Piggott  Cardiff University 230 
 
Falschlehner, C. et al. 2007. TRAIL signalling: decisions between life 
and death. The international journal of biochemistry & cell biology 
39(7-8), pp. 1462-1475. 
 
Fang, L. W. et al. 2004. Phosphatidylinositide 3-kinase priming couples 
c-FLIP to T cell activation. The Journal of biological chemistry 279(1), 
pp. 13-18. 
 
Farnie, G. and Clarke, R. B. 2007. Mammary stem cells and breast 
cancer--role of Notch signalling. Stem cell reviews 3(2), pp. 169-175. 
 
Fehm, T. et al. 2008. ERalpha-status of disseminated tumour cells in 
bone marrow of primary breast cancer patients. Breast cancer 
research 10(5), p. R76. 
 
Fillmore, C. M. and Kuperwasser, C. 2008. Human breast cancer cell 
lines contain stem-like cells that self-renew, give rise to phenotypically 
diverse progeny and survive chemotherapy. Breast Cancer Research : 
BCR 10(2), pp. R25-R25-R25-R25. 
 
Frese, S. et al. 2003. PG490-mediated sensitization of lung cancer 
cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. 
Oncogene 22(35), pp. 5427-5435. 
 
Frew, A. J. et al. 2008. Combination therapy of established cancer 
using a histone deacetylase inhibitor and a TRAIL receptor agonist. 
Proceedings of the National Academy of Sciences of the United States 
of America 105(32), pp. 11317-11322. 
 
Fridlyand, J. et al. 2006. Breast tumor copy number aberration 
phenotypes and genomic instability. BMC cancer 6, p. 96. 
 
Gasparini, G. et al. 2007. Randomized Phase II Trial of weekly 
paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line 
therapy of patients with Her-2 positive advanced breast cancer. Breast 
cancer research and treatment 101(3), pp. 355-365. 
 
Gee, J. M. et al. 2004. Extreme growth factor signalling can promote 
oestrogen receptor-alpha loss: therapeutic implications in breast 
cancer. Breast cancer research 6(4), pp. 162-163. 
 
Gee, J. M. et al. 2001. Phosphorylation of ERK1/2 mitogen-activated 
protein kinase is associated with poor response to anti-hormonal 
  Bibliography 
L Piggott  Cardiff University 231 
therapy and decreased patient survival in clinical breast cancer. 
International journal of cancer 95(4), pp. 247-254. 
 
Gee, J. M. et al. 2005. Epidermal growth factor receptor/HER2/insulin-
like growth factor receptor signalling and oestrogen receptor activity in 
clinical breast cancer. Endocrine-related cancer 12 Suppl 1, pp. S99-
S111. 
 
Gee, J. M. et al. 2006. Deciphering antihormone-induced 
compensatory mechanisms in breast cancer and their therapeutic 
implications. Endocrine-related cancer 13 Suppl 1, pp. S77-88. 
 
Gerber, B. et al. 2010. Recurrent breast cancer: treatment strategies 
for maintaining and prolonging good quality of life. Deutsches 
Arzteblatt international 107(6), pp. 85-91. 
 
Geyer, C. E. et al. 2006. Lapatinib plus capecitabine for HER2-positive 
advanced breast cancer. The New England journal of medicine 
355(26), pp. 2733-2743. 
 
Ginestier, C. et al. 2007. ALDH1 is a marker of normal and malignant 
human mammary stem cells and a predictor of poor clinical outcome. 
Cell stem cell 1(5), pp. 555-567. 
 
Girardi, M. et al. 2001. Regulation of cutaneous malignancy by 
gammadelta T cells. Science (New York, N.Y 294(5542), pp. 605-609. 
 
Gnant, M. et al. 2009. Endocrine therapy plus zoledronic acid in 
premenopausal breast cancer. The New England journal of medicine 
360(7), pp. 679-691. 
 
Gober, H. J. et al. 2003. Human T cell receptor gammadelta cells 
recognize endogenous mevalonate metabolites in tumor cells. The 
Journal of experimental medicine 197(2), pp. 163-168. 
 
Goldhirsch, A. et al. 2005. Meeting highlights: international expert 
consensus on the primary therapy of early breast cancer 2005. Annals 
of oncology 16(10), pp. 1569-1583. 
 
Golks, A. et al. 2006. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-
kappaB activation. The Journal of experimental medicine 203(5), pp. 
1295-1305. 
 
  Bibliography 
L Piggott  Cardiff University 232 
Gomes, A. Q. et al. 2010. Identification of a panel of ten cell surface 
protein antigens associated with immunotargeting of leukemias and 
lymphomas by peripheral blood gammadelta T cells. Haematologica 
95(8), pp. 1397-1404. 
 
Gomez-Benito, M. et al. 2007. Membrane expression of DR4, DR5 and 
caspase-8 levels, but not Mcl-1, determine sensitivity of human 
myeloma cells to Apo2L/TRAIL. Experimental cell research 313(11), 
pp. 2378-2388. 
 
Gong, B. et al. 1999. Ionizing radiation-induced, Bax-mediated cell 
death is dependent on activation of cysteine and serine proteases. Cell 
growth & differentiation 10(7), pp. 491-502. 
 
Greco, F. A. et al. 2008. Phase 2 study of mapatumumab, a fully 
human agonistic monoclonal antibody which targets and activates the 
TRAIL receptor-1, in patients with advanced non-small cell lung 
cancer. Lung cancer (Amsterdam, Netherlands) 61(1), pp. 82-90. 
 
Groh, V. et al. 1999. Broad tumor-associated expression and 
recognition by tumor-derived gamma delta T cells of MICA and MICB. 
Proceedings of the National Academy of Sciences of the United States 
of America 96(12), pp. 6879-6884. 
 
Guo, B. L. et al. 2005. Innate anti-breast cancer immunity of 
apoptosis-resistant human gammadelta-T cells. Breast cancer research 
and treatment 93(2), pp. 169-175. 
 
Hanahan, D. and Weinberg, R. A. 2000. The hallmarks of cancer. Cell 
100(1), pp. 57-70. 
 
Hardy, K. M. et al. 2010. ErbB/EGF signaling and EMT in mammary 
development and breast cancer. Journal of mammary gland biology 
and neoplasia 15(2), pp. 191-199. 
 
Harper, N. et al. 2001. Modulation of tumor necrosis factor apoptosis-
inducing ligand- induced NF-kappa B activation by inhibition of apical 
caspases. The Journal of biological chemistry 276(37), pp. 34743-
34752. 
 
Harrison, H. et al. 2010. Regulation of breast cancer stem cell activity 
by signaling through the Notch4 receptor. Cancer research 70(2), pp. 
709-718. 
 
  Bibliography 
L Piggott  Cardiff University 233 
Hay, E. D. 1995. An overview of epithelio-mesenchymal 
transformation. Acta anatomica 154(1), pp. 8-20. 
 
Hay, E. D. 2005. The mesenchymal cell, its role in the embryo, and the 
remarkable signaling mechanisms that create it. Developmental 
dynamics 233(3), pp. 706-720. 
 
Hayday, A. C. 2000. [gamma][delta] cells: a right time and a right 
place for a conserved third way of protection. Annual review of 
immunology 18, pp. 975-1026. 
 
Helbig, G. et al. 2003. NF-kappaB promotes breast cancer cell 
migration and metastasis by inducing the expression of the chemokine 
receptor CXCR4. The Journal of biological chemistry 278(24), pp. 
21631-21638. 
 
Henderson, I. C. and Canellos, G. P. 1980. Cancer of the breast: the 
past decade (first of two parts). The New England journal of medicine 
302(1), pp. 17-30. 
 
Herbst, R. S. et al. 2006. Phase I dose-escalation study of recombinant 
human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients 
with advanced cancer. Journal of clinical oncology 28(17), pp. 2839-
2846. 
 
Hinohara, K. et al. 2012. ErbB receptor tyrosine kinase/NF-kappaB 
signaling controls mammosphere formation in human breast cancer. 
Proceedings of the National Academy of Sciences of the United States 
of America 109(17), pp. 6584-6589. 
 
Hirsch, H. A. et al. 2009. Metformin selectively targets cancer stem 
cells, and acts together with chemotherapy to block tumor growth and 
prolong remission. Cancer research 69(19), pp. 7507-7511. 
 
Hiscox, S. et al. 2006. Tamoxifen resistance in MCF7 cells promotes 
EMT-like behaviour and involves modulation of beta-catenin 
phosphorylation. International journal of cancer 118(2), pp. 290-301. 
 
Holen, I. et al. 2005. Osteoprotegerin (OPG) expression by breast 
cancer cells in vitro and breast tumours in vivo--a role in tumour cell 
survival? Breast cancer research and treatment 92(3), pp. 207-215. 
 
Horak, P. et al. 2005. Contribution of epigenetic silencing of tumor 
necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to 
  Bibliography 
L Piggott  Cardiff University 234 
TRAIL resistance and ovarian cancer. Molecular cancer research 3(6), 
pp. 335-343. 
 
Hotte, S. J. et al. 2008. A phase 1 study of mapatumumab (fully 
human monoclonal antibody to TRAIL-R1) in patients with advanced 
solid malignancies. Clinical cancer research 14(11), pp. 3450-3455. 
 
Howell, A. and Abram, P. 2005. Clinical development of fulvestrant 
("Faslodex"). Cancer treatment reviews 31 Suppl 2, pp. S3-9. 
 
Hu, W. H. et al. 1999. Tumor necrosis factor-related apoptosis-
inducing ligand receptors signal NF-kappaB and JNK activation and 
apoptosis through distinct pathways. The Journal of biological 
chemistry 274(43), pp. 30603-30610. 
 
Huff, C. A. et al. 2006. The paradox of response and survival in cancer 
therapeutics. Blood 107(2), pp. 431-434. 
 
Hugo, H. et al. 2007. Epithelial--mesenchymal and mesenchymal--
epithelial transitions in carcinoma progression. Journal of cellular 
physiology 213(2), pp. 374-383. 
 
Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation 
of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast 
cancer research and treatment 81(1), pp. 81-93. 
 
Hyer, M. L. et al. 2005. Synthetic triterpenoids cooperate with tumor 
necrosis factor-related apoptosis-inducing ligand to induce apoptosis of 
breast cancer cells. Cancer research 65(11), pp. 4799-4808. 
 
Iliopoulos, D. et al. 2011. Inducible formation of breast cancer stem 
cells and their dynamic equilibrium with non-stem cancer cells via IL6 
secretion. Proceedings of the National Academy of Sciences of the 
United States of America 108(4), pp. 1397-1402. 
 
Irmler, M. et al. 1997. Inhibition of death receptor signals by cellular 
FLIP. Nature 388(6638), pp. 190-195. 
 
Ishioka, T. et al. 2007. Impairment of the ubiquitin-proteasome 
system by cellular FLIP. Genes to cells 12(6), pp. 735-744. 
 
Ito, R. et al. 2003. Expression of osteoprotegerin correlates with 
aggressiveness and poor prognosis of gastric carcinoma. Virchows 
Archiv 443(2), pp. 146-151. 
  Bibliography 
L Piggott  Cardiff University 235 
 
Jaiyesimi, I. A. et al. 1995. Use of tamoxifen for breast cancer: 
twenty-eight years later. Journal of clinical oncology 13(2), pp. 513-
529. 
 
Janeway, C. A., Jr. 2001. How the immune system protects the host 
from infection. Microbes and infection / Institut Pasteur 3(13), pp. 
1167-1171. 
 
Janeway, C. A., Jr. and Bottomly, K. 1994. Signals and signs for 
lymphocyte responses. Cell 76(2), pp. 275-285. 
 
Jeon, Y. K. et al. 2005. Resistance to Fas-mediated apoptosis is 
restored by cycloheximide through the downregulation of cellular FLIPL 
in NK/T-cell lymphoma. Laboratory investigation; a journal of technical 
methods and pathology 85(7), pp. 874-884. 
 
Jin, H. et al. 2008. Cooperation of the agonistic DR5 antibody apomab 
with chemotherapy to inhibit orthotopic lung tumor growth and 
improve survival. Clinical cancer research 14(23), pp. 7733-7740. 
 
Jin, X. et al. 2007. Enhancement of death receptor 4 mediated 
apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic 
concentrations of doxorubicin. The Journal of urology 177(5), pp. 
1894-1899. 
 
Jin, Z. et al. 2004. Deficient tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) death receptor transport to the cell surface in 
human colon cancer cells selected for resistance to TRAIL-induced 
apoptosis. The Journal of biological chemistry 279(34), pp. 35829-
35839. 
 
Johnston, S. J. and Cheung, K. L. 2010. Fulvestrant - a novel 
endocrine therapy for breast cancer. Current medicinal chemistry 
17(10), pp. 902-914. 
 
Johnston, S. R. 1997. Acquired tamoxifen resistance in human breast 
cancer--potential mechanisms and clinical implications. Anti-cancer 
drugs 8(10), pp. 911-930. 
 
Johnston, S. R. 2008. Integration of endocrine therapy with targeted 
agents. Breast cancer research 10 Suppl 4, p. S20. 
 
  Bibliography 
L Piggott  Cardiff University 236 
Johnston, S. R. et al. 2008. Enhancing endocrine response with novel 
targeted therapies: why have the clinical trials to date failed to deliver 
on the preclinical promise? Cancer 112(3 Suppl), pp. 710-717. 
 
Johnston, S. R. et al. 1995. Changes in estrogen receptor, 
progesterone receptor, and pS2 expression in tamoxifen-resistant 
human breast cancer. Cancer research 55(15), pp. 3331-3338. 
 
Jonsson, G. et al. 2003. High level of cFLIP correlates with resistance 
to death receptor-induced apoptosis in bladder carcinoma cells. 
Anticancer research 23(2B), pp. 1213-1218. 
 
Jordan, V. C. 2006. Tamoxifen (ICI46,474) as a targeted therapy to 
treat and prevent breast cancer. British journal of pharmacology 147 
Suppl 1, pp. S269-276. 
 
Kabelitz, D. et al. 2007. Perspectives of gammadelta T cells in tumor 
immunology. Cancer research 67(1), pp. 5-8. 
 
Kabelitz, D. et al. 2004. Characterization of tumor reactivity of human 
V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in 
vivo. Journal of immunology (Baltimore, Md. 173(11), pp. 6767-6776. 
 
Kasper, M. et al. 2009. Hedgehog signalling in breast cancer. 
Carcinogenesis 30(6), pp. 903-911. 
 
Kataoka, T. et al. 2000. The caspase-8 inhibitor FLIP promotes 
activation of NF-kappaB and Erk signaling pathways. Current biology 
10(11), pp. 640-648. 
 
Kataoka, T. and Tschopp, J. 2004. N-terminal fragment of c-FLIP(L) 
processed by caspase 8 specifically interacts with TRAF2 and induces 
activation of the NF-kappaB signaling pathway. Molecular and cellular 
biology 24(7), pp. 2627-2636. 
 
Katayama, R. et al. 2010. Modulation of Wnt signaling by the nuclear 
localization of cellular FLIP-L. Journal of cell science 123(Pt 1), pp. 23-
28. 
 
Kato, S. et al. 1995. Activation of the estrogen receptor through 
phosphorylation by mitogen-activated protein kinase. Science (New 
York, N.Y 270(5241), pp. 1491-1494. 
 
  Bibliography 
L Piggott  Cardiff University 237 
Kayagaki, N. et al. 1999. Type I interferons (IFNs) regulate tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) expression 
on human T cells: A novel mechanism for the antitumor effects of type 
I IFNs. The Journal of experimental medicine 189(9), pp. 1451-1460. 
 
Keane, M. M. et al. 1999. Chemotherapy augments TRAIL-induced 
apoptosis in breast cell lines. Cancer research 59(3), pp. 734-741. 
 
Kelley, S. K. and Ashkenazi, A. 2004. Targeting death receptors in 
cancer with Apo2L/TRAIL. Current opinion in pharmacology 4(4), pp. 
333-339. 
 
Kendrick, J. E. et al. 2007. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) and its therapeutic potential in breast and 
gynecologic cancers. Gynecologic oncology 106(3), pp. 614-621. 
 
Kerr, J. F. et al. 1972. Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British journal of cancer 
26(4), pp. 239-257. 
 
Kim, D. Y. et al. 2011. Suppression of multidrug resistance by 
treatment with TRAIL in human ovarian and breast cancer cells with 
high level of c-Myc. Biochimica et biophysica acta 1812(7), pp. 796-
805. 
 
Kim, M. J. et al. 2009. Sensitization of human K562 leukemic cells to 
TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell 
survival pathway. Biochemical pharmacology 78(6), pp. 573-582. 
 
Kim, S. et al. 2000. In vivo natural killer cell activities revealed by 
natural killer cell-deficient mice. Proceedings of the National Academy 
of Sciences of the United States of America 97(6), pp. 2731-2736. 
 
Kindler, H. L. et al. 2012. A randomized, placebo-controlled phase 2 
study of ganitumab (AMG 479) or conatumumab (AMG 655) in 
combination with gemcitabine in patients with metastatic pancreatic 
cancer. Annals of oncology. 
 
Kinoshita, H. et al. 2000. Cisplatin (CDDP) sensitizes human 
osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating 
FLIP-L expression. International journal of cancer 88(6), pp. 986-991. 
 
Kirchhoff, S. et al. 2000. TCR-mediated up-regulation of c-FLIPshort 
correlates with resistance toward CD95-mediated apoptosis by 
  Bibliography 
L Piggott  Cardiff University 238 
blocking death-inducing signaling complex activity. Journal of 
immunology (Baltimore, Md. 165(11), pp. 6293-6300. 
 
Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor 
receptor/c-erbB2 heterodimers mediate an autocrine growth 
regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 
144(3), pp. 1032-1044. 
 
Kobayashi, H. et al. 2011. Phase I/II study of adoptive transfer of 
gammadelta T cells in combination with zoledronic acid and IL-2 to 
patients with advanced renal cell carcinoma. Cancer immunology, 
immunotherapy 60(8), pp. 1075-1084. 
 
Kobayashi, H. et al. 2007. Safety profile and anti-tumor effects of 
adoptive immunotherapy using gamma-delta T cells against advanced 
renal cell carcinoma: a pilot study. Cancer immunology, 
immunotherapy 56(4), pp. 469-476. 
 
Kondo, M. et al. 2008. Zoledronate facilitates large-scale ex vivo 
expansion of functional gammadelta T cells from cancer patients for 
use in adoptive immunotherapy. Cytotherapy 10(8), pp. 842-856. 
 
Korkaya, H. et al. 2009. Regulation of mammary stem/progenitor cells 
by PTEN/Akt/beta-catenin signaling. PLoS biology 7(6), p. e1000121. 
 
Korkaya, H. et al. 2008. HER2 regulates the mammary 
stem/progenitor cell population driving tumorigenesis and invasion. 
Oncogene 27(47), pp. 6120-6130. 
 
Kreuz, S. et al. 2004. NFkappaB activation by Fas is mediated through 
FADD, caspase-8, and RIP and is inhibited by FLIP. The Journal of cell 
biology 166(3), pp. 369-380. 
 
Kreuz, S. et al. 2001. NF-kappaB inducers upregulate cFLIP, a 
cycloheximide-sensitive inhibitor of death receptor signaling. Molecular 
and cellular biology 21(12), pp. 3964-3973. 
 
Krueger, A. et al. 2001. Cellular FLICE-inhibitory protein splice variants 
inhibit different steps of caspase-8 activation at the CD95 death-
inducing signaling complex. The Journal of biological chemistry 
276(23), pp. 20633-20640. 
 
Kruyt, F. A. 2008. TRAIL and cancer therapy. Cancer letters 263(1), 
pp. 14-25. 
  Bibliography 
L Piggott  Cardiff University 239 
 
Kunzmann, V. et al. 2000. Stimulation of gammadelta T cells by 
aminobisphosphonates and induction of antiplasma cell activity in 
multiple myeloma. Blood 96(2), pp. 384-392. 
 
Kurokawa, H. and Arteaga, C. L. 2001. Inhibition of erbB receptor 
(HER) tyrosine kinases as a strategy to abrogate antiestrogen 
resistance in human breast cancer. Clinical cancer research 7(12 
Suppl), pp. 4436s-4442s; discussion 4411s-4412s. 
 
Kurokawa, H. and Arteaga, C. L. 2003. ErbB (HER) receptors can 
abrogate antiestrogen action in human breast cancer by multiple 
signaling mechanisms. Clinical cancer research 9(1 Pt 2), pp. 511S-
515S. 
 
Kurokawa, H. et al. 2000. Inhibition of HER2/neu (erbB-2) and 
mitogen-activated protein kinases enhances tamoxifen action against 
HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer 
research 60(20), pp. 5887-5894. 
 
Kushner, P. J. et al. 2000. Oestrogen receptor function at classical and 
alternative response elements. Novartis Foundation symposium 230, 
pp. 20-26; discussion 27-40. 
 
Kuukasjarvi, T. et al. 1996. Loss of estrogen receptor in recurrent 
breast cancer is associated with poor response to endocrine therapy. 
Journal of clinical oncology 14(9), pp. 2584-2589. 
 
Lawrence, D. et al. 2001. Differential hepatocyte toxicity of 
recombinant Apo2L/TRAIL versions. Nature medicine 7(4), pp. 383-
385. 
 
Lee, J. et al. 2009. The sesquiterpene lactone eupatolide sensitizes 
breast cancer cells to TRAIL through down-regulation of c-FLIP 
expression. Oncology reports 23(1), pp. 229-237. 
 
Lee, S. H. et al. 2001. Somatic mutations of TRAIL-receptor 1 and 
TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20(3), 
pp. 399-403. 
 
Lee, T.-J. et al. 2006. Acquired TRAIL resistance in human breast 
cancer cells are caused by the sustained cFLIPL and XIAP protein levels 
and ERK activation. Biochemical and Biophysical Research 
Communications 351(4), pp. 1024-1030. 
  Bibliography 
L Piggott  Cardiff University 240 
 
Leong, K. G. et al. 2007. Jagged1-mediated Notch activation induces 
epithelial-to-mesenchymal transition through Slug-induced repression 
of E-cadherin. The Journal of experimental medicine 204(12), pp. 
2935-2948. 
 
Leong, S. et al. 2009. Mapatumumab, an antibody targeting TRAIL-R1, 
in combination with paclitaxel and carboplatin in patients with 
advanced solid malignancies: results of a phase I and pharmacokinetic 
study. Journal of clinical oncology 27(26), pp. 4413-4421. 
 
Li, Q. Q. et al. 2009. Twist1-mediated adriamycin-induced epithelial-
mesenchymal transition relates to multidrug resistance and invasive 
potential in breast cancer cells. Clinical cancer research 15(8), pp. 
2657-2665. 
 
Li, X. et al. 2008. Intrinsic resistance of tumorigenic breast cancer cells 
to chemotherapy. Journal of the National Cancer Institute 100(9), pp. 
672-679. 
 
Liu, M. et al. 2010. The canonical NF-kappaB pathway governs 
mammary tumorigenesis in transgenic mice and tumor stem cell 
expansion. Cancer research 70(24), pp. 10464-10473. 
 
Liu, S. et al. 2011. Breast cancer stem cells are regulated by 
mesenchymal stem cells through cytokine networks. Cancer research 
71(2), pp. 614-624. 
 
Liu, S. and Wicha, M. S. 2010. Targeting breast cancer stem cells. 
Journal of clinical oncology 28(25), pp. 4006-4012. 
 
Liu, Z. et al. 2008. Protective immunosurveillance and therapeutic 
antitumor activity of gammadelta T cells demonstrated in a mouse 
model of prostate cancer. Journal of immunology (Baltimore, Md. 
180(9), pp. 6044-6053. 
 
Liu, Z. et al. 2005. Ex vivo expanded human Vgamma9Vdelta2+ 
gammadelta-T cells mediate innate antitumor activity against human 
prostate cancer cells in vitro. The Journal of urology 173(5), pp. 1552-
1556. 
 
Logan, A. E. et al. 2010. In vitro and in vivo characterisation of a novel 
c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis 
15(12), pp. 1435-1443. 
  Bibliography 
L Piggott  Cardiff University 241 
 
Lombardo, L. J. et al. 2004. Discovery of N-(2-chloro-6-methyl- 
phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-
4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl 
kinase inhibitor with potent antitumor activity in preclinical assays. 
Journal of medicinal chemistry 47(27), pp. 6658-6661. 
 
Long, B. et al. 1992. Changes in epidermal growth factor receptor 
expression and response to ligand associated with acquired tamoxifen 
resistance or oestrogen independence in the ZR-75-1 human breast 
cancer cell line. British journal of cancer 65(6), pp. 865-869. 
 
Longcope, C. et al. 1986. Androgen and estrogen metabolism: 
relationship to obesity. Metabolism: clinical and experimental 35(3), 
pp. 235-237. 
 
Longley, D. B. et al. 2006. c-FLIP inhibits chemotherapy-induced 
colorectal cancer cell death. Oncogene 25(6), pp. 838-848. 
 
Lopez-Tarruella, S. and Martin, M. 2009. Recent advances in systemic 
therapy: advances in adjuvant systemic chemotherapy of early breast 
cancer. Breast cancer research 11(2), p. 204. 
 
Lowe, L. C. et al. 2005. Induction of apoptosis in breast cancer cells by 
apomine is mediated by caspase and p38 mitogen activated protein 
kinase activation. Biochemical and biophysical research 
communications 329(2), pp. 772-779. 
 
Lu, D. and Carson, D. A. 2011. Inhibition of Wnt signaling and cancer 
stem cells. Oncotarget 2(8), p. 587. 
 
Lu, G. et al. 2002. Innate direct anticancer effector function of human 
immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), 
Fas ligand, and TNF-related apoptosis-inducing ligand. Journal of 
immunology (Baltimore, Md. 168(4), pp. 1831-1839. 
 
Lykkesfeldt, A. E. et al. 1994. Altered expression of estrogen-regulated 
genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 
sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer 
research 54(6), pp. 1587-1595. 
 
MacFarlane, M. 2003. TRAIL-induced signalling and apoptosis. 
Toxicology letters 139(2-3), pp. 89-97. 
 
  Bibliography 
L Piggott  Cardiff University 242 
Maeurer, M. J. et al. 1996. Human intestinal Vdelta1+ lymphocytes 
recognize tumor cells of epithelial origin. The Journal of experimental 
medicine 183(4), pp. 1681-1696. 
 
Magnifico, A. et al. 2009. Tumor-initiating cells of HER2-positive 
carcinoma cell lines express the highest oncoprotein levels and are 
sensitive to trastuzumab. Clinical cancer research 15(6), pp. 2010-
2021. 
 
Mani, S. A. et al. 2008. The epithelial-mesenchymal transition 
generates cells with properties of stem cells. Cell 133(4), pp. 704-715. 
 
Mariani, S. M. et al. 1997. Interleukin 1 beta-converting enzyme 
related proteases/caspases are involved in TRAIL-induced apoptosis of 
myeloma and leukemia cells. The Journal of cell biology 137(1), pp. 
221-229. 
 
Martin, S. S. and Leder, P. 2001. Human MCF10A mammary epithelial 
cells undergo apoptosis following actin depolymerization that is 
independent of attachment and rescued by Bcl-2. Molecular and 
cellular biology 21(19), pp. 6529-6536. 
 
Martin, S. S. et al. 2004. A cytoskeleton-based functional genetic 
screen identifies Bcl-xL as an enhancer of metastasis, but not primary 
tumor growth. Oncogene 23(26), pp. 4641-4645. 
 
Mattarollo, S. R. et al. 2007. Chemotherapy and zoledronate sensitize 
solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer 
immunology, immunotherapy 56(8), pp. 1285-1297. 
 
Mauri, D. et al. 2005. Neoadjuvant versus adjuvant systemic 
treatment in breast cancer: a meta-analysis. Journal of the National 
Cancer Institute 97(3), pp. 188-194. 
 
Mawji, I. A. et al. 2007. Critical role for Fas-associated death domain-
like interleukin-1-converting enzyme-like inhibitory protein in anoikis 
resistance and distant tumor formation. Journal of the National Cancer 
Institute 99(10), pp. 811-822. 
 
May, C. D. et al. 2011. Epithelial-mesenchymal transition and cancer 
stem cells: a dangerously dynamic duo in breast cancer progression. 
Breast cancer research 13(1), p. 202. 
 
  Bibliography 
L Piggott  Cardiff University 243 
McClelland, R. A. et al. 2001. Enhanced epidermal growth factor 
receptor signaling in MCF7 breast cancer cells after long-term culture 
in the presence of the pure antiestrogen ICI 182,780 (Faslodex). 
Endocrinology 142(7), pp. 2776-2788. 
 
McDermott, S. P. and Wicha, M. S. 2010. Targeting breast cancer stem 
cells. Molecular oncology 4(5), pp. 404-419. 
 
McDonnell, D. P. and Norris, J. D. 2002. Connections and regulation of 
the human estrogen receptor. Science (New York, N.Y 296(5573), pp. 
1642-1644. 
 
McKenna, N. J. et al. 1999. Nuclear receptor coregulators: cellular and 
molecular biology. Endocrine reviews 20(3), pp. 321-344. 
 
Mehlen, P. and Puisieux, A. 2006. Metastasis: a question of life or 
death. Nature reviews 6(6), pp. 449-458. 
 
Meraviglia, S. et al. 2010. In vivo manipulation of Vgamma9Vdelta2 T 
cells with zoledronate and low-dose interleukin-2 for immunotherapy 
of advanced breast cancer patients. Clinical and experimental 
immunology 161(2), pp. 290-297. 
 
Meyer, M. J. et al. 2009. Dynamic regulation of CD24 and the invasive, 
CD44posCD24neg phenotype in breast cancer cell lines. Breast cancer 
research 11(6), p. R82. 
 
Micheau, O. et al. 2001. NF-kappaB signals induce the expression of c-
FLIP. Molecular and cellular biology 21(16), pp. 5299-5305. 
 
Micheau, O. et al. 2002. The long form of FLIP is an activator of 
caspase-8 at the Fas death-inducing signaling complex. The Journal of 
biological chemistry 277(47), pp. 45162-45171. 
 
Miller, D. K. 1997. The role of the Caspase family of cysteine proteases 
in apoptosis. Seminars in immunology 9(1), pp. 35-49. 
 
Mitsiades, C. S. et al. 2001. TRAIL/Apo2L ligand selectively induces 
apoptosis and overcomes drug resistance in multiple myeloma: 
therapeutic applications. Blood 98(3), pp. 795-804. 
 
Mizutani, Y. et al. 2004. Prognostic significance of serum 
osteoprotegerin levels in patients with bladder carcinoma. Cancer 
101(8), pp. 1794-1802. 
  Bibliography 
L Piggott  Cardiff University 244 
 
Mom, C. H. et al. 2009. Mapatumumab, a fully human agonistic 
monoclonal antibody that targets TRAIL-R1, in combination with 
gemcitabine and cisplatin: a phase I study. Clinical cancer research 
15(17), pp. 5584-5590. 
 
Morel, A. P. et al. 2008. Generation of breast cancer stem cells 
through epithelial-mesenchymal transition. PloS one 3(8), p. e2888. 
 
Morimoto, K. et al. 2009. Stem cell marker aldehyde dehydrogenase 
1-positive breast cancers are characterized by negative estrogen 
receptor, positive human epidermal growth factor receptor type 2, and 
high Ki67 expression. Cancer science 100(6), pp. 1062-1068. 
 
Morony, S. et al. 2001. Osteoprotegerin inhibits osteolysis and 
decreases skeletal tumor burden in syngeneic and nude mouse models 
of experimental bone metastasis. Cancer research 61(11), pp. 4432-
4436. 
 
Muller, A. et al. 2001. Involvement of chemokine receptors in breast 
cancer metastasis. Nature 410(6824), pp. 50-56. 
 
Musgrove, E. A. and Sutherland, R. L. 2009. Biological determinants of 
endocrine resistance in breast cancer. Nature reviews 9(9), pp. 631-
643. 
 
Naito, M. et al. 2004. Cellular FLIP inhibits beta-catenin ubiquitylation 
and enhances Wnt signaling. Molecular and cellular biology 24(19), pp. 
8418-8427. 
 
Nakajima, A. et al. 2006. An antiapoptotic protein, c-FLIPL, directly 
binds to MKK7 and inhibits the JNK pathway. The EMBO journal 
25(23), pp. 5549-5559. 
 
Naoe, M. et al. 2010. Zoledronate stimulates gamma delta T cells in 
prostate cancer patients. Oncology research 18(10), pp. 493-501. 
 
Neve, R. M. et al. 2006. A collection of breast cancer cell lines for the 
study of functionally distinct cancer subtypes. Cancer cell 10(6), pp. 
515-527. 
 
Newman, S. P. et al. 2000. Cofactor competition between the ligand-
bound oestrogen receptor and an intron 1 enhancer leads to oestrogen 
  Bibliography 
L Piggott  Cardiff University 245 
repression of ERBB2 expression in breast cancer. Oncogene 19(4), pp. 
490-497. 
 
Nicholson, R. I. et al. 2003. The biology of antihormone failure in 
breast cancer. Breast cancer research and treatment 80 Suppl 1, pp. 
S29-34; discussion S35. 
 
Nicholson, R. I. et al. 2005. Growth factor signalling and resistance to 
selective oestrogen receptor modulators and pure anti-oestrogens: the 
use of anti-growth factor therapies to treat or delay endocrine 
resistance in breast cancer. Endocrine-related cancer 12 Suppl 1, pp. 
S29-36. 
 
Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and 
anti-growth factor resistant breast cancer. Reviews in endocrine & 
metabolic disorders 8(3), pp. 241-253. 
 
Nicholson, R. I. et al. 2004a. Nonendocrine pathways and endocrine 
resistance: observations with antiestrogens and signal transduction 
inhibitors in combination. Clinical cancer research 10(1 Pt 2), pp. 
346S-354S. 
 
Nicholson, R. I. and Johnston, S. R. 2005. Endocrine therapy--current 
benefits and limitations. Breast cancer research and treatment 93 
Suppl 1, pp. S3-10. 
 
Nicholson, R. I. et al. 2004b. Growth factor-driven mechanisms 
associated with resistance to estrogen deprivation in breast cancer: 
new opportunities for therapy. Endocrine-related cancer 11(4), pp. 
623-641. 
 
Nicol, A. J. et al. 2011. Clinical evaluation of autologous gamma delta 
T cell-based immunotherapy for metastatic solid tumours. British 
journal of cancer 105(6), pp. 778-786. 
 
Niyazi, M. et al. 2009. Efficacy of triple therapies including ionising 
radiation, agonistic TRAIL antibodies and cisplatin. Oncology reports 
21(6), pp. 1455-1460. 
 
Normanno, N. et al. 2005. Mechanisms of endocrine resistance and 
novel therapeutic strategies in breast cancer. Endocrine-related cancer 
12(4), pp. 721-747. 
 
  Bibliography 
L Piggott  Cardiff University 246 
Nowell, P. C. 1976. The clonal evolution of tumor cell populations. 
Science (New York, N.Y 194(4260), pp. 23-28. 
 
Nyambo, R. et al. 2004. Human bone marrow stromal cells protect 
prostate cancer cells from TRAIL-induced apoptosis. Journal of bone 
and mineral research 19(10), pp. 1712-1721. 
 
O'Brien, C. S. et al. 2011. Breast cancer stem cells and their role in 
resistance to endocrine therapy. Hormones & cancer 2(2), pp. 91-103. 
 
O'Shaughnessy, J. 2005. Extending survival with chemotherapy in 
metastatic breast cancer. The oncologist 10 Suppl 3, pp. 20-29. 
 
Ogasawara, J. et al. 1993. Lethal effect of the anti-Fas antibody in 
mice. Nature 364(6440), pp. 806-809. 
 
Olsson, A. et al. 2001. Sensitization to TRAIL-induced apoptosis and 
modulation of FLICE-inhibitory protein in B chronic lymphocytic 
leukemia by actinomycin D. Leukemia 15(12), pp. 1868-1877. 
 
Ortiz-Ferron, G. et al. 2008. Roscovitine sensitizes breast cancer cells 
to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 
18(6), pp. 664-676. 
 
Osborne, C. K. 1999. Aromatase inhibitors in relation to other forms of 
endocrine therapy for breast cancer. Endocrine-related cancer 6(2), 
pp. 271-276. 
 
Osborne, C. K. et al. 2003. Role of the estrogen receptor coactivator 
AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. 
Journal of the National Cancer Institute 95(5), pp. 353-361. 
 
Osborne, C. K. et al. 1994. The importance of tamoxifen metabolism in 
tamoxifen-stimulated breast tumor growth. Cancer chemotherapy and 
pharmacology 34(2), pp. 89-95. 
 
Ozoren, N. and El-Deiry, W. S. 2002. Defining characteristics of Types 
I and II apoptotic cells in response to TRAIL. Neoplasia (New York, N.Y 
4(6), pp. 551-557. 
 
Palacios, C. et al. 2010. Down-regulation of RIP expression by 17-
dimethylaminoethylamino-17-demethoxygeldanamycin promotes 
TRAIL-induced apoptosis in breast tumor cells. Cancer letters 287(2), 
pp. 207-215. 
  Bibliography 
L Piggott  Cardiff University 247 
 
Palacios, C. et al. 2006. Flavopiridol induces cellular FLICE-inhibitory 
protein degradation by the proteasome and promotes TRAIL-induced 
early signaling and apoptosis in breast tumor cells. Cancer research 
66(17), pp. 8858-8869. 
 
Panner, A. et al. 2010. Ubiquitin-specific protease 8 links the PTEN-
Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity 
in glioblastoma multiforme. Cancer research 70(12), pp. 5046-5053. 
 
Panner, A. et al. 2009. A novel PTEN-dependent link to ubiquitination 
controls FLIPS stability and TRAIL sensitivity in glioblastoma 
multiforme. Cancer research 69(20), pp. 7911-7916. 
 
Pardal, R. et al. 2003. Applying the principles of stem-cell biology to 
cancer. Nat Rev Cancer 3(12), pp. 895-902. 
 
Parisot, J. P. et al. 1999. Altered expression of the IGF-1 receptor in a 
tamoxifen-resistant human breast cancer cell line. British journal of 
cancer 79(5-6), pp. 693-700. 
 
Park, B. K. et al. 2007. NF-kappaB in breast cancer cells promotes 
osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. 
Nature medicine 13(1), pp. 62-69. 
 
Patrawala, L. et al. 2005. Side population is enriched in tumorigenic, 
stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are 
similarly tumorigenic. Cancer research 65(14), pp. 6207-6219. 
 
Peng, H. et al. 2005. Cellular IAP1 regulates TRAIL-induced apoptosis 
in human fetal cortical neural progenitor cells. Journal of neuroscience 
research 82(3), pp. 295-305. 
 
Perey, L. et al. 2007. Clinical benefit of fulvestrant in postmenopausal 
women with advanced breast cancer and primary or acquired 
resistance to aromatase inhibitors: final results of phase II Swiss 
Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of 
oncology 18(1), pp. 64-69. 
 
Perez, L. E. et al. 2010. Bortezomib restores stroma-mediated 
APO2L/TRAIL apoptosis resistance in multiple myeloma. European 
journal of haematology 84(3), pp. 212-222. 
 
  Bibliography 
L Piggott  Cardiff University 248 
Perou, C. M. et al. 2000. Molecular portraits of human breast tumours. 
Nature 406(6797), pp. 747-752. 
 
Phillips, T. M. et al. 2006. The response of CD24(-/low)/CD44+ breast 
cancer-initiating cells to radiation. Journal of the National Cancer 
Institute 98(24), pp. 1777-1785. 
 
Piccart, M. 2008. Circumventing de novo and acquired resistance to 
trastuzumab: new hope for the care of ErbB2-positive breast cancer. 
Clinical breast cancer 8 Suppl 3, pp. S100-113. 
 
Pinkas, J. et al. 2004. Bcl-2-mediated cell survival promotes 
metastasis of EpH4 betaMEKDD mammary epithelial cells. Molecular 
cancer research 2(10), pp. 551-556. 
 
Pitti, R. M. et al. 1996. Induction of apoptosis by Apo-2 ligand, a new 
member of the tumor necrosis factor cytokine family. The Journal of 
biological chemistry 271(22), pp. 12687-12690. 
 
Place, A. E. et al. 2011. The microenvironment in breast cancer 
progression: biology and implications for treatment. Breast cancer 
research 13(6), p. 227. 
 
Polyak, K. and Weinberg, R. A. 2009. Transitions between epithelial 
and mesenchymal states: acquisition of malignant and stem cell traits. 
Nature reviews 9(4), pp. 265-273. 
 
Ponti, D. et al. 2005. Isolation and in vitro propagation of tumorigenic 
breast cancer cells with stem/progenitor cell properties. Cancer 
research 65(13), pp. 5506-5511. 
 
Pritchard, K. I. et al. 1997. Randomized trial of cyclophosphamide, 
methotrexate, and fluorouracil chemotherapy added to tamoxifen as 
adjuvant therapy in postmenopausal women with node-positive 
estrogen and/or progesterone receptor-positive breast cancer: a report 
of the National Cancer Institute of Canada Clinical Trials Group. Breast 
Cancer Site Group. Journal of clinical oncology 15(6), pp. 2302-2311. 
 
Quintavalle, C. et al. 2010. c-FLIPL enhances anti-apoptotic Akt 
functions by modulation of Gsk3beta activity. Cell death and 
differentiation 17(12), pp. 1908-1916. 
 
  Bibliography 
L Piggott  Cardiff University 249 
Rachner, T. D. et al. 2009. Zoledronic acid induces apoptosis and 
changes the TRAIL/OPG ratio in breast cancer cells. Cancer letters 
287(1), pp. 109-116. 
 
Rahman, M. et al. 2009a. TRAIL induces apoptosis in triple-negative 
breast cancer cells with a mesenchymal phenotype. Breast cancer 
research and treatment 113(2), pp. 217-230. 
 
Rahman, M. et al. 2009b. The TRAIL to targeted therapy of breast 
cancer. Advances in cancer research 103, pp. 43-73. 
 
Restifo, N. P. et al. 2012. Adoptive immunotherapy for cancer: 
harnessing the T cell response. Nature reviews 12(4), pp. 269-281. 
 
Restifo, N. P. et al. 1996. Loss of functional beta 2-microglobulin in 
metastatic melanomas from five patients receiving immunotherapy. 
Journal of the National Cancer Institute 88(2), pp. 100-108. 
 
Reya, T. et al. 2001. Stem cells, cancer, and cancer stem cells. Nature 
414(6859), pp. 105-111. 
 
Ricci, M. S. et al. 2004. Direct repression of FLIP expression by c-myc 
is a major determinant of TRAIL sensitivity. Molecular and cellular 
biology 24(19), pp. 8541-8555. 
 
Ricci, M. S. et al. 2007. Reduction of TRAIL-induced Mcl-1 and cIAP2 
by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-
induced death. Cancer cell 12(1), pp. 66-80. 
 
Riccioni, R. et al. 2005. TRAIL decoy receptors mediate resistance of 
acute myeloid leukemia cells to TRAIL. Haematologica 90(5), pp. 612-
624. 
 
Robertson, J. F. 1996. Oestrogen receptor: a stable phenotype in 
breast cancer. British journal of cancer 73(1), pp. 5-12. 
 
Rosato, R. R. et al. 2007. The multikinase inhibitor sorafenib 
potentiates TRAIL lethality in human leukemia cells in association with 
Mcl-1 and cFLIPL down-regulation. Cancer research 67(19), pp. 9490-
9500. 
 
Rosen, L. S. et al. 2001. Zoledronic acid versus pamidronate in the 
treatment of skeletal metastases in patients with breast cancer or 
  Bibliography 
L Piggott  Cardiff University 250 
osteolytic lesions of multiple myeloma: a phase III, double-blind, 
comparative trial. Cancer journal (Sudbury, Mass 7(5), pp. 377-387. 
 
Rosen, L. S. et al. 2004. Long-term efficacy and safety of zoledronic 
acid in the treatment of skeletal metastases in patients with nonsmall 
cell lung carcinoma and other solid tumors: a randomized, Phase III, 
double-blind, placebo-controlled trial. Cancer 100(12), pp. 2613-2621. 
 
Rosevear, H. M. et al. 2010. Conatumumab, a fully human mAb 
against death receptor 5 for the treatment of cancer. Current opinion 
in investigational drugs (London, England 11(6), pp. 688-698. 
 
Rossin, A. et al. 2009. Palmitoylation of the TRAIL receptor DR4 
confers an efficient TRAIL-induced cell death signalling. The 
Biochemical journal 419(1), pp. 185-192, 182 p following 192. 
 
Rouzier, R. et al. 2005. Breast cancer molecular subtypes respond 
differently to preoperative chemotherapy. Clinical cancer research 
11(16), pp. 5678-5685. 
 
Rusnak, D. W. et al. 2001. The characterization of novel, dual ErbB-
2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. 
Cancer research 61(19), pp. 7196-7203. 
 
Safa, A. R. et al. 2008. Cellular FLICE-like inhibitory protein (C-FLIP): 
a novel target for cancer therapy. Current cancer drug targets 8(1), 
pp. 37-46. 
 
Saitoh, A. et al. 2008. Anti-tumor cytotoxicity of gammadelta T cells 
expanded from peripheral blood cells of patients with myeloma and 
lymphoma. Medical oncology (Northwood, London, England) 25(2), pp. 
137-147. 
 
Sajithlal, G. B. et al. 2010. Permanently blocked stem cells derived 
from breast cancer cell lines. Stem cells (Dayton, Ohio) 28(6), pp. 
1008-1018. 
 
Sakamoto, M. et al. 2011. Adoptive immunotherapy for advanced non-
small cell lung cancer using zoledronate-expanded gammadeltaTcells: 
a phase I clinical study. Journal of immunotherapy (Hagerstown, Md. 
34(2), pp. 202-211. 
 
Salceda, S. and Caro, J. 1997. Hypoxia-inducible factor 1alpha (HIF-
1alpha) protein is rapidly degraded by the ubiquitin-proteasome 
  Bibliography 
L Piggott  Cardiff University 251 
system under normoxic conditions. Its stabilization by hypoxia 
depends on redox-induced changes. The Journal of biological chemistry 
272(36), pp. 22642-22647. 
 
Sanchez-Perez, T. et al. 2009. Mitotic arrest and JNK-induced 
proteasomal degradation of FLIP and Mcl-1 are key events in the 
sensitization of breast tumor cells to TRAIL by antimicrotubule agents. 
Cell death and differentiation 17(5), pp. 883-894. 
 
Santisteban, M. et al. 2009. Immune-induced epithelial to 
mesenchymal transition in vivo generates breast cancer stem cells. 
Cancer research 69(7), pp. 2887-2895. 
 
Sarrio, D. et al. 2012. Epithelial and mesenchymal subpopulations 
within normal basal breast cell lines exhibit distinct stem 
cell/progenitor properties. Stem cells (Dayton, Ohio) 30(2), pp. 292-
303. 
 
Sayers, T. J. et al. 2003. The proteasome inhibitor PS-341 sensitizes 
neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-
FLIP. Blood 102(1), pp. 303-310. 
 
Scaffidi, C. et al. 1999. The role of c-FLIP in modulation of CD95-
induced apoptosis. The Journal of biological chemistry 274(3), pp. 
1541-1548. 
 
Scheel, C. and Weinberg, R. A. 2011. Phenotypic plasticity and 
epithelial-mesenchymal transitions in cancer and normal stem cells? 
International journal of cancer 129(10), pp. 2310-2314. 
 
Schiff, R. et al. 2003. Breast cancer endocrine resistance: how growth 
factor signaling and estrogen receptor coregulators modulate 
response. Clinical cancer research 9(1 Pt 2), pp. 447S-454S. 
 
Schiff, R. et al. 2004. Cross-talk between estrogen receptor and 
growth factor pathways as a molecular target for overcoming 
endocrine resistance. Clinical cancer research 10(1 Pt 2), pp. 331S-
336S. 
 
Schimmer, A. D. et al. 2006. Identification of small molecules that 
sensitize resistant tumor cells to tumor necrosis factor-family death 
receptors. Cancer research 66(4), pp. 2367-2375. 
 
  Bibliography 
L Piggott  Cardiff University 252 
Schneider, B. P. and Miller, K. D. 2005. Angiogenesis of breast cancer. 
Journal of clinical oncology 23(8), pp. 1782-1790. 
 
Seki, N. et al. 2010. Bortezomib sensitizes human esophageal 
squamous cell carcinoma cells to TRAIL-mediated apoptosis via 
activation of both extrinsic and intrinsic apoptosis pathways. Molecular 
cancer therapeutics 9(6), pp. 1842-1851. 
 
Selbert, S. et al. 1998a. Efficient BLG-Cre mediated gene deletion in 
the mammary gland. Transgenic research 7(5), pp. 387-396. 
 
Selbert, S. et al. 1998b. Efficient BLG-Cre mediated gene deletion in 
the mammary gland. Transgenic Res 7(5), pp. 387-396. 
 
Seo, S. K. et al. 2011. Histone deacetylase inhibitors sensitize human 
non-small cell lung cancer cells to ionizing radiation through acetyl 
p53-mediated c-myc down-regulation. Journal of thoracic oncology 
6(8), pp. 1313-1319. 
 
Sethi, J. K. and Vidal-Puig, A. 2010. Wnt signalling and the control of 
cellular metabolism. The Biochemical journal 427(1), pp. 1-17. 
 
Shankar, S. et al. 2009. Suberoylanilide hydroxamic acid 
(Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells 
orthotopically implanted in BALB/c nude mice. Molecular cancer 
therapeutics 8(6), pp. 1596-1605. 
 
Shanker, A. et al. 2008. Treating metastatic solid tumors with 
bortezomib and a tumor necrosis factor-related apoptosis-inducing 
ligand receptor agonist antibody. Journal of the National Cancer 
Institute 100(9), pp. 649-662. 
 
Sharp, D. A. et al. 2005. Selective knockdown of the long variant of 
cellular FLICE inhibitory protein augments death receptor-mediated 
caspase-8 activation and apoptosis. The Journal of biological chemistry 
280(19), pp. 19401-19409. 
 
Sheikh, M. S. et al. 1999. The antiapoptotic decoy receptor 
TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is 
overexpressed in primary tumors of the gastrointestinal tract. 
Oncogene 18(28), pp. 4153-4159. 
 
Shi, Y. 2002. Apoptosome: the cellular engine for the activation of 
caspase-9. Structure (London, England 10(3), pp. 285-288. 
  Bibliography 
L Piggott  Cardiff University 253 
 
Shiau, A. K. et al. 1998. The structural basis of estrogen 
receptor/coactivator recognition and the antagonism of this interaction 
by tamoxifen. Cell 95(7), pp. 927-937. 
 
Shimizu, C. et al. 2007. Current trends and controversies over pre-
operative chemotherapy for women with operable breast cancer. 
Japanese journal of clinical oncology 37(1), pp. 1-8. 
 
Shipman, C. M. and Croucher, P. I. 2003. Osteoprotegerin is a soluble 
decoy receptor for tumor necrosis factor-related apoptosis-inducing 
ligand/Apo2 ligand and can function as a paracrine survival factor for 
human myeloma cells. Cancer research 63(5), pp. 912-916. 
 
Shirley, S. and Micheau, O. 2010. Targeting c-FLIP in cancer. Cancer 
letters. 
 
Shivapurkar, N. et al. 2004. Aberrant methylation of trail decoy 
receptor genes is frequent in multiple tumor types. International 
journal of cancer 109(5), pp. 786-792. 
 
Shostak, K. and Chariot, A. 2011. NF-kappaB, stem cells and breast 
cancer: the links get stronger. Breast cancer research 13(4), p. 214. 
 
Shou, J. et al. 2004. Mechanisms of tamoxifen resistance: increased 
estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast 
cancer. Journal of the National Cancer Institute 96(12), pp. 926-935. 
 
Shrader, M. et al. 2007. Gefitinib reverses TRAIL resistance in human 
bladder cancer cell lines via inhibition of AKT-mediated X-linked 
inhibitor of apoptosis protein expression. Cancer research 67(4), pp. 
1430-1435. 
 
Siegers, G. M. et al. 2011. Anti-leukemia activity of in vitro-expanded 
human gamma delta T cells in a xenogeneic Ph+ leukemia model. PloS 
one 6(2), p. e16700. 
 
Sinha, S. et al. 1998. Effect of CGS 20267 on ovarian aromatase and 
gonadotropin levels in the rat. Breast cancer research and treatment 
48(1), pp. 45-51. 
 
Slamon, D. J. et al. 2001. Use of chemotherapy plus a monoclonal 
antibody against HER2 for metastatic breast cancer that overexpresses 
HER2. The New England journal of medicine 344(11), pp. 783-792. 
  Bibliography 
L Piggott  Cardiff University 254 
 
Smith, C. L. and O'Malley, B. W. 2004. Coregulator function: a key to 
understanding tissue specificity of selective receptor modulators. 
Endocrine reviews 25(1), pp. 45-71. 
 
Smith, M. R. et al. 2007. Bortezomib sensitizes non-Hodgkin's 
lymphoma cells to apoptosis induced by antibodies to tumor necrosis 
factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 
and TRAIL-R2. Clinical cancer research 13(18 Pt 2), pp. 5528s-5534s. 
 
Smith, S. C. and Theodorescu, D. 2009. Learning therapeutic lessons 
from metastasis suppressor proteins. Nature reviews 9(4), pp. 253-
264. 
 
Smyth, M. J. et al. 2006. Cancer immunosurveillance and 
immunoediting: the roles of immunity in suppressing tumor 
development and shaping tumor immunogenicity. Advances in 
immunology 90, pp. 1-50. 
 
Smyth, M. J. et al. 2003. Nature's TRAIL--on a path to cancer 
immunotherapy. Immunity 18(1), pp. 1-6. 
 
Song, J. H. et al. 2007. Lipid rafts and nonrafts mediate tumor 
necrosis factor related apoptosis-inducing ligand induced apoptotic and 
nonapoptotic signals in non small cell lung carcinoma cells. Cancer 
research 67(14), pp. 6946-6955. 
 
Soria, J. C. et al. 2010. Randomized phase II study of dulanermin in 
combination with paclitaxel, carboplatin, and bevacizumab in advanced 
non-small-cell lung cancer. Journal of clinical oncology 29(33), pp. 
4442-4451. 
 
Sorlie, T. et al. 2001. Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proceedings of 
the National Academy of Sciences of the United States of America 
98(19), pp. 10869-10874. 
 
Sorlie, T. et al. 2003. Repeated observation of breast tumor subtypes 
in independent gene expression data sets. Proceedings of the National 
Academy of Sciences of the United States of America 100(14), pp. 
8418-8423. 
 
Sotiriou, C. et al. 2003. Breast cancer classification and prognosis 
based on gene expression profiles from a population-based study. 
  Bibliography 
L Piggott  Cardiff University 255 
Proceedings of the National Academy of Sciences of the United States 
of America 100(18), pp. 10393-10398. 
 
Stagni, V. et al. 2010. ATM kinase activity modulates cFLIP protein 
levels: potential interplay between DNA damage signalling and TRAIL-
induced apoptosis. Carcinogenesis 31(11), pp. 1956-1963. 
 
Staka, C. M. et al. 2005. Acquired resistance to oestrogen deprivation: 
role for growth factor signalling kinases/oestrogen receptor cross-talk 
revealed in new MCF-7X model. Endocrine-related cancer 12 Suppl 1, 
pp. S85-97. 
 
Streuli, C. H. and Gilmore, A. P. 1999. Adhesion-mediated signaling in 
the regulation of mammary epithelial cell survival. Journal of 
mammary gland biology and neoplasia 4(2), pp. 183-191. 
 
Sussman, R. T. et al. 2007. Chemotherapy-resistant side-population of 
colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a 
higher expression of c-Myc and TRAIL-receptor DR4. Cancer biology & 
therapy 6(9), pp. 1490-1495. 
 
Szegezdi, E. et al. 2009. Stem cells are resistant to TRAIL receptor-
mediated apoptosis. Journal of cellular and molecular medicine 13(11-
12), pp. 4409-4414. 
 
Takahashi-Yanaga, F. and Kahn, M. 2010. Targeting Wnt signaling: 
can we safely eradicate cancer stem cells? Clinical cancer research 
16(12), pp. 3153-3162. 
 
Tan, D. S. et al. 2008. Triple negative breast cancer: molecular 
profiling and prognostic impact in adjuvant anthracycline-treated 
patients. Breast cancer research and treatment 111(1), pp. 27-44. 
 
Tanei, T. et al. 2009. Association of breast cancer stem cells identified 
by aldehyde dehydrogenase 1 expression with resistance to sequential 
Paclitaxel and epirubicin-based chemotherapy for breast cancers. 
Clinical cancer research 15(12), pp. 4234-4241. 
 
Tao, L. et al. 2011. Repression of mammary stem/progenitor cells by 
p53 is mediated by Notch and separable from apoptotic activity. Stem 
cells (Dayton, Ohio) 29(1), pp. 119-127. 
 
  Bibliography 
L Piggott  Cardiff University 256 
Taylor, P. D. and Howell, A. 1999. The therapeutic potential of novel 
aromatase inhibitors in breast cancer. Expert opinion on investigational 
drugs 8(3), pp. 269-279. 
 
Tazzari, P. L. et al. 2008. Synergistic proapoptotic activity of 
recombinant TRAIL plus the Akt inhibitor Perifosine in acute 
myelogenous leukemia cells. Cancer research 68(22), pp. 9394-9403. 
 
Thedrez, A. et al. 2007. Self/non-self discrimination by human 
gammadelta T cells: simple solutions for a complex issue? 
Immunological reviews 215, pp. 123-135. 
 
Thiery, J. P. and Sleeman, J. P. 2006. Complex networks orchestrate 
epithelial-mesenchymal transitions. Nature reviews 7(2), pp. 131-142. 
 
Thorburn, A. et al. 2008. TRAIL receptor-targeted therapeutics: 
resistance mechanisms and strategies to avoid them. Drug resistance 
updates 11(1-2), pp. 17-24. 
 
Tischkowitz, M. et al. 2007. Use of immunohistochemical markers can 
refine prognosis in triple negative breast cancer. BMC cancer 7, p. 134. 
 
Tiwary, R. et al. 2010. Role of endoplasmic reticulum stress in alpha-
TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PloS 
one 5(7), p. e11865. 
 
Tobinai, K. 2007. Proteasome inhibitor, bortezomib, for myeloma and 
lymphoma. International journal of clinical oncology / Japan Society of 
Clinical Oncology 12(5), pp. 318-326. 
 
Todaro, M. et al. 2009. Efficient killing of human colon cancer stem 
cells by gammadelta T lymphocytes. Journal of immunology 
(Baltimore, Md. 182(11), pp. 7287-7296. 
 
Tran, S. E. et al. 2001. MAPK/ERK overrides the apoptotic signaling 
from Fas, TNF, and TRAIL receptors. The Journal of biological 
chemistry 276(19), pp. 16484-16490. 
 
Trarbach, T. et al. 2010. Phase II trial of mapatumumab, a fully 
human agonistic monoclonal antibody that targets and activates the 
tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-
R1), in patients with refractory colorectal cancer. British journal of 
cancer 102(3), pp. 506-512. 
 
  Bibliography 
L Piggott  Cardiff University 257 
Twiddy D, N. S., Mistry R, Edwards J, Walker RA, Cohen GM, 
MacFarlane M 2010. A TRAIL-R1-specific ligand in combination with 
doxorubicin selectively targets primary breast tumour cells for 
apoptosis. Breast Cancer Research 12(Suppl 1):P58. 
 
Uddin, S. and Al-Kuraya, K. S. 2011. Localization of death receptor 4 
in lipid rafts sensitizes chronic lymphocytic leukemia to 
chemotherapeutic drug mediated apoptosis. Leukemia & lymphoma 
52(7), pp. 1176-1177. 
 
Valabrega, G. et al. 2007. Trastuzumab: mechanism of action, 
resistance and future perspectives in HER2-overexpressing breast 
cancer. Annals of oncology 18(6), pp. 977-984. 
 
van der Pluijm, G. et al. 1996. Bisphosphonates inhibit the adhesion of 
breast cancer cells to bone matrices in vitro. The Journal of clinical 
investigation 98(3), pp. 698-705. 
 
van Geelen, C. M. et al. 2011. Modulation of TRAIL resistance in colon 
carcinoma cells: different contributions of DR4 and DR5. BMC cancer 
11, p. 39. 
 
van Noesel, M. M. et al. 2002. Tumor-specific down-regulation of the 
tumor necrosis factor-related apoptosis-inducing ligand decoy 
receptors DcR1 and DcR2 is associated with dense promoter 
hypermethylation. Cancer research 62(7), pp. 2157-2161. 
 
Varfolomeev, E. E. et al. 1998. Targeted disruption of the mouse 
Caspase 8 gene ablates cell death induction by the TNF receptors, 
Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9(2), pp. 267-
276. 
 
Vargo-Gogola, T. and Rosen, J. M. 2007. Modelling breast cancer: one 
size does not fit all. Nature reviews 7(9), pp. 659-672. 
 
Vaux, D. L. et al. 1988. Bcl-2 gene promotes haemopoietic cell survival 
and cooperates with c-myc to immortalize pre-B cells. Nature 
335(6189), pp. 440-442. 
 
Vaux, D. L. and Strasser, A. 1996. The molecular biology of apoptosis. 
Proceedings of the National Academy of Sciences of the United States 
of America 93(6), pp. 2239-2244. 
 
  Bibliography 
L Piggott  Cardiff University 258 
Verdijk, R. et al. 2007. Differential effects of bisphosphonates on 
breast cancer cell lines. Cancer letters 246(1-2), pp. 308-312. 
 
Viey, E. et al. 2005. Phosphostim-activated gamma delta T cells kill 
autologous metastatic renal cell carcinoma. Journal of immunology 
(Baltimore, Md. 174(3), pp. 1338-1347. 
 
Visvader, J. E. and Lindeman, G. J. 2008. Cancer stem cells in solid 
tumours: accumulating evidence and unresolved questions. Nature 
reviews 8(10), pp. 755-768. 
 
Voskoboinik, I. et al. 2006. Perforin-mediated target-cell death and 
immune homeostasis. Nature reviews 6(12), pp. 940-952. 
 
Wachter, T. et al. 2004. cFLIPL inhibits tumor necrosis factor-related 
apoptosis-inducing ligand-mediated NF-kappaB activation at the 
death-inducing signaling complex in human keratinocytes. The Journal 
of biological chemistry 279(51), pp. 52824-52834. 
 
Wagner, K. W. et al. 2007. Death-receptor O-glycosylation controls 
tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature 
medicine 13(9), pp. 1070-1077. 
 
Wakelee, H. A. et al. 2009. Phase I and pharmacokinetic study of 
lexatumumab (HGS-ETR2) given every 2 weeks in patients with 
advanced solid tumors. Annals of oncology 21(2), pp. 376-381. 
 
Wakeling, A. E. et al. 1991. A potent specific pure antiestrogen with 
clinical potential. Cancer research 51(15), pp. 3867-3873. 
 
Walczak, H. et al. 1999. Tumoricidal activity of tumor necrosis factor-
related apoptosis-inducing ligand in vivo. Nature medicine 5(2), pp. 
157-163. 
 
Wang, K. H. et al. 2010. Increasing CD44+/CD24(-) tumor stem cells, 
and upregulation of COX-2 and HDAC6, as major functions of HER2 in 
breast tumorigenesis. Molecular cancer 9, p. 288. 
 
Wang, Y. et al. 2004. Synthetic lethal targeting of MYC by activation of 
the DR5 death receptor pathway. Cancer cell 5(5), pp. 501-512. 
 
Warner, M. et al. 1999. The estrogen receptor family. Current opinion 
in obstetrics & gynecology 11(3), pp. 249-254. 
 
  Bibliography 
L Piggott  Cardiff University 259 
Weaver, V. M. et al. 1996. The importance of the microenvironment in 
breast cancer progression: recapitulation of mammary tumorigenesis 
using a unique human mammary epithelial cell model and a three-
dimensional culture assay. Biochemistry and cell biology = Biochimie 
et biologie cellulaire 74(6), pp. 833-851. 
 
Weiss, L. 1993. Deformation-driven destruction of cancer cells in the 
microvasculature. Clinical & experimental metastasis 11(5), pp. 430-
436. 
 
Wellings, S. R. et al. 1975. An atlas of subgross pathology of the 
human breast with special reference to possible precancerous lesions. 
Journal of the National Cancer Institute 55(2), pp. 231-273. 
 
Westley, B. R. and May, F. E. 1988. Oestrogen regulates oestrogen 
receptor mRNA levels in an oestrogen-responsive human breast cancer 
cell line. Biochemical and biophysical research communications 155(3), 
pp. 1113-1118. 
 
Wicha, M. S. et al. 2006. Cancer stem cells: an old idea--a paradigm 
shift. Cancer research 66(4), pp. 1883-1890; discussion 1895-1886. 
 
Wiley, S. R. et al. 1995. Identification and characterization of a new 
member of the TNF family that induces apoptosis. Immunity 3(6), pp. 
673-682. 
 
Wilson, T. R. et al. 2007. c-FLIP: a key regulator of colorectal cancer 
cell death. Cancer research 67(12), pp. 5754-5762. 
 
Wong, C. W. et al. 2001. Apoptosis: an early event in metastatic 
inefficiency. Cancer research 61(1), pp. 333-338. 
 
Woodward, W. A. et al. 2007. WNT/beta-catenin mediates radiation 
resistance of mouse mammary progenitor cells. Proceedings of the 
National Academy of Sciences of the United States of America 104(2), 
pp. 618-623. 
 
Wu, G. S. 2009. TRAIL as a target in anti-cancer therapy. Cancer 
letters 285(1), pp. 1-5. 
 
Wu, R. C. et al. 2005. Transcriptional regulation by steroid receptor 
coactivator phosphorylation. Endocrine reviews 26(3), pp. 393-399. 
 
  Bibliography 
L Piggott  Cardiff University 260 
Wu, X. X. et al. 2007. Low concentrations of doxorubicin sensitizes 
human solid cancer cells to tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing 
TRAIL-R2 expression. Cancer science 98(12), pp. 1969-1976. 
 
Wyckoff, J. B. et al. 2000. A critical step in metastasis: in vivo analysis 
of intravasation at the primary tumor. Cancer research 60(9), pp. 
2504-2511. 
 
Xiao, W. et al. 2011. Death receptor 4 is preferentially recruited to 
lipid rafts in chronic lymphocytic leukemia cells contributing to tumor 
necrosis related apoptosis inducing ligand-induced synergistic 
apoptotic responses. Leukemia & lymphoma 52(7), pp. 1290-1301. 
 
Xu, C. et al. 2007. Gammadelta T cells recognize tumor cells via 
CDR3delta region. Molecular immunology 44(4), pp. 302-310. 
 
Xu, L. et al. 2011. Epirubicin enhances TRAIL-induced apoptosis in 
gastric cancer cells by promoting death receptor clustering in lipid 
rafts. Molecular medicine reports 4(3), pp. 407-411. 
 
Yamashita, H. 2008. Current research topics in endocrine therapy for 
breast cancer. International journal of clinical oncology / Japan Society 
of Clinical Oncology 13(5), pp. 380-383. 
 
Yang, J. and Weinberg, R. A. 2008. Epithelial-mesenchymal transition: 
at the crossroads of development and tumor metastasis. 
Developmental cell 14(6), pp. 818-829. 
 
Yano, T. et al. 1992. Inhibition of growth of MCF-7 MIII human breast 
carcinoma in nude mice by treatment with agonists or antagonists of 
LH-RH. Breast cancer research and treatment 21(1), pp. 35-45. 
 
Yarden, R. I. et al. 2001. Estrogen suppression of EGFR expression in 
breast cancer cells: a possible mechanism to modulate growth. Journal 
of cellular biochemistry Suppl 36, pp. 232-246. 
 
Ye, Y. et al. 2008. ERalpha suppresses slug expression directly by 
transcriptional repression. The Biochemical journal 416(2), pp. 179-
187. 
 
Yeh, J. H. et al. 1998. Mitogen-activated protein kinase kinase 
antagonized fas-associated death domain protein-mediated apoptosis 
  Bibliography 
L Piggott  Cardiff University 261 
by induced FLICE-inhibitory protein expression. The Journal of 
experimental medicine 188(10), pp. 1795-1802. 
 
Yeh, T. C. et al. 2007. Biological characterization of ARRY-142886 
(AZD6244), a potent, highly selective mitogen-activated protein kinase 
kinase 1/2 inhibitor. Clinical cancer research 13(5), pp. 1576-1583. 
 
Yeh, W. C. et al. 2000. Requirement for Casper (c-FLIP) in regulation 
of death receptor-induced apoptosis and embryonic development. 
Immunity 12(6), pp. 633-642. 
 
Yerbes, R. and Lopez-Rivas, A. 2010. Itch/AIP4-independent 
proteasomal degradation of cFLIP induced by the histone deacetylase 
inhibitor SAHA sensitizes breast tumour cells to TRAIL. Investigational 
new drugs 30(2), pp. 541-547. 
 
Yerbes, R. et al. 2012. Control of FLIP(L) expression and TRAIL 
resistance by the extracellular signal-regulated kinase1/2 pathway in 
breast epithelial cells. Cell death and differentiation. 
 
Yook, J. I. et al. 2006. A Wnt-Axin2-GSK3beta cascade regulates 
Snail1 activity in breast cancer cells. Nature cell biology 8(12), pp. 
1398-1406. 
 
Yu, C. C. et al. 2010a. Medulloblastoma-derived tumor stem-like cells 
acquired resistance to TRAIL-induced apoptosis and radiosensitivity. 
Child's nervous system 26(7), pp. 897-904. 
 
Yu, F. et al. 2007a. let-7 regulates self renewal and tumorigenicity of 
breast cancer cells. Cell 131(6), pp. 1109-1123. 
 
Yu, J. W. et al. 2009. Mechanism of procaspase-8 activation by c-
FLIPL. Proceedings of the National Academy of Sciences of the United 
States of America 106(20), pp. 8169-8174. 
 
Yu, K. et al. 2001. mTOR, a novel target in breast cancer: the effect of 
CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. 
Endocrine-related cancer 8(3), pp. 249-258. 
 
Yu, S. T. et al. 2007b. Tryptanthrin inhibits MDR1 and reverses 
doxorubicin resistance in breast cancer cells. Biochemical and 
biophysical research communications 358(1), pp. 79-84. 
 
  Bibliography 
L Piggott  Cardiff University 262 
Yu, W. et al. 2010b. alpha-TEA induces apoptosis of human breast 
cancer cells via activation of TRAIL/DR5 death receptor pathway. 
Molecular carcinogenesis 49(11), pp. 964-973. 
 
Zandi, E. et al. 1997. The IkappaB kinase complex (IKK) contains two 
kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB 
phosphorylation and NF-kappaB activation. Cell 91(2), pp. 243-252. 
 
Zhang, J. et al. 1998. Fas-mediated apoptosis and activation-induced 
T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 
392(6673), pp. 296-300. 
 
Zhang, N. and He, Y. W. 2005. An essential role for c-FLIP in the 
efficient development of mature T lymphocytes. The Journal of 
experimental medicine 202(3), pp. 395-404. 
 
Zhang, X. et al. 2004. Persistent c-FLIP(L) expression is necessary and 
sufficient to maintain resistance to tumor necrosis factor-related 
apoptosis-inducing ligand-mediated apoptosis in prostate cancer. 
Cancer research 64(19), pp. 7086-7091. 
 
Zhang, Y. and Zhang, B. 2008. TRAIL resistance of breast cancer cells 
is associated with constitutive endocytosis of death receptors 4 and 5. 
Molecular cancer research 6(12), pp. 1861-1871. 
 
Zhou, B. B. et al. 2009. Tumour-initiating cells: challenges and 
opportunities for anticancer drug discovery. Nature reviews 8(10), pp. 
806-823. 
 
Zhou, C. et al. 2012. Proteomic analysis of acquired tamoxifen 
resistance in MCF-7 cells reveals expression signatures associated with 
enhanced migration. Breast cancer research 14(2), p. R45. 
 
Zielske, S. P. et al. 2011. Ablation of breast cancer stem cells with 
radiation. Translational oncology 4(4), pp. 227-233. 
 
Zobalova, R. et al. 2008. CD133-positive cells are resistant to TRAIL 
due to up-regulation of FLIP. Biochemical and Biophysical Research 
Communications 373(4), pp. 567-571. 
 
 
 
